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The immune responses generated against tumour cells are not always capable of 
controlling tumour growth. Immunotherapeutic vaccines utilise the immune system’s 
ability to detect and destroy tumour cells and are a promising strategy for effective 
cancer treatment. There is however a need for the development of improved 
immunotherapy strategies as clinically tested immunotherapies have not yet provided 
the hoped for effective anti-tumour responses. Co-delivery of tumour antigen and 
vaccine adjuvant into the same antigen-presenting cell (APC) at the same time has been 
shown to be a more effective way at inducing anti-tumour immune responses compared 
to mixtures of antigen and adjuvant. The co-delivery of antigen and adjuvant is believed 
to generate this enhanced efficacy by mimicking the immunological processing of 
complex pathogens to induce cytotoxic T lymphocyte (CTL) responses, as the complex 
pathogens naturally comprise both antigen and adjuvant. Direct chemical conjugation 
of the antigen to adjuvant may however limit their processing by the APC for immune 
stimulation. The aim of this research was to test this theory and improve the 
effectiveness of soluble vaccine conjugates. Antigen-adjuvant conjugates were designed 
to be cleaved by an intracellular trigger to release antigen and adjuvant from each other 
following internalisation by APC. The intracellular triggers used for targeted release of 
antigen from adjuvant were redox and enzyme triggers. For reduction triggered release 
a disulphide linker was used, we generated two disulphide conjugates with different 
chemistries. For enzyme triggered release a peptide sequence was used which was 
specific for cleavage by Cathepsin S.  
These different linking systems were used to conjugate ovalbumin (OVA) as a model 
tumour antigen and cytosine-phosphate guanosine (CpG) as a vaccine adjuvant. The 
activity of these cleavable conjugates was compared to non-cleavable conjugates and 
mixtures of antigen and adjuvant. Two stable conjugates were synthesised, one with a 
zero length spacer (C-4FB-O) and another that had a longer polyethylene glycol spacer 
(C-PEG-O) to determine whether spatial distance between antigen and adjuvant has an 
impact on the generated immune response. The reversibility of these linkers was tested 
in an in vitro cleavage assay using size-exclusion chromatography. The conjugates were 
incubated with the reductant glutathione (GSH) at extracellular and intracellular 
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concentrations at pH 7.4 at 37 °C for 2 h, one disulphide conjugate (C-SPDP-O) was 
cleaved under extracellular reducing conditions while the second disulphide conjugate 
(C-4FBSS-O) was only cleaved at intracellular reducing conditions. The stable and 
peptide linked conjugates were not cleaved in either reducing condition. The peptide 
conjugate designed to be cleaved by Cathepsin S was not cleaved when exposed to the 
pure enzyme at pH 7.4 at 37 °C overnight. In vitro studies showed that the highest T-cell 
response was generated by the stable C-4FB-O and the intracellular cleavable C-4FBSS-
O conjugates. The stable conjugate C-PEG-O, the extracellular cleaved conjugate C-
SPDP-O and the C-peptide-O conjugate induced a lower T-cell response similar to the 
mixture of CpG and OVA. The conjugates were tested in vivo in a therapeutic tumour 
trial with B16-OVA cells injected subcutaneously into the left flank of C57BL/6 mice. 
After 80 days the surviving mice were re-challenged with B16-OVA tumour cells into 
the opposite flank. At day 160, a survival rate of 9/10 for mice vaccinated with the 
intracellular cleavable C-4FBSS-O conjugate was observed while 6/10 mice vaccinated 
with the stable C-4FB-O conjugate survived. All other conjugates and the mixture of 
CpG and OVA induced a survival rate of ≤ 3/10. 
In summary this study supported our hypotheses and demonstrated that intracellular 
triggered antigen-adjuvant conjugates that release the antigen from the adjuvant induce 
an effective anti-tumour immunity. This intracellular cleavable conjugation strategy 
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Cancer has been the focus of research for decades. In 1971, then United States President 
Richard Nixon signed the National Cancer Act to declare “War on Cancer”, hoping to 
find a cure for cancer within years of signing the bill (1). Forty five years later cancer is 
still a leading cause of death with 8.2 million worldwide deaths due to cancer in 2012 
(2). The term cancer refers to over 100 different forms of disease, all demonstrating rapid 
growth of mutated cells that are able to form tumours and acquire the ability to migrate 
from the site of origin into distant tissues (3,4). Cancer is a genetic disease, it arises from 
mutations in deoxyribonucleic acid (DNA). In healthy cells, DNA is constantly 
controlled and any mutations are repaired without errors. Due to a variety of factors, 
this DNA repair mechanism can be affected resulting in mutations which are not 
recognised and every time the DNA is replicated more errors occur (5). Factors that 
increase mutations are genetic defects, age or exposure to environmental risk factors 
such as radiation, ultraviolet light, tobacco, viruses, alcohol or inadequate diet (6). Not 
all mutations induce cancer but first a specific “gatekeeping” mutation has to occur 
which induces enhanced growth compared to the surrounding cells. The mutated cell 
clonally expands very slowly until a second mutation occurs in a different gene which 
promotes the uncontrolled growth further (7). Every mutation in a gene that induces a 
growth advantage is called a “driver” mutation, they are associated with mutations in 
proto-oncogenes and tumour suppressor genes. Proto-oncogenes control the positive 
regulation of cell growth, when mutated they can produce a more active form of the 
encoded growth protein or overproduce it. The ras gene that encodes for intracellular 
transduction proteins is a well-studied proto-oncogene (8,9). Tumour suppressor genes 
control the negative regulation of cell growth, inducing cell-cycle arrest, senescence or 
apoptosis. They contribute to tumour cell growth when mutations inactivate them. The 
p53 gene and the retinoblastoma (RB) gene are prominent examples of tumour 
suppressor genes (10). Every driver mutation only contributes to 0.4% enhanced growth 
of the cell compared to healthy cells, however with mutations accumulating over 
months and years billions of cells form the large mass of a tumour. With increasing 
mutation burden the tumour can transform from a benign tumour into an invasive 




tumour that can invade into the adjacent organs and metastasise in lymph nodes and 
distant organs (7,11). 
 
1.1.1. Cancer treatment 
Traditional treatments of cancer include surgical removal of the tumour, chemotherapy 
and radiation therapy. Chemotherapeutic agents are a diverse set of drugs that kill 
rapidly dividing cells either by damaging the cell’s DNA or preventing DNA synthesis 
(12–15). The cytotoxic activity is targeted at cancer cells, as most cancers display 
increased cell division rates. Although chemotherapy has improved largely in the last 
decade, there are still severe adverse effects and complications associated with it, 
including nausea, anaemia, reduced immune responses and hair loss. In radiation 
therapy, high-energy ionizing radiation from x-rays, gamma rays or charged particles 
is directed at cancer cells to damage their DNA and thereby kill the cells (16,17). The 
radiation can be either applied externally or internally by radioactively charged 
particles (18). It is commonly used in combination with other anti-cancer treatments. 
These therapies can cure cancer, however there are many cases where patients go on to 
develop advanced disease. Residual cancer cells in the patients’ body can adapt to the 
treatment, become resistant and lead to another outgrowth of therapy resistant cells, 
reverting the disease (19–21). Vaccination against cancer has been proposed as an 
alternative therapy, as traditional vaccination has been successful for decades to protect 
the body from viral and bacterial infections.  
 
1.2. Immune responses to cancer 
1.2.1. Innate immune responses 
Induction of an innate immune response is a key component for the initiation of an anti-
cancer immune response.  
The innate immune response has developed evolutionary as a first line of defence to 
fight against invading microorganisms. When an antigen penetrates through the 
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physical barriers (e.g. skin, mucosal membranes) and first enters the system of the host, 
the innate immune system gets activated by specific pathogen-associated molecular 
patterns (PAMPs). Antigen-presenting cells (APC), such as dendritic cells (DC), 
macrophages and B-cells recognise these PAMPs via pattern-recognition receptors 
(PRRs) (22,23). PAMPs are conserved structures of the invading organism invariant 
between different bacteria or virus, therefore one single PRR has a broad specificity and 
a variety of different organisms can be targeted with just the one receptor. The patterns 
that are recognised are essential for the survival of the pathogens and are therefore 
difficult for the pathogens to change them in order to evade immune recognition (22). 
Examples for PAMPs are lipopolysaccharides (LPS) on gram-negative bacteria, DNA 
and ribonucleic acid (RNA) of viruses or cytosine-phosphate-guanosine (CpG) DNA of 
bacteria and mycobacteria (24–27).  
Apart from exogenous acquired pathogen-derived molecules, also endogenous host-
derived molecules can activate the innate immune system, these endogenous molecules 
are termed danger-associated molecular patterns (DAMPs) (28). Dying, injured and 
stressed cells release and present DAMPs on the cell surface. DAMPs have been mainly 
associated with necrotic cells, as these are the most immunogenic, however DAMPs are 
also actively expressed by late-stage apoptotic cells (29–31). Similar to PAMPs, DAMPs 
are mainly recognised by PRRs on innate immune cells, however also non-PRR 
pathways have been associated with DAMP recognition and immune cell activation, 
including the purinergic receptor. Some DAMPs are released from necrotically dying 
cells and activate immune cells indirectly, examples are the intracellular high-mobility 
box group 1 (HBGB1) protein which strongly activates PPRs, nucleic acids such as DNA 
and RNA released from the cell nucleus and adenosine triphosphate (ATP), which binds 
to the purinergic receptor. Other DAMPs are expressed on the dying cell’s surface, these 
include calreticulin and heat shock protein (HSP) 90 and are recognised by PRRs on 
APCs through direct cell to cell contact (32–36). Induction of cancer cell death either 
through cancer treatments like chemotherapy or radiation or naturally through hypoxia 
in a large tumour mass promotes the release of DAMPs and can thereby help with the 
immune response against the cancer cells (37–39).  




There are different classes of PRRs, including Toll-like Receptors (TLRs), retinoic acid-
inducible gene (RIG) I-like receptors and Nod-like Receptors, with TLR being the most 
thoroughly studied ones. PRRs are encoded in mammalian germ line and are therefore 
available from birth onwards, unlike components of the acquired immune system. PRRs 
are expressed continuously, not depending on pathogens entering the host or on the 
lifecycle of the cell (22,24,40,41). Recognition of PAMPs or DAMPs by PRR induces 
activation of APCs, such as DCs. Activated APCs upregulate activation markers that are 
important for T-cell activation, including major histocompatibility complex (MHC)-I, 
MHC-II, cluster of differentiation (CD) 40, CD86 and CD80 and they release pro-
inflammatory cytokines, chemokines, interferons (IFN) such as tumour necrosis factor 
(TNF)-α, IFN-α, IFN-β, interleukin (IL) -1β , IL-6, IL-12 and IL-18 as well as antimicrobial 
peptides. The release of these cytokines mediates inflammatory responses and also 
further activates immune cells indirectly in a positive feedback loop, triggering an 
autocrine as well as paracrine effect (24,42–45).  
To date, twelve different TLR family members have been identified in mouse and ten in 
humans (46). TLRs are expressed mainly on immune cells, predominantly on DC, 
macrophages, B-cells and T-cells but can also be found on epithelial cells and fibroblasts. 
They are single-pass transmembrane proteins that form homo- or heterodimers to 
recognise different PAMPs and DAMPs. The extracellular domain is characterized by 
leucine-rich repeats which recognises the molecular patterns whereas the cytoplasmic 
domain is a Toll/IL-1R homology domain homologous to the interleukin receptor 
(22,47,48). TLR can be grouped either by the ligands they bind or their location. TLR 1, 
2, 4, 5 and 6 are located at the cell surface, whereas TLR 3, 7, 8 and 9 are found 
intracellular, predominantly in the endosome. Intracellular TLR recognise pathogens 
that enter the cell, mostly viruses or mycobacteria (49,50). The expression of TLR differs 
between species. For instance TLR 9, which recognises CpG is expressed in humans 
selectively by B-cells and plasmacytoid DC, whereas in mice it is also expressed by 
myeloid cells (51,52). Synthesis of cytokines, chemokines, prostaglandins and 
membrane-bound molecules following activation of the TLR all further activate the 
immune response. All of these mediators help activating immune cells, in particular DC, 
but the direct binding of a PAMP or DAMP to a PRR is still necessary to fully activate 
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an APC (44,53). Some TLR classes can recognise more than one set ligand, with each 
ligand having a different structure (22). A selection of ligands for the different TLR 
classes can be seen in Table 1.1.  
 
Table 1.1: Selected toll-like receptor ligands, adapted from Akira et al. (22) 
 
 
1.2.2. Antigen uptake and processing 
Internalisation of extracellular antigen by APCs, including DCs, macrophages and B-
cells, is the first important step to generate an immune response. APCs have three main 
mechanisms for internalisation of antigens, these are macropinocytosis, phagocytosis 
and receptor-mediated endocytosis. Macropinocytosis is a non-specific uptake 
mechanism that allows APCs to sample large quantities of soluble molecules, which are 
then concentrated to macrosolutes for further processing (54–57). Particulate, insoluble 
molecules are internalised by APCs via phagocytosis. Phagocytosis can be either specific 
by binding of the molecules to receptors or non-specific (58,59).  
APCs can target specific antigens for internalisation by receptor-mediated endocytosis. 
Uptake receptors include the C-type lectin receptors comprising mannose receptor (MR) 
and DEC-205 (CD205), low affinity Fc-receptors, scavenging receptors and complement 
receptors (60–66). The DEC-205 receptor for example has been identified to bind to CpG 
DNA and facilitate its uptake in the DC in both human and mice (67). Tumour antigens 
can be acquired by APCs in a variety of forms, these include (i) soluble antigens (68), (ii) 
Receptor Ligand
TLR1/TLR2 Triacyl lipopeptides, lipoteichonic acid, β-glycans
TLR2 PG, Porins, Lipoarabinomannan, Glucuronoxylomannan, HMGB1, HSP
TLR2/6 Diacyl lipopeptides, LTA, Zymosan
TLR3 dsRNA, mRNA, genomic DNA
TLR4 LPS, envelope proteins, heat shock proteins, Glucuronoxylomannan, HMGB1, HSP
TLR5 Flagellin
TLR7 and TLR8 ssRNA
TLR9 CpG DNA, viral DNA, Histones
TLR11 and TLR12 Profilin-like molecule
DNA, deoxynucleic acid; ds, double stranded; HMGB1, high-mobility box group 1; HSP, Heat shock protein; RNA, ribonucleic 
acid; LPS, lipopolysaccharide; LTA, lipoteichoic acid; PG, peptidoglycan; ss, single stranded; TLR, toll-like receptor




soluble antigens bound to chaperones like HSPs (69,70), (iii) antigens from dead or 
necrotic cells (71,72), (iv) antigens in the form of exosomes (73), (v) transfer of antigens 
through gap junctions (74), (vi) direct acquisition of peptide-MHC-I complexes from 
dead tumour cells (75) and (vii) DCs can “nibble” off antigens from the plasma 
membrane of live tumours (76). These last two mechanisms do not require processing 
of the antigen but the antigen is presented directly on the APC.  
The confirmation of the antigen, whether it is in soluble or particulate form has an effect 
on  the internalisation mechanism. It has been shown that particles in the viral size range 
of 20-200 nm enhance uptake of the particles by professional DCs as well as prevent 
degradation of the antigen compared to larger particles (77,78). Different particles have 
been tested, comprising liposomes, nanoparticles, virus-like particles, dendrimers or 
micelles (79–82). These small particles can directly drain to the lymph node and can be 
internalised by resident DCs there. Larger particles need to be internalised by peripheral 
DCs which then move into lymph nodes to present the antigen to effector cells in the 
lymph node. Particle size of the vaccine formulation determines transport into lymph 
nodes, internalisation pathway by APCs and processing of antigen. Large particles 
>200 nm require uptake by peripheral APCs for transport to lymph nodes while soluble 
formulations and small particles <200 nm can drain directly into lymph nodes to be 
internalised by resident APCs there (83–85). Upon uptake of antigen and presence of a 
danger signal, DCs develop from an immature cell with a high endocytic capacity to a 
mature cell that shows lower endocytic activity but an increase in antigen processing 
and presentation. Mature DCs also display increased motility to facilitate migration to 
lymph nodes, expression of co-stimulatory molecules and secretion of pro-
inflammatory cytokines for T-cell activation (54,86–91). Processing of the internalised 
antigen involves digestion of the antigen by enzymes into small peptide epitopes. The 
peptide epitopes are loaded onto MHC molecules and are presented as epitope-MHC 
complexes on the surface of the DCs to T-cells. T-cells are activated through binding to 
the epitope-MHC complexes as well as co-stimulatory molecules expressed on the DCs 
which is important for the induction of a strong antigen-specific immune response. 
Presentation of antigens on MHC-I and MHC-II molecules with subsequent CD8+ and 
CD4+ T-cell activation follow different processing pathways within the cell.  
8 
 
1.2.3. Antigen presentation on MHC-II 
The MHC-II pathway is considered the main presentation pathway for exogenous 
acquired antigens. Tumour antigen epitopes presented on MHC-II allows for binding 
and activation of CD4+ T-cells. MHC-II molecules are primarily a feature of APCs (92). 
After internalisation of antigens, the endocytic vesicle fuses with lysosomes and 
antigens are degraded to immune epitopes. Degradation occurs through endocytic 
proteases that become active at lower pH as the endosome matures (93–95). MHC-II 
molecules are assembled in the endoplasmic reticulum (ER) by association of its α- and 
β-chain with the invariant chain Ii. The invariant chain Ii provides guidance for 
intracellular transport and prevention of unspecific protein binding (96–98). The MHC-
II complex is then transferred from the ER to a late endosomal compartment specialised 
in MHC-II-peptide binding, called MHC-II compartment (MIIC). Transport of MHC-II 
to MIIC occurs either through direct trafficking of MHC-II through the trans-golgi 
network or transfer of the MHC-II complex to the plasma membrane followed by its re-
endocytosis to form MIIC (99–101). In MIIC, MHC-II is stabilised by the chaperone H2-
DM (murine, or human leukocyte antigen (HLA)-DM in humans) while the proteases 
cathepsin (Cat) S and L degrade the invariant chain Ii to the class II-associated Ii peptide 
(CLIP). CLIP attaches to the peptide-binding groove of MHC-II (92,102). H2-DM then 
facilitates the exchange of CLIP for the high-affinity peptide epitope. Once the peptide 
is bound, H2-DM dissociates and the loaded MHC-II complex is transferred to the 
plasma membrane for peptide presentation (92,103–105). Formation of MHC-II in DCs 
is regulated by the MHC class II transactivator (CIITA), in immature DCs high levels of 
CIITA are transcribed which leads to high levels of MHC-II molecules (106,107). As DCs 
mature, CIITA is inhibited and no more new MHC-II molecules are made. At the same 
time, maturation signals induce more efficient loading of antigen onto MHC-II and 
higher expression of MHC-II on the plasma membrane. LPS for example has been 
shown to stimulate tubule formation for increased transport of MIIC vesicles to the 
plasma membrane (108,109). 
 





Figure 1.1: Presentation of exogenous antigen on MHC-II 
Extracellular antigens are internalised by APC and degraded in endo-lysosomes to peptide 
epitopes. MHC-II molecules are assembled in the ER with the invariant chain Ii and transported 
to the MIIC compartment either through the Golgi Apparatus or indirectly through the plasma 
membrane. In the MIIC peptide epitopes are loaded onto MHC-II molecules and then presented 
on the cell surface.  
 
1.2.4. Antigen presentation on MHC-I 
Unlike MHC-II, MHC-I presentation is a feature of all nucleated cells. It presents 
modified-self or foreign peptides derived from within the cell, thereby the immune 
system can recognise any mutated or infected cells (110,111). 
Abnormal proteins within the cell are ubiquitinated in the cytosol and thereby tagged 
for degradation by the proteasome. Proteasome activity varies in different cell types, in 
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immune cells specific immunoproteasomes are found (112). Immunoproteasomes 
generate distinct immunogenic peptides as the degradation pattern differs slightly from 
the general 26S proteasome in other cells (113,114). Additionally when immune cells are 
exposed to immune stress such as IFN-γ, immunoproteasomes are more active, they can 
handle more substrates to produce more peptides to be presented, while proteasome 
activity in non-immune cells decreases under the same conditions (115,116). Peptides 
generated by proteasome degradation in the cytosol are transported into the ER by 
transporter associated with antigen processing (TAP) 1 and TAP 2 (117). In the ER MHC-
I complexes are folded and stabilised by the chaperones ERp57, calreticulin and tapasin. 
Before the peptide is loaded onto MHC-I it may require further trimming in the ER, this 
is done by the ER aminopeptidase associated with antigen processing (ERAAP) (92,118–
120). Once the peptide epitope is in the required state a peptide-loading complex is 
formed; the chaperone tapasin interacts with TAP, the peptide is loaded onto MHC-I 
and the chaperones disassemble. The peptide-loaded MHC-I complex is then shuttled 
to the plasma membrane via the Golgi apparatus and presented (111,121–124).  
T-cells however are not activated directly by internal peptides presented on any 
nucleated cell, but need to be activated by professional APCs which cross-present 
exogenous antigen on MHC-I.  
 
1.2.5. Cross-presentation of antigen to MHC-I 
Cross-presentation of tumour antigen epitopes onto MHC-I allows for binding and 
activation of CD8+ T-cells. Cross-presentation is still not fully understood but two main 
pathways have been identified through which exogenous proteins are loaded onto 
MHC-I, however various variations or interconnections between these pathways exist.  
In the cytosolic pathway, antigen are processed in the cytosol by the proteasome and 
then fed into the classical MHC-I pathway. Export of antigens from endosomes into  the 
cytosol is believed to be facilitated by the ER resident proteins SEC61 and p97, which 
are traditionally used to retrotranslocate misfolded ER proteins but in immune cells play 
a role in facilitating antigen shuttling into the cytosol (125–128).  




In the vacuolar pathway antigens are processed and loaded onto MHC-I molecules in 
endocytic compartments. This pathway is independent of the proteasome and TAP. 
Antigen that is internalised into endocytic compartments is processed by endosome 
resident proteases, such as Cat S (129). As peptide epitopes are not loaded onto MHC-I 
in the ER, MHC-I molecules need to be transported into endocytic compartments by 
trafficking of new assembled molecules from the ER into the endosome. Trafficking of 
ER proteins into endocytic compartments is promoted through CD74 signalling and 
mediated through the ER resident soluble NSF attachment protein receptor (SNARE) 
protein SEC22B (130,131). An alternative route to traffic MHC-I molecules into 
endocytic compartments for antigen loading is through receptor-recycling, whereby 
MHC-I molecules are recycled from the plasma membrane directly into the endosome 
(132–134). Processed antigen is loaded onto MHC-I molecules in the endo-lysosome and 
is then directly presented on the plasma membrane. The mechanism of antigen 
processing and which of the cross-presentation pathways is used is dependent on the 
cell type, the nature and size of the antigen and the mechanism of uptake. It has been 
shown that cross-presentation of antigens can be specifically enhanced by targeting 
uptake of antigen into early endosomes instead of late endosomes (135). Receptors that 
target antigens into early endosomal compartments are in the neck region of DC-specific 
ICAM3-grabbing non-integrin (DC-SIGN) (136), the MR (CD206) (137) and DNGR-1 
(138).  
DCs have been shown to be superior in cross-presentation compared to other APCs, this 
has been associated with lower proteolytic activity of lysosomal proteases in the 
endosome. Less degradation of antigens in DC endosomes preserves MHC-I binding 
epitopes which is essential for loading and presentation of peptides onto MHC-I 
molecules (139,140). DC subsets are very heterogeneous, they display various receptors 
and show different efficiencies of cross-presentation which also results in different 
levels of activation of CD8+ effector cells. In the mouse secondary lymphoid organs two 
different types of DCs can be found, the conventional and the plasmacytoid DCs. 
Conventional DCs express high level of CD11c, whereas plasmacytoid DCs express low 
levels of CD11c but secrete large amounts of type I IFN. Subgroups of conventional DCs 
are resident DCs which can be divided into CD8+, CD4+, CD8-4- and migratory DCs 
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like Langerhans (LH) cells which reside in the epidermis (141–143). The most potent DC 
subset to cross-present in mice are conventional CD8α+ DCs, they are further 
characterized by expressing Batf3, IRF8 as well as high levels of CD24, CD208, XCR1 
and CLEC9A. The reason why CD8α+ DCs seem to be more efficient in cross-presenting 
is that they can actively control the maturation and acidification of the endosome and 
thereby have an efficient transporting strategy of antigen to the cytosol (144–147). 
Interestingly, CD8α- DCs cross-present certain bacterial derived antigens much better 
than CD8α+ DCs (148,149). The formulation in which antigens are presented to the cells 
are also crucial on the cross-presenting ability of DCs, for example CD11b+CD8α- DCs 
only cross-present immune complexes, but not cell-associated antigens, soluble antigens 
or antigen coated beads (150–153). Migratory DCs reside in non-lymphoid organs and 
migrate to lymph nodes following antigen encounter. The phenotype of migratory DCs 
depends on the surrounding microenvironment. Migratory CD103 (αE integrin) and 
CD207 (Langerin) DCs have been shown to be able to cross-present, although they first 
have to be activated by IL-12 and type I IFNs (154–156). Differences in cross-presentation 
between CD8+, CD4+ and CD8-4- DCs were found due to a different intracellular 
antigen handling, not because of different antigen uptake (141). In a more recent study 
CD4+ DCs were shown to cross-present soluble antigens when they were administered 
together with saponin-based adjuvants (144). This demonstrates that not only the DC 
subset is crucial to the cross-presenting ability but also the environment and the 
immunostimmulatory features of the antigen define the cross-presentation capacity of 
DCs. 
In addition to presentation of antigen on cell intrinsic MHC-I, APCs can also acquire 
antigen–MHC-I complexes from dead cells by direct cell to cell contact. This mechanism 
of antigen presentation on MHC-I from donor cells is defined as “cross-dressing” 
(75,157). The antigen–MHC-I complexes acquired from the dead donor cells and 
presented via cross-dressing may then stimulate naïve T-cells, most effectively in 
combination with antigen cross-presented by the same APC.  
 





Figure 1.2: Cross-presentation of exogenous antigen on MHC-I 
Exogenous antigens are cross-presented on MHC-I molecules through multiple pathways. In the 
cytosolic pathway phagocytosed antigens are released into the cytosol, processed by the 
proteasome and translocated by TAP into the ER. In the ER peptide epitopes are loaded onto 
MHC-I molecules and transferred through the Golgi Apparatus for presentation on the cell 
surface. In the vacuolar pathway internalised antigen are processed in endo-lysosomes to 
peptide epitopes. MHC-I molecules are transferred to the endo-lysosome either directly from the 
ER or through receptor recycling from the plasma membrane. Peptide epitopes are loaded onto 




1.2.6. Acquired immune responses  
Antigen recognition by lymphocytes initiates acquired immune responses. Acquired 
immune responses can be broadly grouped into two classes: (i) antibody responses 
mediated by B-cells and (ii) cellular responses mediated by T-cells.  
B-cells recognise antigen in their native form via the B-cell receptor. Upon antigen 
recognition, B-cells process the antigen and display it on MHC molecules for T-cell 
activation. With the help of T-helper (TH) cells, activated B-cells clonally expand, 
differentiate into plasma cells and undergo class switching whereby high affinity 
antibodies are generated to neutralise the antigen (158,159). Different functions of B-
cells in anti-cancer immune responses have been reported. B-cells can function as APCs 
by cross-presenting antigens to T-cells, provide co-stimulatory signals to T-cells and 
release tumour antigen specific antibodies to induce antibody-dependent cell-mediated 
cytotoxicity (ADCC) (160).  
A cellular immune response targeted against cancer cells is mediated through cytotoxic 
T lymphocytes (CTL) and TH1 cells. Activation and differentiation of CD8+ T-cells and 
CD4+ T-cells into CTL and TH1 cells, respectively, is initiated by recognition of antigen 
presented on mature APC and amplified through cytokine release and positive 
stimulation between the participating cells.  
 
1.2.7. CD4 T-cells 
CD4+ TH cells dictate and shape acquired immune responses through cytokine 
production and direct cell-to-cell contact. Differentiated CD4+ T-cells facilitate a range 
of immune responses by providing ‘help’ to B-cells and T-cells for differentiation, 
promote DCs maturation and antigen presentation and by inducing suppression of 
autoimmunity, among others (161). A variety of TH-cell subsets have been identified 
with different functions, these include TH1, TH2, TH17 and regulatory T (Treg) cells.  
Naïve CD4+ T-cells require several factors to activate and differentiate. The first and 
main signal for activation is received through binding of the T-cell receptor (TCR) to 




MHC-II-peptide epitope complexes presented on DCs. As a second verification signal 
the co-stimulatory molecule CD28 on the T-cell binds to CD80/86 on the activated DC 
(109). The cytokine microenvironment around the CD4+ T-cell at the time of antigen 
recognition determines into which TH-cell subset the CD4+ T-cells differentiates (161).  
IL-2 and IL-4 are important cytokines for TH2-cell differentiation (162,163). TH2-cells 
induce stimulation of B-cells to produce and secrete the antigen-specific antibodies 
immunoglobulin (Ig) E and certain types of IgG. Secreted antibodies are very effective 
at eliminating bacterial and viral infections but are of limited effect for anti-tumour 
responses as cytokines connected with a TH2 response inhibit phagocytosis by APCs 
(164,165). However, tumour-specific antibodies have been identified that can induce 
target cell apoptosis through ADCC, therefore induction of TH2 cells to a certain degree 
can be advantageous for an anti-tumour response (166). Differentiation of CD4+ T-cells 
into TH17 cells has been associated with exposure to transforming-growth factor (TGF)-
β, IL-6 and IL-21 (167,168). The main function of TH17 cells has been identified as the 
recruitment of macrophages and neutrophils to the site of infection through release of 
IL-17. Additionally TH17-cells have been associated with autoimmune disease and 
tumour responses (169–171). Treg cell differentiation has been associated with exposure 
to TGF-β and IL-10 along with IL-2. Treg cells maintain peripheral tolerance through 
release of immunosuppressive cytokines like IL-10 and TGF-β (172). Although tolerance 
is important to prevent autoimmune disease an immunosuppressive environment is 
unwanted for anti-tumour responses (173).  
Differentiation of naïve T-cells into TH1 cells is facilitated through stimulation with IL-
12, IFN-α and IFN-β by activated DCs (174–176). TH1 cells are required for induction of 
a cellular anti-tumour immune response. TH1-cells provide help to DCs to increase CTL-
licensing and induce phagocyte-dependent inflammation through secretion of the pro-
inflammatory cytokines IFN-γ, IL-2, IL-21 and TNF-β and direct binding of CD40L to 
CD40 on DCs (44,177). In a positive feedback loop, TH1 cells induce further 
differentiation of CD4+ T-cells into TH1 cells. Additionally TH1 cells have been shown to 




1.2.8. CD8 T-cells 
Differentiated CD8+ T-cells, CTL, are capable of killing cancer cells due to their cytotoxic 
activity. Induction of this potent cellular immune response is therefore critical for anti-
cancer immunotherapies.  
Antigen-presenting DCs interact with naïve CD8+ T-cells in the lymph node to induce 
T-cell activation and differentiation (180). Three signals are required for T-cell 
differentiation, these are exchanged between the T-cell and DC by formation of an 
immunological synapse (181). Naïve CD8+ T-cells bind via their TCR along with the co-
receptor CD3 to peptide epitopes presented through cross-presentation on MHC-I, this 
is the first signal to differentiate into effector CTL (181–183). The activated DC expresses 
the co-stimulatory molecules CD40, CD80 and CD86. Binding of the T-cell via CD28 and 
CD40L to CD80/86 and CD40, respectively provides the second signal for T-cell 
differentiation (184,185). The third signal for T-cell differentiation is the recognition of 
polarising cytokines. Activated DCs release the pro-inflammatory cytokine IL-12 
directly into the immunological synapse for T-cell activation (186,187). IL-12 production 
by DCs stabilises the immunological synapse and is further upregulated following 
binding of CD40L on the T-cell to CD40 on the DC. Additionally IL-12 stimulates 
differentiation of CD4+ T-cells into TH1 cells (188,189). As mentioned above, TH1 cells 
activate and stimulate differentiation of CD8+ T-cells both through direct binding and 
release of pro-inflammatory cytokines. The cytokine IFN-γ is secreted by TH1 cells and 
CTL to induce T-cell differentiation but also to drive a positive feedback loop for 
induction of a strong cellular immune response (186,188).  
 
1.2.9. Effector T-cell function 
Differentiated effector CTLs target and eliminate cancer cells through induction of 
apoptosis via two direct cell contact pathways and via release of cytokines. Recognition 
of antigen and subsequent differentiation of naïve CD8+ T-cell into CTL changes the 
metabolism of the cell from oxidative phosphorylation to aerobic glycolysis to prepare 
for the high energy requirements associated with the effector functions (190). In the 




‘Ca2+-dependent perforin/granzyme mediated pathway’ which is dependent on direct 
cell to cell contact, CTL transport granules containing granzymes, perforin and the 
proteoglycan serglycan to target cells. Perforin binds to the plasma membrane of target 
cells to form pores which facilitates transfer of granzymes into the cells (191). 
Granzymes are serine proteases that induce caspase activity as well as activation of 
caspase-independent proteins responsible for apoptosis, thereby inducing programmed 
cell death in target cells (192,193). CTL also act through the ‘Ca2+-independent Fas/Fas-
ligand mediated pathway’ whereby the transmembrane protein Fas-ligand on CTL 
binds to Fas ligand on the target cell which induces caspase-dependent cell-death in the 
target cell (194,195). High levels of TNF-α and IFN-γ released by CTL further promote 
apoptosis in the target cells. TNF-α binds to receptors on target cells and thereby induces 
caspase-dependent apoptosis (196–198). IFN-γ induces upregulation of Fas-ligand in 
target cells as well as upregulation of presentation of endogenous peptides on MHC-I 
molecules, enhancing cell-to-cell apoptosis (199–202). Differentiated effector CD8+ T-
cells can be classified into two main subpopulations, dependent on their cytokine 
secretion profile following the antigen encounter. Type 1 CD8+ T-cells (TC1) have been 
shown to predominantly secrete IFN-γ and kill by both the Fas-mediated and perforin 
pathways, while TC2 predominantly secrete IL-4, IL-5 and IL-10 and kill mainly via the 
perforin pathway (203,204).  
In addition to the cytotoxicity generated by CD8+ CTL, also CD4+ T-cells with cytotoxic 
effector functions (THCTL) have been identified, although in lower numbers than CD8+ 
CTL. THCTL recognise antigen expressed on MHC-II on APCs and exert their cytotoxic 
function to target cells mainly through expression of granzymes and perforin, however 
also Fas/Fas-ligand mediated cytotoxicity has been reported (205,206). Adoptively 
transferred tumour-reactive THCTL have been shown to eradicate tumours, thereby 




Figure 1.3: Simplified diagram of the immune responses towards cancer  
(1) Tumour antigens are internalised by antigen-presenting cells (APC), (2) APC get activated, 
mature and (3) present antigen to CD8 and CD4 T-cells in the lymph node. (4) T-cells differentiate 
into T Helper cells and Cytotoxic T cells, migrate to the tumour and (5) Cytotoxic T cells kill the 
tumour supported by ‘help’ from TH1 Helper cells. 
 
1.2.10. T-cell memory development 
The development of memory T-cells is important for the long-lived protection against 
recurring antigenic challenges. The generation of an immunological memory has been 
predominantly studied in the context of prophylactic vaccination, however the 
development of tumour antigen specific memory cells is also beneficial to control 
metastatic spread and recurring secondary tumours in an immunotherapy setting. 
Following target cell clearance by effector CTL, 90-95 % of the effector T-cell population 
undergoes apoptosis while the remaining 5-10 % pathogen-specific T-cells survive and 
make the memory T-cell pool (209–214). Memory T-cells have been shown to persist 
long term in the body in an antigen and TCR independent but cytokine dependent 




manner, with members of the γc-cytokine family being responsible for the long-term 
maintenance of the memory T-cells (209,215–220). Two main subsets of memory T-cells 
have been identified, these are defined by their function, tissue location and surface 
markers. These subsets have in common that they are antigen-experienced (CD44high) 
and proliferate rapidly upon re-exposure to that antigen (211,221). Central memory T 
cells (TCM) are characterised by the expression of the lymph-node homing receptors 
CD62Lhigh and CCR7high and are primarily located in lymph nodes, the spleen and blood 
(54,222). TCM do not express effector molecules and display a high turnover rate (223). 
Effector memory T-cells (TEM) express the effector molecules granzyme and perforin as 
well as IFN-γ. They are characterised by a CD62Llow and CCR7low phenotype and are 
mainly located in peripheral non-lymphoid tissues, the spleen and blood (224). 
Additionally a third subset termed tissue-resident memory T-cells have been identified 
which display similar characteristics as TEM but have been shown to permanently reside 
in non-lymphoid peripheral tissues (221,225). TEM have a low threshold for activation by 
a reoccurring antigen and require ten-fold less antigen presented on APC compared to 
naïve T-cells to induce activation (226). As the location of the TRM is closer to the 
pathogen contact and as they respond rapidly to the antigen by expression of effector 
molecules without prior cell division they are able to start controlling the antigen. While 
TEM are short-lived and have a low proliferative potential, the TCM show self-renewal 
properties and within days of the memory recall secondary effector cells generated by 
TCM in large numbers are able to replace the TEM primary effector cells (221).  
 
1.2.11. Natural Killer and invariant Natural Killer T cells 
Natural killer (NK) cells are a population of innate lymphoid cells that display cytotoxic 
functions, acting as a link between the innate and the adaptive immune systems. NK 
cells detect ‘stressed’ cells such as virally infected and tumour cells and kill them 
through expression of Fas-ligand (227,228), expression of lytic granules containing 
perforin and granzymes (229,230) and expression of the effector cytokines TNF-α and 
IFN-γ (231,232). Unlike CTL or B-cells, NK cells detect their target cells in absence of 
MHC molecules and antibodies. Instead, NK cells detect down regulated MHC-I on 
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virus infected (233,234) or cancer cells (235,236) as well as expression of ‘stress proteins’ 
that are associated with tumorigenesis (237,238). Due to their alternative cancer cell 
recognition and powerful cytolytic potential, NK cells display promising features as a 
target for anti-cancer immunotherapies (239,240).  
Invariant Natural Killer T (iNKT) cells are a subset of T-cells that display phenotypes of 
both T-cells and NK cells. iNKT cells express a specialised invariant TCR which 
recognises self and foreign glycolipids presented on CD1d as antigens (241,242). Weak 
endogenous glycolipid stimulation causes iNKT cells to be in a “poised effector” state 
(243,244). Being constantly in this “poised effector” state allows iNKT cells to react to 
infections within hours in an innate-like manner. Exogenous cytokines, including IL-12 
released from DCs as well as PAMPs and DAMPs can stimulate iNKT cells and thereby 
induce IFN-γ production (245–248). iNKT cells have been shown to have both protective 
and harmful roles in the tumour microenvironment, associated with suppression as well 
as promotion of tumour growth (249,250). However when stimulated with vaccine 
adjuvants, especially α-galactosylceramide, NKT cells can provide potent help to DCs 
to enhance CTL priming and differentiation (251–253).   
 
1.2.12. Cancer immunoediting 
The immune system has a strong influence on cancer control and establishment. The 
hypothesis of immunoediting states that the immune system not only plays a role in 
controlling or destroying cancer cells but that it can also promote tumour progression. 
Three phases of immunoediting have been described: elimination, equilibrium and 
escape (254,255). In the elimination phase the innate and adaptive branches of the 
immune system work together to recognise transformed cells and eliminate them (256). 
Cancer cells with specific mutations may be able to evade elimination by the immune 
system and are able to grow. In the equilibrium phase a balance between the immune 
response and the cancer cells establishes, whereby the cancer cells continue to grow but 
are kept from expanding to a large size by the immune system. In the escape phase 
cancer cells have further mutated (255,257). These three phases of immunoediting may 
either happen in progression or independently. Cells that respond to immune responses 




are eliminated early on or are kept under control while poorly immunogenic variants 
can grow progressively and develop into malignant tumours. Cancer cells can evade the 
immune system through many different mechanisms. Examples are reduced immune 
recognition including loss of tumour antigens, enhanced resistance to cytotoxic immune 
responses or inhibition of immune cells by the tumour microenvironment (258,259). An 
immunosuppressive tumour microenvironment can be promoted by release of 
immunosuppressive cytokines and growth factors like TGF-β, vascular endothelial 
growth factor (VEGF) or galectin by the tumour cells. Treg and myeloid-derived 
suppressor cells are recruited by the released cytokines and take part in inhibiting 
antitumor responses (256,260–262).  
The theory of immunoediting illustrates that the natural immune responses are not 
sufficient to clear tumours from patient’s bodies. Development of therapies inducing 
robust, anti-cancer immune responses are required for the treatment of cancer. 
 
1.2.13. Tumour antigens 
Tumour antigens can be loosely classified into the following categories: (i) tumour 
antigens that are tissue specific and are overexpressed in cancer cells compared to 
normal cells (ii) tumour-specific and shared antigens that are only expressed in cancer 
cells and testis, but not in normal cells and (iii) tumour-specific and unique antigens 
which arise from genetic mutations or transcriptional modifications, including 
neoantigens (263,264). These antigen categories can be summarised with the term 
“tumour-associated antigens”. Further classifications of tumour antigens have been 
proposed to distinguish antigens that are for example present in somatic cancer cells, 
encoded by cancerous viruses or transformed by posttranslational modifications, but 
these categories are mostly not exclusive, as tumour antigens have several features (265). 
Every cancer is different but common tumour antigens that are expressed across 
patients in specific cancer types like breast cancer or colon cancer have been identified 
(266–268). Tumour antigens that promise an enhanced therapeutic effect are tumour 
antigens that are encoded in cancer-germline genes, viral antigens and neoantigens 
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which arise from genetic mutations or rearrangement of gene-coding sequences in 
tumour cells, as they are tumour specific (269,270).  
In research, model tumour antigens can be used, they are not expressed in cancers, but 
are well characterised to test immunotherapies. Transgenic mouse models have been 
established to recognise specific peptide epitopes of the model antigens. In this study 
the model tumour antigen ovalbumin (OVA) is used as transgenic mouse models are 
available with T-cell receptors that either recognise the MHC-I epitope SIINFEKL 
(OVA257-264, OT-I model) or the MHC-II epitope OVA323-339 (OT-II model) (271,272).  
 
1.3. Vaccination 
Vaccination to immunise the body against invading pathogens has a long history, from 
Edward Jenner’s experiments with cowpox in the late 1700’s to the large variety of 
vaccines preventing infections caused by approximately 25 microbes that are available 
today (273). Vaccination is considered second only to clean water in reducing mortality 
rates, saving every year approximately 2.5 million lives and protecting over 750,000 
children from disability (274,275). The aim of vaccines is to initiate a potent immune 
response and establish long-term protection against the vaccinated disease. Vaccines 
developed in past decades have been highly successful in controlling or eradicating 
several former severe diseases such as smallpox, tetanus, polio or measles, these 
vaccines mainly targeted viral and selected bacterial infections (276).  
Traditional vaccines are delivered as whole live-attenuated or inactivated pathogens. 
These vaccines display a strong initial immune response followed by a long lasting 
protective immune memory. This activity is linked to the resemblance of the vaccine 
pathogens to the active disease-causing pathogen. Furthermore the PAMPs intrinsic to 
the pathogen as well as the high levels of diverse immunogenic antigens contribute to 
the effectiveness of traditional vaccines (154). There are however risks involved in using 
live-attenuated or inactivated pathogen vaccines. The attenuated pathogen can revert to 
virulence, causing severe infection, or live viruses can be shed from vaccinated 
individuals which can cause a threat to immune-compromised patients and non-




vaccinated individuals (277). Additionally the use of inactivated or attenuated 
pathogens has been associated with adverse effects including anaphylaxis, encephalitis 
or neurological complications (278). Due to these safety issues and to address concerns 
of the anti-vaccination movement which has led to a drop in vaccination rates in 
industrial countries, research has focused on the development of subunit vaccines.  
Subunit vaccines only utilize one part of the pathogen, such as either DNA, peptides or 
proteins (274). They pose lower risks to patients, as due to their nature they cannot revert 
to an active pathogen and they can be produced synthetically or recombinant to a high 
quality standard (279). Nowadays the majority of vaccines used are subunit vaccines. 
As subunit vaccines only utilise a single feature as an antigen they lack further danger 
signals to cause a strong and lasting immune response which can lead to inefficient 
protection of the patient against the disease (280,281). In order to address this lack of 
danger signals and to produce strong immune responses leading to long lasting 
protection, subunit vaccines need to be formulated with immunostimmulatory 
adjuvants (282,283). Examples for licensed subunit vaccines are the influenza vaccine 
Fluarix Quadrivalent (GlaxoSmithKline) (284); the meningitis B vaccine Bexsero 
(Novartis) (285); the hexavalent vaccine Hexyon (Sanofi Pasteur), a paediatric vaccine 
formulation against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and 
invasive infections caused by Haemophilus influenza type b (286) and the human 
papilloma virus (HPV) vaccines Gardasil (Merck) and Cervarix (GlaxoSmithKine) (287). 
These vaccines all induce an antibody mediated immune response targeted against the 
specific pathogen, not a cellular, T-cell mediated response that is needed for anti-tumour 
responses. 
 
1.4. Cancer immunotherapy 
Given the success of vaccination to protect the body from viral and bacterial infections 
and the knowledge of the immune response to cancer, research has been focussed on 
using a similar mechanism to protect or cure the body from cancer. The first experiments 
date back to 1891 when William Coley injected streptococcal preparations into patients 
with cancer. The cancer regressed when inflammation as a result of infection started 
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(154,288,289). Traditional vaccines against viral or bacterial infections work well as 
quickly generated antibodies can neutralize the pathogens. However, for a response 
against cancer cells a traditional antibody-mediated vaccination response is not suitable 
as a cellular response is needed (290). Activation of CTL and TH cells are essential for 
eradication of cancer cells and cancer vaccination has therefore focused on modulating 
the immune system to establish and enhance cellular responses against tumour 
antigens. Treatments to complement traditional cancer treatment by targeting residual 
cells are investigated with the focus on cancer immunotherapy.  
Cancer immunotherapy is a wide research area with the aim to employ intrinsic immune 
responses of the body to clear cancer cells in order to generate a systemic, long-lasting 
immunity against cancer. It can be classed into “passive” and “active” immunotherapy. 
Passive or adoptive immunotherapy is based on administration of ex-vivo activated 
tumour lymphocytes or tumour reactive antibodies. Active immunotherapy is designed 
to stimulate an immune response by vaccinating against specific tumour antigens or 
amplifying an existing immune response through administration of adjuvants or 
proinflammatory molecules (270). The main focus of investigation is on (i) activation of 
T-cells either in vivo or in vitro to target cancer cells and (ii) overcoming the 
immunosuppressive microenvironment generated by tumours.  
Adoptive cell transfer (ACT) is based on harvesting cells of interest from the patient, 
manipulating them in vitro and then re-administering them back into the patient to 
stimulate an anti-tumour response. (291). The most common ACT is done with T-cells, 
but also in vitro activated and antigen loaded DC have been studied (292,293). ACT with 
T-cells stimulates patient T-cells in vitro by expanding highly active tumour-specific T-
cell populations to large numbers and injecting them back into the patient. Tumour 
specific T-cells from patients however are often supressed in their proliferative and 
cytotoxic activity (294). Recent approaches have therefore been to genetically modify the 
T-cell repertoire to ensure antigen specificity by modification of genes encoding antigen 
receptors in a process called “genetic redirection of specificity” (295). Methods to 
genetically modify T-cells include the introduction of antigen-specific TCR genes into 
recipient T-cells from the patient (296,297) and the use of chimeric antigen receptors 




(CAR). CARs are comprised of three parts, an antibody that binds to a specific tumour 
antigen, a part of the TCR that activates the T-cell and co-stimulatory molecules that 
ensure the proliferation and persistence of the T-cells (298). Genes encoding CARs are 
transfected into patient T-cells and the genetically modified T-cells are adoptively 
transferred back into the patient. Once the CAR binds to its specific tumour antigen 
counterpart, T-cell activation into effector cells is induced to mediate tumour regression 
through induction of cytotoxicity (295,298–300). Numerous clinical trials with both 
genetically modified and unchanged patient T-cells have shown promising results, 
however before these therapies can be universally licensed some challenges have to be 
addressed. ACT is a lengthy process, patients have to wait 4-6 weeks until their T-cells 
are ready for reinjection. Production facilities with specialized staff for expanding 
patients’ T-cells are still rare and only available at certain locations worldwide. Another 
major factor for consideration of ACT is the cost on the health system as the personalized 
manufacturing of ACT per patient is expensive unless the time for cell expansion can be 
radically reduced (298).  
Monoclonal antibodies (mAb) are another passive form of immunotherapy which have 
been used for over 15 years. mAbs have been developed to a variety of targets. Cell 
surface antigens on tumour cells that are either specific for the tumour, are 
overexpressed or mutated are a prime target. The mAb either directly act on the cancer 
by changing the antigen or a receptor function, marking the cell for immune-mediated 
killing, delivery of a ligand or by regulating T-cell function (166,301). All these 
mechanisms have been proven clinically and licensed for treatment. Direct action of the 
mAb on the tumour by blockage of cell signalling, leading to abrogation of tumour cell 
growth is targeted with the licensed mAb cetuximab (Erbitux, anti- epidermal growth 
factor receptor mAb). This treatment is successfully used to treat forms of colorectal, 
head and neck and non-small cell lung cancer (302). Induction of ADCC and 
complement dependent cytotoxicity is utilized by the mAb trastuzumab (Herceptin, 
anti-Her2 mAb) which is used as a therapy for breast cancer (303). mAbs are also used 
in the form of targeted cancer therapy. The mAbs deliver therapeutic agents to the 
tumour site to improve specificity and efficacy of the treatment. These agents include 
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chemotherapeutic agents, cytokines, radioactive isotopes, toxins or whole conjugated 
cells (301,304–306).  
Immune-checkpoints are inhibitory pathways in immune cells that are crucial for 
modulating the duration and quality of immune responses to minimise tissue damage 
and maintaining self-tolerance (307). Immune checkpoints are primarily activated 
through direct receptor-ligand interaction (308,309). Tumour cells have been shown to 
gain immune resistance through activation of immune-checkpoint pathways, 
specifically through activation of the cytotoxic T lymphocyte antigen-4 (CTLA-4) and 
programmed death 1 (PD-1) immune regulators on T-cells (310,311). mAbs have been 
developed to block the immune-checkpoint regulators, thereby enhancing anti-tumour 
immunity by T-cells (312–314). Examples of mAbs investigated as checkpoint inhibitors 
include ipilimumab (CTLA blockade) and pembrolizumab (PD-1 blockade) (313,314). 
As previously described, cytokines secreted by immune cells regulate both innate and 
adaptive immune responses by enhancing activation, proliferation, differentiation, 
effector functions and survival of leukocytes (315). The suitability of cytokines as cancer 
immunotherapy have been explored as they can modulate the immune system to 
increase anti-tumour responses. Several cytokines have been licensed already and are 
used as immunotherapy treatments (IFN α, IFN-β, IFN-γ, IL-2, granulocyte macrophage 
colony-stimulating factor (GM-CSF) and TNF-α-1a) while others are being investigated 
in clinical trials (IL-7, IL-12, IL-15, IL-18 and IL-21) for a variety of tumours including 
melanoma, lymphoma and lung cancer (315,316). A drawback of cytokine therapy is 
that the cytokines are administered systematically. The systemic administration can lead 
to systemic inflammation, vascular leakage syndrome and it reduces the efficacy of the 
cytokines as their concentrations at the tumour sites are low. To improve the specificity 
of the treatment and minimalize adverse effects, antibody-cytokine fusion bodies, 
“immunocytokines” have been investigated to target the cytokines specifically to the 
cancer site (315).  
Active immunotherapy by therapeutic vaccination against cancer is based on generating 
a strong CTL response to kill the cancer cells as well as induction of long-lived memory 
T-cells that protect the body from relapse (86). The immune response is directed against 




tumour antigens that are either cancer specific or overexpressed in the cancer cells (270). 
A range of vaccine strategies has been developed, aiming to present the tumour antigens 
either as peptides or whole proteins to T-cells as current findings propose that T-cell 
clones with their extensive variety of antigen receptors have the diversity and 
adaptability to target the complex biology of cancers (317). In the majority of vaccine 
formulations DCs are the targeted APC as DCs display a high diversity in antigen 
uptake as well as processing and presentation. In addition to DCs, also macrophages or 
NKT cells have been studied as targets for vaccination (251,253,318). Hallmarks for 
effective therapeutic vaccination are activation of T-cells and their displayed features. 
Both CTL and CD4+ T-cells need to be activated to elicit a strong immune response, with 
CD4+ T-cells enhancing CD8+ T-cell activation and memory formation (86,319,320). 
Features that the effector T-cells need to display are: production of high levels of 
perforin and granzymes; high affinity and avidity of TCR; migration into tumour and 
persistence there and a high proliferation potential (86). To analyse how effective T-cells 
are at killing cancer cells, their capacity for degranulation as well as the production of 
IFN-γ can be measured (321).  
DC based vaccines have shown initial promising results in inducing a strong CTL 
response to tumour antigens in animal models but have then fallen short to deliver 
strong anti-cancer results in clinical trials (322–324). The cancer vaccine Sipuleucel-T 
(Provenge®) which has been developed for prostate cancer, has been shown to increase 
the survival of the patients by 4 months on average (325,326). Sipuleucel-T was the first 
licensed cancer vaccine as it showed successful anti-cancer effects in clinical trials. Many 
other anti-cancer vaccines could either not provide successful anti-cancer effects in 
clinical trials or only similar small improvements in the overall survival rate were 
observed (327).  
There are different theories why the developed vaccines show good results in animal 
models but not in clinical trials. For example DCs might not be completely activated to 
produce the right conditions and amount of cytokines and chemokines to fully activate 
cytotoxic T-cells. If DCs are not fully activated and matured they can produce anti-
inflammatory cytokines such as IL-10 or TGF-β which instead of activating, dampen the 
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immune response. Immunosuppressive Treg could get activated, these suppress DCs and 
CTLs. Due to the immunosuppressive nature of Treg cells, the balance of CTL to Treg in 
the tumour microenvironment is important for the success of a vaccine (173). The 
tumour antigen needs to be correctly presented on the fully activated DC on MHC-I as 
wells as MHC-II with the additional expression of co-stimulatory receptors for a 
complete T-cell response of both CTL as well as TH cells. If T-cells upregulate the 
immune-checkpoint CTLA-4 receptor and co-stimulatory molecules from APCs bind to 
CTLA-4 instead of the stimulatory CD28 receptor, an inhibitory effect is exerted (262). 
Once activated, CD4+ T-cells need to secrete immunostimmulatory cytokines like IFN-
γ to create a paracrine and autocrine stimulatory environment to activate CD8+ CTL 
and additional CD4+ T-cells. In case CD4+ T-cells are not antigen-specific they can 
secrete Type 2 cytokines such as IL-4 and IL-5 which do not allow CTL activation (86). 
T-cells are exhausted when they are constantly exposed to antigen without further 
stimuli and as a result of this they cannot be activated completely. This is the case in 
chronic diseases, including cancer, where DCs constantly present antigens without 
being fully activated. In T-cell exhaustion, chronic antigen expose induces T-cells that 
display an altered differentiation state from effector and memory T-cells. Characteristics 
for exhausted T-cells have been described to include upregulation of inhibitory 
receptors such as PD-1, CTLA-4, LAG-3 and TIM-3, loss of effector functions as well as 
failure to differentiate, transfer into quiescence and acquire antigen-independent T-cell 
memory functions (328,329). 
The task of immunotherapy vaccines is to ensure strong activation of APCs, 
presentation of antigens to T-cells with upregulated co-stimulatory molecules and 
strong activation of T-cells with active cytokine production. Additionally exhausted T-
cells are aimed to be reversed to naïve T-cells so that they can differentiate and 
proliferate again (86,262). The two main component of active immunotherapy vaccines 
are therefore a vaccine adjuvant that induces a strong innate stimulation of APCs and 
the choice of the tumour antigen.  
 




1.5. Vaccine adjuvants 
Adjuvants are added to vaccines to help with the stimulation and activation of the 
immune system and to establish an immune memory. Adjuvants contribute to the 
immune response in several ways, these include (i) reduction of the needed antigen 
dose, (ii) reduction of the total number of doses given, (iii) reduction of the non-
responder rate, (iv) induction of a broader antibody response by inducing a greater 
magnitude and functionality of antibodies, (v) enhancement of the general 
immunogenicity towards the antigen and (vi) induction of a specific cell-mediated 
immunity. First described by Gaston Ramon in the 1920s as agents that induce an 
increased immune response towards an antigen, many different formulations have been 
identified since then. Adjuvant can be grouped into two classes: delivery systems which 
help targeting the vaccine to the desired site and immunopotentiators that boost an 
immune response by enhancing, prolonging as well as accelerating the immune reaction 
(283,330–333). The classifications are very broad, as some immunopotentiators 
additionally target to a specific cell type while delivery systems can have 
immunostimmulatory effects, thereby blending the borders between the classifications. 
Examples of adjuvants helping with delivery of the antigen are microparticles, 
liposomes, mineral salts, virosomes, cell penetrating peptides (CPP) or emulsions. The 
carriers protect the antigens from degradation, allow for a longer and sustained release 
and target the antigen to APCs (333). Immunopotentiators such as the TLR agonists CpG 
oligodeoxynucleotides (ODN), LPS, flagellin or lipopeptides stimulate PRRs on APCs 
(283,331). Nucleic acids that are being used as immunopotentiators, including CpG or 
polyinosinic-polycytidylic acid (poly I:C), induce the generation of high levels of type I 
IFN (42,51,86,330,334). There are examples of vaccine formulations that combine both 
classes of adjuvants. For example the HPV vaccine Cervarix (GSK) utilises both an 
immunopotentiator as well as a delivery agent by incorporating both monophosphoryl 
lipid (MPL) A, an adjuvant containing certain structures of LPS and alum, a mineral salt 
in the formulation (283,335). 
Usage of adjuvants in approved vaccines has been very limited, from the 1920s when 
they were developed until 2009 only mineral salts (alum) had been licensed in the 
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United States. In Europe, MF59™, the first non-alum adjuvant was licensed in 1997 and 
has been successfully administered in the influenza vaccination Fluad® (Novartis) to 
over 65 Million people. A summary of vaccine adjuvants currently licensed and 

























Table 1.2: Vaccine adjuvants licensed and in clinical investigations 





1.5.1.1. Mineral salts  
Mineral salts (aluminium phosphate, aluminium hydroxide or aluminium potassium 
sulphate; summarised as ‘alum’) were first investigated in the 1920s as vaccine 
adjuvants that enhance antibody responses. Due to its well-established safety profile 
and billions of doses given alum has been extensively used in a wide variety of vaccines, 
including hepatitis A and B vaccines, diphtheria and tetanus vaccines (336). Only 
recently more studies have discovered different mechanisms of action by alum apart 
from enhancing antibody responses. Alum has been shown to form aggregates which 
absorb antigen on their surface, thereby acting as a delivery system for the antigens. The 
alum aggregates form a depot around the site of injection enhancing uptake of the 
antigen into APCs. Additionally alum generates a nonspecific local inflammation which 
recruits further immune cells. The immune response induced by alum has been 
demonstrated to be mediated through activation of the nucleotide-binding domain 
leucine-rich repeat-containing protein 3 (NLRP3) (338). This induces a response biased 
towards a TH2 type response, including production of IL-4, IL-5, IL-13 and the antibodies 
IgE and IgG1 (274,339,340). The strong induction of a TH2 response is undesired for 
vaccination against cancer or intracellular viruses where a strong CD8+ T-cell response 
is required. By combining alum with other adjuvants, such as MPL for example the TH2 
response can be skewed into a more cellular, TH1-type response.  
 
1.5.1.2. Monophosphoryl lipid A (MPL) 
MPL is derived from LPS from the gram-negative bacterium Salmonella Minnesota R595. 
Like LPS, MPL binds to TLR4 and stimulates it to induce an immune response however 
it does not induce the high toxicity of excessive inflammatory cytokine production that 
pure LPS displays (341,342). By signalling through TLR4, MPL enhances IFN-γ 
production which is desired for a strong TH1-type anti-cancer immune response (342). 
Formulation of MPL in either a liposome (AS01), in an oil-in-water emulsion (AS02) or 
with alum (AS04) have been successful in clinical trials and AS01 has been approved for 
vaccination against Hepatitis B virus (Fendrix®) and HPV (Cervarix®, both from 
GlaxoSmithKline (GSK)) (283).  





Emulsions (mineral oil-in-water) have been developed in the 1930s as vaccine adjuvants 
but it hasn’t been until 1997 that the water-in-oil emulsion MF59 was licensed as a 
vaccine adjuvant in Europe. The incomplete Freud’s adjuvant (IFA) emulsion was used 
as a vaccine adjuvant in influenza vaccines in the 1960s but was withdrawn due to 
several strong local reactions and is only used in veterinary medicines today (343,344). 
MF59 was developed in the 1990s, licensed as a vaccine adjuvant in 1997 in Italy and in 
several European states in the following years while it is expected to be licensed in the 
USA in the coming years. It is a water-in-oil emulsion based on squalene which forms 
<250 nm droplets and induces a balanced TH1/TH2 response as well as increases antibody 
titers (345,346). Once administered MF59 increases the uptake of antigen into APCs as 
well as stimulates the production of cytokines and chemokines to enhance the activation 
and migration of DCs (336,347). AS03 contains an oil-in-water emulsion similar to MF59 
as well as α-tocopherol and was licensed in Europe in 2008 for use in the pandemic 
influenza vaccine Prepandrix® (GSK) (336).  
 
1.5.1.4. Emerging adjuvants 
Traditional vaccines using live attenuated or also inactivated pathogens have been 
successful in combination with alum or also emulsions. Part of their success however is 
also attributed to the pathogens’ intrinsic adjuvant features, especially PAMPs (LPS, 
flagellin, CpG-containing DNA). Adjuvants under investigation are trying to 
incorporate TLR agonist features to induce a strong, directed immune response for use 
in subunit vaccines. They are of special interest in regards to creating a cellular T-cell 
response for cancer, human immunodeficiency virus (HIV), malaria or tuberculosis 
vaccination (49,283,334). A variety of adjuvants targeting TLRs are tested in clinical trials 
with promising results especially for the TLR9 agonist CpG ODN, TLR5 agonist flagellin 
and different formulations and combinations of the TLR4 agonist MPL (283,336). The 
TLR9 agonist CpG ODN that is used in this study has been tested in over 100 clinical 




1.6. Cytosine-phosphate-guanosine oligodeoxynucleotides 
(CpG ODN) 
DNA containing CpG motifs which are enclosed by two 5’ purines and two 3’ 
pyrimidines is recognised as pathogenic DNA by the immune system due to the 
following features: (i) in eukaryotic DNA CpG sequences are suppressed or occur only 
with immunosuppressive flanking sequences, (ii) bacterial and viral CpG DNA 
sequences are unmethylated while vertebrate CpG sequences, if they are expressed at 
all, are methylated (348–351) and (iii) TLR9 is located in the endosome of immune cells, 
which is free from chromosomal DNA, therefore only pathogenic DNA can reach it. The 
endosomal location of TLR9 allows for degradation of bacteria and viruses inside the 
cell which frees the pathogenic DNA, thereby allowing for interaction with TLR9 (352).  
 
1.6.1. CpG ODN as vaccine adjuvants 
CpG ODNs are used as a vaccine adjuvant as they activate APCs including DC and B-
cells in humans and myeloid derived cells like monocytes, macrophages, myeloid DCs 
and NK cells in mice and improve their antigen presenting function (353). Activation of 
TLR9 induces a downstream signalling cascade generating a TH1 immune response, 
leading to a release of IFN-γ and IL-12, which are TH1 cytokines that repress a TH2 
response (43). The generation of a TH1-type immune response makes CpG ODN a 
suitable adjuvant for cancer therapy. CpG has been tested in numerous clinical trials for 
cancer therapy and is considered a safe adjuvant, however it has not been licensed yet 









Table 1.3: CpG ODN used as adjuvant in clinical trials 
Adapted from Shirota et al. (2014) (348,356–366) 
 
 
CpG is used as a vaccine adjuvant in form of an ODN and not as natural bacterial DNA 
as the ODN are designed to improve activation of APCs through a stable backbone. 
Additionally CpG motifs are placed at distinct intervals and directions in the ODN 
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which induces a superior adjuvant effect compared to natural bacterial DNA. ODNs 
containing one or several CpG motifs are single-stranded, short DNA strands and are 
manufactured with a phosphorothioate (PT) or a phosphodiester (PDE) backbone. The 
PT backbone stabilizes the ODN against degradation by nucleases. Increasing its 
stability is achieved by substituting a non-bridging oxygen of the phosphate group to a 
sulphur atom (367). For PT ODNs, CpG motifs are necessary to activate APCs, therefore 
PT ODNs lacking CpG motifs cannot stimulate APCs, although they also bind to TLR9. 
PDE ODN are more susceptible to nuclease degradation than PT ODN. They also 
display a difference in TLR9 activation compared to PT ODN as PDE ODN lacking CpG 
motifs can activate APCs, however to a much lesser degree than with CpG motifs 
(331,368,369). PD and PT backbone ODNs containing CpG motifs exhibit different 
properties of APC activation, not only on magnitude but also on type of immune 
response, therefore depending on what immune response is wanted the specific 
backbone is selected. An example is that for secretion of IFN-α in plasmacytoid DCs a 
conventional PD base linkage is preferable over a PT ODN (367). Also the number, 
distance between and orientation of CpG motifs modify the observed immune response. 
Best immune activation was shown with ODN sequences containing two to four CpG 
motifs with a space of at least two nucleotides in between. Thymine residues in between 
CpG motifs have been shown to result in the best activity of the ODN (350). ODNs can 
be grouped into different classes, as shown in Table 1.4. Class B CpG ODNs can be 
further distinguished by orientation and number of CpG motifs, the most common ones 
used are 1668 and 1826 CpG, with 1668 having two CpG motifs in opposite directions: 
5’-tccatgacgttcctgatgct-3’ and 1826 having two CpG motifs in the same direction: 










Table 1.4: Classification of CpG oligodeoxynucleotides (ODN) 
Adapted from Krieg et al. and Klinman et al. (55,64) 
 
 
1.6.1.1. Immune response towards Class B CpG ODNs 
CpG ODNs activate APCs through binding to TLR9 in the endosome, inducing both 
adaptive and innate immune responses. In resting cells TLR9 is located in the ER but 
upon uptake of CpG ODN, TLR9 is trafficked from the ER into the endosome. The usual 
trafficking way from the ER to the endosome is via the Golgi apparatus, but for TLR9 it 
has been hypothesised that it is shuttled directly from the ER into the endosome by ER-
mediated phagocytosis (331,352,371). Once TLR9 and CpG ODN are in the endosome, 
TLR9 binds to CpG ODN by changes in the ectodomain of TLR9 (372). Binding of TLR9 
onto CpG ODN induces a signalling cascade that proceeds through the activation of 
myeloid differentiation primary response 88 (MyD88), interleukin-1-receptor associated 
kinase (IRAK) and tumour-necrosis factor-α receptor activated factor-6 (TRAF-6). 
Upregulation of pro-inflammatory genes is subsequently facilitated through activation 
of mitogen-activated protein (MAP) kinases and the transcription factors nuclear factor 
kappa-light-chain-enhancer of activated B-cells (NF-κB), activator protein (AP) 1 and 
interferon regulatory factor (IRF-7) (42,373). About 1000 genes are upregulated that are 
important for immune response, cell movement as well as cell signalling (42,374). 
Prominent changes in DCs and macrophages are expression of MHC-I and MHC-II, co-
stimulatory molecules CD40, CD80 and CD86 as well as production of type I IFN, TNF-
α, IL-1, IL-6, IL-12 and IL-18 (42,351). It also causes changes in the DC phenotype, 
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leading to differentiation into mature APCs with increased antigen processing and 
presentation (349). In B-cells, TLR9 activation through CpG ODNs also lead to 
upregulation of co-stimulatory molecules, secretion of cytokines and chemokines (IL-6, 
IL-12, CXCR3 chemokines) and secretion of IgM antibodies (355,375,376). Amongst the 
many responses and activation cascades, secretion of type I IFN enhances the 
cytotoxicity of CD8+ T-cells, TH1 and NK cells (377,378), IL-6 contributes to activation of 
T-cells and B-cells and IL-12 regulated IFN-γ production by T-cells, contributing to both 
T-cell and NK cell activation. 
Taken together, CpG induces a TH1-type immune response that supports activation and 
maturation of APCs, differentiation, proliferation and persistence of CTL, TH1 cells and 
NK cells as well as production of opsonizing antibodies (379–381).  
 
1.7. Co-delivery of antigen and adjuvant 
Complex pathogens induce the most robust cellular immune responses as they induce 
DC maturation through PRR binding as well as antigen processing and presentation at 
the same time (382). Since pure subunit vaccines like purified protein or peptides do not 
induce the required immune response, vaccine strategies against tumour cells are being 
developed with properties that mimic pathogen composition and immunological 
processing to generate similar strong immune responses (383). Delivery of antigen and 
adjuvant into the same APC at the same time has been shown to induce a stronger 
cellular immune response compared to delivery of antigen and adjuvant as a mixture 
(351,353,384,385). A variety of delivery systems have been developed to co-deliver 
antigen and adjuvant, these include either particulate vaccine formulations or soluble 
conjugates. Particulate formulations developed include nano- and microparticles while 
soluble formulations simply conjugate antigen directly to adjuvant. In the literature 
there is controversy as to whether antigens delivered in soluble or particulate form 
induce a stronger immune response.  
A variety of studies show that delivery of antigen in a particulate form induces a 
stronger immune response than soluble antigens. This greater immune response is 




believed to be due to the particles resembling biological pathogens such as viruses and 
bacteria (383). However the preferred particle size for strong immune stimulation is 
under discussion with a range of studies showing different particle sizes to be optimal 
and some studies also showing that soluble formulations can generate a strong immune 
response (137,386–389). The particle size of the vaccine formulation has been shown to 
determine antigen transport into lymph nodes. Particles larger than 200 nm are taken 
up by peripheral APCs and transported to lymph nodes while soluble formulations and 
particles smaller than 200 nm can drain directly into lymph nodes to be internalised by 
resident APCs (83,84).  
The different sized particles influence the uptake mechanism by APCs which 
determines their processing pathway and thereby influences the extent of cross-
presentation and activation of T-cells. Antigen internalised by macropinocytosis and 
then transported into late endosomes has been shown to be loaded onto MHC-II 
molecules for presentation to CD4+ T-cells while antigen internalised by receptor-
mediated endocytosis into early endosomes has been shown to be cross-presented onto 
MHC-I molecules (55,386,390). The main internalisation route for particulate 
formulations is through receptor-mediated endocytosis which may explain the 
observed enhanced cross-presentation. Soluble formulations however have been shown 
to be internalised both via macropinocytosis and via receptor-mediated endocytosis 
(mainly the mannose receptor) leading to presentation of epitopes on both MHC-I and 
MHC-II molecules (137,391). A previous study directly compared the effect of OVA 
formulated with a pH responsive carrier in a nanoparticle (NP) and OVA directly 
conjugated to the carrier in a soluble formulation. Interestingly the particle showed 
better performance in vitro compared to the soluble formulation while in vivo tumour 
studies showed comparable protection against the tumour by both the particulate and 
the soluble OVA formulations (392). This was believed to be due to limited access to the 
antigen through unpacking of the complexed particle in the APC. 
Particulate formulations have been shown to be more effective than soluble 
formulations when delivered orally, as particles can be engineered to protect the antigen 
load from degradation in the gastrointestinal tract, allowing for specific uptake of 
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microparticles in the Peyer’s patches in the small intestine. Macrophages then transport 
intestinally internalised microparticles to the spleen and lymph node for immune 
activation (393–395).  
Biodegradable particles displaying either sustained or tunable release profiles have been 
investigated as a delivery form for antigen and adjuvant to APCs (396–398). Although 
co-delivery of antigen and adjuvant in the biodegradable particles induces strong anti-
cancer immune responses, the sustained release of antigen and adjuvant can also induce 
an immunosuppressive environment and expansion of tumour specific Treg cells (399).  




NPs are a versatile delivery method by which antigen and adjuvant can be encapsulated 
in NP to be protected from degradation or can be attached to the NP surface to mimic 
biological pathogens. Particles smaller than 1000 nm are classed as NP (400). Different 
materials are being explored to prepare NPs including viral envelopes, lipids, micelles 
and polymers. NPs have displayed enhanced protection of antigen from degradation 
compared to soluble antigen (401,402). However, concerns about safety of NPs in 
humans have been raised, as materials have been shown to take on different 
characteristics when formulated into NPs (400,403,404). As an example, gold is routinely 
used as an inert material for implants but when formulated into 1.4 nm NPs, it diffuses 
through membranes and binds irreversibly to DNA grooves which causes instability of 
the DNA (405).  
Virus-like particles (VLP) consist of empty viral envelopes which are used as particles 
to deliver vaccines. Viral structural proteins self-assemble into a viral envelope, 
mimicking the structural confirmation of the source virus (406,407). The size of VLP 
varies between 20 – 150 nm dependent on the source virus used. As no viral genomic 
DNA or RNA is used, VLPs are non-replicating and non-infections, displaying a high 
safety profile (408). Antigen for immunotherapy can be either (i) encapsulated in VLP, 




(ii) associated with or conjugated to the surface, or (iii) the VLP can be modified to 
express the desired antigen in the inside or on the outside of the envelope (409). Multiple 
antigens can be delivered by VLP simultaneously, either through assembly of multiple 
different viral proteins to form a chimeric envelope or loading of multiple antigens onto 
a pre-assembled VLP (410). VLPs can be engineered to be self-adjuvanting or adjuvants 
can be conjugated to the surface of the VLP. 
Liposomes are self-assembling NPs, they consist of a phospholipid bilayer shell with an 
aqueous core (411,412). Antigen and adjuvant can be either incorporated into the 
hydrophilic core or the hydrophobic bilayer, dependent on their polarity. Liposomes 
can be synthesised in a variety of sizes, with typical sizes ranging from 20 – 400 nm 
(413). A limit of liposomes as a delivery form is however the reproducibility of antigen 
loading, as the concentration of antigen in liposomes has been shown to vary between 
preparations (414).  
Immune-stimulating complexes (ISCOM) are colloidal saponin containing micelles with 
a size of about 40 nm. They self-assemble from a mixture of cholesterol, phospholipids 
like phosphatidylethanolamine or phosphatidylcholine and saponin. For 
immunotherapy, antigens are trapped inside the micelles and as ISCOM are self-
adjuvanting, additional adjuvants can be omitted for delivery, as tested in clinical trials 
(415,416).  
Polymeric NPs are biodegradable with the release kinetics for the delivered antigen and 
adjuvants being adjustable dependent on the composition of polymers used 
(398,417,418). Commonly used polymers for NP preparations are poly(α-hydroxy 
acids), including poly(lactic-co- glycolic acid), polysaccharides and poly(amine acids) 
(419–422). The properties of the preparations can be modified dependent on what 
characteristics are required for the antigen and adjuvant delivery (400). Molecules can 
be either entrapped or displayed on the surface and the core and surface can be adjusted 
to be either hydrophobic, hydrophilic or amphiphilic. The size of polymeric NPs is in 
the range of 20 – 400 nm, dependent on the polymers used. 
Non-degradable NPs are commonly made from gold, carbon or silica, the antigen is 
either entrapped in the core or conjugated onto the surface (423). The rigid structure of 
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these inorganic NPs is easily modified to attach antigen and adjuvant molecules and the 
production is controlled with a size range of 2 – 150 nm and fabrication into different 
shapes like spheres, rods or cubes (424,425). Non-degradable NPs display good 
biocompatibility but accumulation of NPs in cells and toxicity of very small NPs should 
be further addressed (426). 
 
1.7.2. Microparticles 
Microparticles are a delivery system in the micrometre size range with characteristics 
similar to polymeric NPs. The larger size was developed to mimic bacterial pathogen 
size more closely to generate a stronger and longer lasting immune response compared 
to smaller particles. However a range of studies have been inconclusive of the relative 
effectiveness of microparticles compared to NPs or soluble antigens (68,386,387). 
Biodegradable polymers such as poly(α-hydroxy acids) are commonly used to 
formulate microparticles. The microparticles are designed to either encapsulate both 
antigen and adjuvant or one or both components are adhered on the surface allowing 
for immune recognition of the particle and controlled release of the loaded antigen, 
adjuvant or both. With the controlled slow release of loaded vaccine components, 
microparticles were hoped to show the potential as delivery systems for single-shot 
vaccinations, making the administration of boost injections redundant. However, a 
pulsed release of vaccine components as in booster vaccine doses may generate a 
stronger immune response than continuous release of antigen in microparticles (427).  
 
1.7.3. Three-dimensional biomaterials 
Biomaterials provide a stable site for presentation of tumour antigens and vaccine 
adjuvants to immune cells. Three-dimensional biomaterials can be either fabricated in 
vitro as an implant which requires surgical placement or self-assembling scaffolds have 
been developed which allows injection of the material that then assembles into a three 
dimensional scaffold in vivo (428,429). Porous biomaterials have been shown to attract 
and provide residence for APCs where they are programmed by the presented antigen 




and adjuvants to then home to the lymph node as fully matured APCs (429,430). 
Antigen and adjuvant can be either immobilised on the material to be presented in situ 
to APCs or loaded onto the material in conjunction with cytokines for slow release to 
APCs. This in situ material mimics a solid tumour site which may enhance induction of 
a cellular anti-tumour response (428–430).  
 
1.7.4. Soluble formulations 
Co-delivery of antigen and adjuvant as a soluble formulation is an alternative approach 
to particulate delivery systems. Antigen and adjuvant are directly chemically 
conjugated to each other which ensures uptake of both components into the same APC 
at the same time (431–433). To further enhance efficacy by cell targeting, additional 
conjugation of an antibody to target a specific uptake receptor or addition of a specific 
cell-penetrating peptide to enhance internalisation of conjugate into APCs have been 
explored (335,434). Compared to particulate formulations, soluble vaccines may be 
internalised through a variety of mechanisms, including receptor-mediated endocytosis 
through the MR or DEC-205 and macropinocytosis. Internalisation via a variety of 
uptake mechanisms may lead to induction of a stronger cellular immune response 
compared to phagocytosis restricted uptake of particulate formulations due to 
presentation of antigen epitopes on both MHC-I and MHC-II molecules (55,68,137,435–
437).  
 
1.8. Conjugation of tumour antigen to vaccine adjuvant 
Co-delivery of tumour antigen and vaccine adjuvant for enhanced immune stimulation 
is achieved through chemical conjugation of the two molecules. Conjugation links 
molecules via a chemical bond either through direct conjugation of the two molecules 
or via a chemical cross-linker.  
Cross-linkers employed are designed either as a homobifunctional or a 
heterobifunctional linker, a homobifunctional linker contains the same functional 
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groups on both ends of the linker while the heterobifunctional linker has a different 
functional group on either end of the linker. Homobifunctional linkers are limited by 
specificity as they can conjugate the same two molecules together instead of linking the 
vaccine adjuvant to the tumour antigen (438). Heterobifunctional linkers enable the 
specific conjugation of two different molecules at each end, for example one end of the 
cross-linker reacts specifically with an amine group on a tumour antigen while the other 
functional group reacts selectively with a thiol group on the vaccine adjuvant CpG (439). 
The functional groups targeted for conjugation are either naturally occurring groups on 
proteins or artificial groups that are introduced to the vaccine adjuvant or tumour 
antigen. These functional groups used in conjugation reaction are described in the 
following sections. 
 
1.8.1. Primary amines 
Amines exist on the side chain of the amino acids lysine, histidine and on the N-terminus 
of each polypeptide chain. The most commonly targeted amines for conjugation are the 
primary amines on the lysine side chain and on the N-terminus of the protein. As these 
primary amines are positively charged at physiological pH, they are typically exposed 
on the outside of proteins, making them accessible for conjugation without 
compromising the secondary or tertiary structure of the proteins (439). Figure 1.4 shows 
primary amines on the model tumour antigen OVA as an example for their ubiquitous 
presence on proteins. The figure was made by obtaining the protein sequence from the 
National Center for Biotechnology Information (NCBI) and generating the OVA 
structure with the “Cn3D macromolecular structure viewer”, highlighting all lysines in 
the sequence. The accessibility and ubiquitous availability of primary amines on 
proteins makes them the most common target for conjugation. Many different reactive 
groups have been found to form a stable chemical bond with primary amines, with 
acetylation and alkylation reactions being the common reactions used. An acetylation 
reaction comprises addition of the active carbonyl group to the amine group while in an 
alkylation reaction the alkyl group of the linker is transferred to the amine group, losing 
a hydrogen atom (439–441). Of all reactions that are used for conjugating onto an amine 




group, N-hydroxysuccinimide (NHS) ester chemistry is the most common. The NHS 
ester group on a linker reacts with the primary amine to form a stable amide bond while 
releasing NHS, as shown in Figure 1.5 (442–444). Since the rate of NHS group hydrolysis 
increases with pH above neutral, the reaction is typically performed between pH 7.2-
8.5.  
Primary amines can also be modified into other functional groups to be used for 
different conjugation chemistries. This gives more flexibility for the choice of 
conjugation reaction as the functional groups of interest may either not be available on 
proteins or may be less accessible than amines as they are located more in the middle of 
the protein. In some cases direct conjugation may destroy the secondary or tertiary 
structure of the protein. An example for introducing a new functional group for specific 
conjugation is the introduction of a thiol group to an amine. The cyclic thiomidate 
compound 2-iminothiolane (2-IT), also known as ‘Traut’s Reagent’ reacts with the 
primary amine in a ring-opening reaction to generate a free thiol group (445). This 
modification does not affect the charge properties of the protein. The cross-linker 
succinimidyl 3-(2-pyridyldithio)propionate (SPDP) can be used as an alternative to 2-IT 
to modify primary amines into thiol groups. The NHS ester group on one end of SPDP 
reacts with the primary amine to form a stable amide bond. The disulphide group in the 
cross-linker is then reduced by a disulphide reducing agent like dithiothreitol (DTT) to 





Figure 1.4: Three dimensional molecular structure of the model tumour antigen 
ovalbumin  
Lysine amino acids containing primary amine residues in their side chain are highlighted in 
yellow 
 
1.8.2. Thiol groups 
Thiol groups (sulfhydryl groups) are the second most commonly targeted functional 
groups for conjugation, however cysteine is the only amino acid with a side chain that 
contains a thiol group. The cysteine thiol group exists either as a free cysteine (-SH) or a 
disulphide (S-S) in the protein. As free thiol groups are present only in low number in 
proteins, conjugation onto them can be very selective, targeting only the few free thiols 
or disulphide bonds available (447). Other functional groups such as amines and 
carboxylates can be modified into thiols to generate more available thiol groups to 
conjugate onto. Similar to amine reactive linkers, many different functional groups have 
been discovered to form covalent bonds when reacted with thiols. The formation of a 
covalent bond with thiol groups either occurs through alkylation or disulphide 
exchange. For disulphide exchange reactions, disulphide bonds in the protein are 
targeted for conjugation which involves breaking them to attach the linker onto the 
generated free thiol. This strategy is however limited as the disulphide bonds are 




important for the stability of the protein structure and therefore also the protein 
function.  
Maleimide groups are popular functional groups used to form a stable thioether bond 
between the double bond of the maleimide and a free thiol in an alkylation reaction. The 
alkylation reaction is specific for thiols at pH values of 6.5-7.5 as at this pH the 
maleimide reaction with thiol groups is typically 1000 times greater than an alkylation 
reaction with an amine (448).  
 
1.8.3. Carboxylate groups 
The amino acids aspartic and glutamic acid both contain carboxylate side chains, which 
can be targeted for conjugation. However as carboxylate groups are unreactive to 
nucleophilic addition reactions only limited carboxylate reactive linkers have been 
developed (439). One successful reaction to conjugate onto carboxylate groups is 
facilitated through carbodiimides. Conjugation of carboxylate to an amine group via 
carbodiimides is a two – step process. The carbodiimide first reacts with the carboxylate 
to form a reaction intermediate, called O-acylisourea. In a second step, the intermediate 
is removed by a nucleophilic attack by the amine group and the amine forms a stable 
amide bond with the carboxylate. The carbodiimide by-product is released as a soluble 
urea derivative (449,450). As carbodiimides only facilitate the conjugation without being 
part of the final chemical bond they are referred to as zero-length linkers. Like primary 
amines, carboxylic groups can also be modified into thiol groups to utilise thiol reactive 
conjugation strategies on more side groups than just the naturally occurring cysteine 
side group (451).  
 
1.8.4. Aldehyde groups 
Aldehyde groups are a common target for conjugation strategies, however they are not 
naturally present on proteins or other biologic macromolecules. Aldehyde groups for 
conjugation can be created by modification of an existing functional group, for example 
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an amine group (439). An example for this is the modification linker succinimidyl 4-
formylbenzoate (4FB). The NHS group on one end of the 4FB linker is reacted with a 
primary amine to introduce an aromatic aldehyde on to the molecule of interest (452).  
The aldehyde group can be reacted with either a primary amine or a hydrazine group. 
When reacted with a primary amine through reductive amination, a Schiff base is 
formed between the aldehyde and the amine. Typically this Schiff base linkage is not 
stable and requires an additional reducing step to be converted into a highly stable 
alkylamine linkage (453,454). An alternative approach to make a stable linkage is to react 
the aldehyde group with a hydrazine group, creating a hydrazone linkage (see Figure 
1.5). Hydrazone formation results in a more stable linkage than the reductive amination, 
however to form a secure covalent linkage an additional reduction reaction may be 
performed (455–457). Solulink Inc. has developed an innovative reaction technology 
linking an aromatic aldehyde to an aromatic hydrazine group to form a stable bis-
arylhydrazone bond, which does not require a reducing step for bond stability. The 
formation of the bis-arylhydrazone bond can be accelerated by the addition of aniline, 
resulting in fast reaction kinetics. In addition, the bis-arylhydrazone bond has been 
shown to be colorimetric, simplifying quantification of the conjugation product (452).  
 
1.8.5. Azide groups 
Apart from naturally occurring functional groups, artificial functional groups can be 
introduced into proteins or adjuvants to facilitate conjugation via bioorthogonal click 
chemistry. Bioorthogonal reactions are highly selective, show fast reaction kinetics and 
are inert to biological functions (458,459). Azide groups are popular functional groups 
used for click chemistry as unlike the side groups of amino acids, they do not naturally 
occur in biological systems and do not react with biological molecules. Copper-
catalysed click reactions between azide and alkyne groups are used in a variety of 
application due to their selective and fast reaction. Copper is however cytotoxic at low 
concentrations, therefore copper-catalysed reactions are undesirable for conjugates used 
in cells. An alternative is the use of copper-free click chemistry, in this reaction azide 
groups selectively react with cyclooctynes in a cycloaddition reaction to form a triazole 




product. The reaction kinetics are very fast due to the high ring strain of the cyclooctyne 
molecules, which is released when reacted with the azide (458). Azide groups are also 
used in copper-catalysed cycloaddition reactions. 
 
Figure 1.5: Chemistry for conjugation reactions 
Common functional groups for conjugation reactions are outlined: primary amines, carboxylate, 
thiol, aldehyde and azide groups. 
 
1.9. Triggered release delivery systems 
A triggered drug release system is designed to selectively release the active agent from 
the delivery device when it reaches a specific target location in the body. This drug 
release can be activated either by an internal or an external trigger. The triggered release 
of the drug enhances the bioavailability and efficacy of the drug at a specific target site 
while reducing adverse side effects or toxicity in surrounding healthy tissues (453). 
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Targeted drug delivery is especially important in cancer therapy where only cancer cells 
should be selectively targeted without harming healthy surrounding cells. Typically, 
these triggerable drug delivery systems are either in the form of a drug polymer 
conjugate or entrapped in a particle which is sensitive to a trigger.  
Different stimuli have been explored as triggers to induce release of the active drug, 
these include external and internal stimuli. Internal stimuli can be further classed into 
extracellular and intracellular stimuli, depending on whether they act inside or outside 
of the cell.  
Mechanisms explored as externally applied triggers include temperature, magnetic 
field, ultrasound and light (460–463). An example are drug encapsulating micellular 
microbubbles sensitive to ultrasound. These microbubbles release their drug load when 
the specific target site is sonicated, while microbubbles at other places in the system stay 
intact (464). Externally applied triggers actively target a specific site of the body and 
they ensure minimally invasive delivery of the drug to the target site, however they can 
be limited by the depth of penetration into tissues.  
Apart from the more conventional drug delivery research, triggered release systems 
have also shown potential for the delivery of immunotherapeutic vaccines. Triggered 
release systems for immunotherapies are designed to allow concurrent uptake of 
antigen and adjuvant by APCs but to then release the antigen and the adjuvant inside 
the cell. Release of the antigen and adjuvant inside the cell is hypothesised to induce 
enhanced processing of antigen for presentation on MHC-I and MHC-II molecules as 
well as enhanced APC activation by the adjuvant. Particulate formulations have been 
investigated that co-deliver tumour antigen and vaccine adjuvant into APCs which 
release the antigen, adjuvant or both when cleaved by a specific targeted trigger 
(383,465,466). Reversible conjugation of antigen to an APC delivery carrier has also been 
reported, the carrier targeted delivery of the antigen into the APC and was then cleaved 
from the antigen by a specific trigger (467). 
For immunotherapeutic vaccines, internal, intracellular stimuli are targeted that induce 
release of the vaccine components inside the APC. Examples for internal triggers used 
for drug delivery and immunotherapy are detailed below: 




1.9.1. Enzyme facilitated triggered release 
Enzymes can be used as a specific internal trigger, a protease or lipase can specifically 
cleave peptide or lipid linkers, respectively. Linkers developed for enzyme cleavage 
should be designed as specific substrates for the enzyme that is exclusively found at the 
targeted site. An example is the lipid enzyme phospholipase A which is upregulated in 
certain tumours. It has been used as a targeted trigger for liposomes carrying a cytotoxic 
drug load. Upon interaction with phospholipase A the drug is released from the 
liposomes to the tumour (462).  
Cathepsin is a cysteine protease, Cat B and S are well studied protein enzyme triggers 
used for drug delivery. Cat B is ubiquitously found in endo-lysosomal compartments in 
almost all healthy tissues, its main function is associated with hydrolysis of intracellular 
and endocytosed extracellular proteins (468). In tumour cells however, Cat B is also 
present in various other vesicles throughout the cytoplasm and is excreted into the 
tumour microenvironment where it takes part in degrading the extracellular matrix for 
tumour proliferation, invasion and metastasis (469). The peptide linker glycyl-phenyl-
alanyl-leucyl-glycine (GFLG) tetra-peptide was developed as a substrate for Cat B (470) 
for use in the anti-cancer drug PK1. In PK1, the GFLG tetra-peptide links the 
chemotherapeutic agent doxorubicin to the polymer backbone N-(2-
hydroxypropyl)methacrylamide (HPMA). HPMA reduces toxicity caused by 
doxorubicin to surrounding tissue and prolongs the circulation of the drug compared 
to free doxorubicin. When the PK1 drug encounters Cat B in the tumour 
microenvironment, Cat B cleaves the peptide linker and thereby releases doxorubicin to 
act on the tumour (471,472). PK1 is currently tested in phase II clinical trials 
(469,473,474).  
In contrast to the ubiquitously expressed Cat B, Cat S is selectively expressed in endo-
lysosomes of APCs, where it aids in antigen processing and loading onto MHC-I and 
MHC-II molecules, as described in Section 1.6.3 and 1.6.4 (469,475). Various peptide 
sequences that are known to be cleaved by Cat S have been studied as selective linkers 
for intracellular triggered release of conjugates specifically targeted to immune cells. 
However, due to the broad specificity of Cat proteases, many substrates cleaved by Cat 
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S are found to be also cleaved by Cat B or Cat L. Only the two peptide sequences 
GRWPPMGLPWE and GRWHPMGAPWE have been identified to be specifically 
cleaved by Cat S (476,477).  
 
1.9.2. pH-dependent triggered release 
The physiological pH in the blood and the cytosol of cells is stable between 7.2-7.4 while 
endosomes show a reduced pH of 6-6.8. During the endosomal maturation the pH drops 
to 5-6 in late endosomes to reach an acidic pH of 4-5 in lysosomes (478). Biological 
systems use the change in pH to their advantage, viruses for example enter cells through 
endocytosis into endosomes where the low pH triggers a conformational change of the 
viral proteins. The changed viral proteins induce penetration through, fusion with or 
even disruption of the endosomal membrane in order to enter the cytosol for infection 
of the cell (478). Following the example of viruses, acid-labile delivery systems or linkers 
are designed to hydrolyse at specific low pH levels in endosomal and lysosomal targets. 
A variety of acid-labile chemical linkers have been identified that hydrolyse at low pH, 
these include acetals, cis-aconityl linkers, hydrazones, imines and electron-rich trityl 
linkers (479). For drug delivery, components are either directly linked via the cleavable 
linkers or are encapsulated by particles cross-linked through cleavable linkers. Acid-
labile microparticles made from acetal-crosslinked hydrogel particles that encapsulate 
a tumour antigen and vaccine adjuvant have been developed to transport antigen and 
adjuvant into the same APC but to then disintegrate at a low pH to release the load. 
These microparticles induced a stronger anti-tumour immune response than co-
administered unbound antigen and adjuvant, however they were not compared to an 
uncleavable formulation (383).  
pH specificity is important for the success of acid-labile linkers in targeted delivery. The 
linkers need to be stable at physiological pH long enough to get to their target e.g. in the 
endosome of an APC, to be then cleaved by the pH trigger. Not all acid-labile linkers 
show the same pH specificity as different side groups around the cleavable bonds 
influence their stability towards hydrolysis (480). Hydrazone linkers are the most 
popular and well-studied pH triggered linkers, they are easily prepared under mild 




conditions in aqueous solutions which is advantageous for linking proteins or DNA 
(478). To design a hydrazone linked conjugate that is hydrolysed at the desired pH, the 
chemical side groups around the hydrazone bonds have to be taken into account. 
Previous studies with different hydrazone derivatives have shown that aryl-, oxime- 
and phenylhydrazones are very stable at both physiological pH of 7.4 and lysosomal 
pH of 4.5 due to oxygen and amine groups around the linker that prevent hydrolysis 
(480,481). Acyl- and sulfonylhydrazones on the other hand show slow hydrolysis at pH 
7.0 and much faster hydrolysis at pH 4.5. These hydrolysis rates have been attributed to 
the presence of carbonyl or sulphonyl groups next to the hydrazone that allow 
delocalisation of their lone electron pair to support cleavage of the hydrazone bond 
(481). 
A major limitation for pH triggered conjugates over other triggerable approaches is their 
storage stability. Compared to enzyme facilitated and reduction triggered cleavable 
linkers, acid-labile conjugates are prone to slow hydrolysis at physiological pH on 
storage.  
 
1.9.3. Reduction triggered release 
The different reductive environment within the compartments of the cell compared to 
the outside of the cell provides an opportunity for targeted triggered release of 
disulphide bond linked formulations. A disulphide bond (S-S) is a covalent bond that 
results from oxidation of two free thiol groups. In a biological system the thiol groups 
originate from cysteine side chains while for drug delivery they can be synthetically 
introduced into a molecule of interest (see Section 1.8.2). A reducing agent can cleave 
the disulphide bond to create two free thiol groups.  
It is known that the reduction-oxidation (redox) state of proteins depends on whether 
they are located outside or inside the cell. Extracellular proteins are mainly oxidised, 
they contain disulphide bonds that take part in their structure and function while 
disulphide bonds are generally absent in intracellular proteins unless they are part of 
an enzymatic mechanism (482,483). The differences in the redox state are due to a strong 
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intracellular reductive environment which is maintained by redox proteins and small 
redox molecules. Typically, the redox molecules and proteins require the co-presence of 
enzymes to regenerate and thereby retain their reducing activity. Redox proteins and 
molecules include the thioredoxin family, cysteine, γ-interferon-inducible lysosomal 
thiol reductase (GILT) and glutathione (GSH) (484–487).  
The redox potential and type of redox protein or molecule used for reduction of 
disulphide bonds differs between compartments of the cell. In endosomes and the Golgi 
redox proteins of the thioredoxin family are the main reductants while GILT and 
cysteine are the main reductants in lysosomes. Unlike the reductive environment in 
endosomes and lysosomes, the ER is kept in an oxidative state. This oxidative state is 
maintained by a ratio of reduced GSH to oxidised glutathione disulphide (GSSG) that 
allows the formation of disulphide bond containing proteins. GSH is also the main redox 
molecule in the cytosol, however unlike in the ER, the ratio of GSH to GSSG is biased to 
the reduced GSH, maintaining a redox state that is 100 times more reducing than that in 
the ER (483,488). 
GSH is a tripeptide with the amino acid sequence of L-γ-glutamyl-L-cysteinyl-glycine. 
Being the main reductant in the cytosol and contributing to the redox state in intra- and 
extracellular environments, it is the most abundant low molecular weight thiol in animal 
cells (489). Intracellularly, GSH is present at high concentrations of 0.5-10 mM while 
extracellularly it is present at micromolar concentrations of 2-40 µM (478,490). As the 
main reducing agent, GSH plays a role in a number of different biochemical functions 
including regulation of immune responses, antioxidant defence, nutrient metabolism 
and regulation of cellular events including gene expression and DNA and protein 
synthesis. The deficiency in GSH has been linked with enhanced pathogenesis of cancer 
due to accumulation of oxidative stress in cells leading to increased DNA mutations 
(490). For controlling immune responses, the reductive state inside APCs has been 
linked with induction of TH-cell responses. Low levels of GSH in APCs promote a TH2-
type response while high levels of GSH in APCs promote a TH1-type cell response (491).  
The reduction of disulphide substrates by GSH is shown in Figure 1.6. In its reduced 
state, GSH has a free thiol on the cysteine residue. This free thiol group on the GSH 




molecule attacks the disulphide bond in the substrate in a disulphide exchange reaction. 
Reduction of the substrate involves two GSH molecules. First a free GSH molecule 
reduces the disulphide bond on the substrate to form a GSH-substrate mixed disulphide 
and a substrate free thiol. A second GSH molecule then releases the other part of the 
substrate with a free thiol and forms the oxidised form of GSH, the glutathione 
disulphide (GSSG) molecule. Regeneration of GSH from GSSG is mediated through the 
enzyme glutathione reductase (GRS). GRS uses nicotinamide adenine dinucleotide 
phosphate (NADPH) as a co-factor to reduce one molecule of GSSG to two molecules of 
GSH (488,492). 
Due to the differences in reductive potential between extra- and intracellular 
environments, development of reducible linkers has been popular for intracellular 
targeted triggered formulations. Drug components are either directly conjugated via a 
disulphide bond containing linker or are formulated in reduction-cleavable particles 
that disintegrate in the reductive intracellular environment (493,494). The anti-cancer 
drug conjugate coltuximab ravtansine, SAR3419 (ImmunoGen, Inc.) is an example for a 
reduction cleavable conjugate. In this drug a B-cell lymphoma targeting mAb is 
conjugated to a cytotoxic agent via a reducible disulphide bond containing linker. 
Coltuximab ravtansine is tested in phase II clinical trials as a tumour-activated prodrug 
that acts through direct cytotoxicity when internalised and cleaved inside tumour cells 
(495,496).  
Similar to pH responsive linkers, the stability of disulphide linkers towards GSH 
depends on chemical side groups around the disulphide bond. For example, disulphide 
conjugates linked using succinimidyl 3-(2-pyridyldithio)propionate (SPDP) showed to 
be unstable in circulation in vivo when tested in mice. Experiments in vitro confirmed 
that the unhindered disulphide bond generated from the SPDP linker is reduced faster 
than other disulphide cross-linking agents which had bulky chemical side groups 
adjacent to the disulphide bond (497,498). For a conjugate designed to be cleaved by 
intracellular concentrations of GSH, the stability towards extracellular reducing 
conditions is critical to prevent cleavage of the conjugate in the bloodstream before 





Figure 1.6: Glutathione (GSH) reduces disulphide substrate to free thiols 
(1) GSH attacks disulphide bond in substrate, forms a GSH-substrate mixed disulphide and a 
free thiol from substrate; (2) a second GSH molecule reduces GSH-substrate disulphide and 
forms the oxidised glutathione disulphide (GSSG) with the first GSH molecule, the second 
substrate is freed; (3) GSSG is reduced back to GSH by the nicotinamide adenine dinucleotide 
phosphate (NADPH) dependent glutathione reductase (GSR). 
  




1.10. Thesis statement 
The aim of this thesis was to develop improved tumour antigen-vaccine adjuvant 
conjugates to generate an effective anti-tumour immune response. 
Previous research has shown that conjugation of tumour antigen to vaccine adjuvant for 
co-delivering them to the same APCs at the same time induces enhanced anti-tumour 
immune responses over delivery of the antigen and adjuvant as a mixture (335,431,432). 
However, it is not known whether direct chemical conjugation of the antigen and 
adjuvant limits the processing of antigen and adjuvant by the APC.  
The objective of this study was therefore to design a reversible antigen-adjuvant 
conjugate that is cleaved inside an APC, using OVA as a model tumour antigen and 
CpG as a clinically relevant vaccine adjuvant. The reversible antigen-adjuvant conjugate 
is designed to remain stable at extracellular conditions, to be internalised by the APC as 
a conjugate and to then be cleaved inside the APC by a specific intracellular 
environmental trigger. The release of antigen from adjuvant inside the cell may enhance 
processing of the antigen by the APC as well as enhance activation and maturation of 
the APC through improved adjuvant binding. This enhanced activation of the APC 
processing of the antigen may lead to enhanced presentation of antigen epitopes to T-
cells and thereby generate an improved cellular, TH1-type anti-cancer immune 
responses. Figure 1.7 displays an overview of this concept. The hypothesis tested in this 
study was therefore whether intracellular reversible conjugation of antigen to adjuvant 





Figure 1.7: Concept for cleavable antigen-adjuvant conjugates 
A soluble conjugate of ovalbumin (OVA, antigen) and CpG (adjuvant) is internalised by an 
antigen-presenting cell and cleaved by an intracellular trigger. Release of CpG from OVA may 
enhance processing of OVA for presentation on MHC-I and MHC-II and activation and 
maturation of the APC by CpG. Presentation of antigen epitopes on the activated APC may lead 
to enhanced activation and proliferation of cytotoxic T cells and T helper 1 cells which induce 


























2.1. Conjugation of CpG to OVA 
2.1.1. General experiment procedures  
2.1.1.1. Desalting and buffer exchange of samples  
For sample volumes of 400 µl or less a Vivaspin® 500 centrifugal concentrator (Amicon 
Ultra - 0.5ml Centrifugal Filters, Regenerated Cellulose 3000 NMWL, Millipore, Cork, 
IRL) was used, the volume was made up to 500 µl with the buffer detailed in the relevant 
sections and the unit was centrifuged for 15 min at 14,000 x g at 4 °C (5810R centrifuge, 
Eppendorf AG, Hamburg, Germany). When concentrated to approximately 50 μl, 450 μl 
of the relevant buffer was added to the concentrated solution and the spun as described 
above. This process of filtration was repeated five times. After the final spin, the spin 
unit was added in reverse in a new collection tube and spun for 30 sec at 500 x g to 
collect the desalted sample. 
For sample volumes of above 400 µl a Vivaspin® 2 spin filter (3kDa MWCO, GE 
Healthcare UK Ltd., Little Chalfont Buckinhamshire, UK) was used, the volume was 
made up to 3 ml with the buffer detailed in the relevant sections and the unit was 
centrifuged for 30 min at maximum speed of 3442 x g at 4 °C (5415R centrifuge, 
Eppendorf AG). When concentrated to approximately 500 μl, 2.5 ml of the relevant 
buffer was added and centrifuged as described above. This filtration process was 
repeated four times. After the final spin, the spin unit was spun in reverse for 1 min at 
500 x g to collect the desalted sample. 
 
2.1.1.2. Oligodeoxynocleotide estimation 
Oligodeoxynocleotide (ODN) sample (2 µl) and the buffer detailed in the relevant 
sections were added to microtubes containing 998 µl of distilled water and mixed. 
Absorbance at 260 nm using a NanoDrop-1000 spectrophotometer (NanoDrop, Version 
3.7.1, Thermo Fisher Scientific, Waltham, MA, USA) was blanked against the buffer. 
Absorbance of the ODN was measured in triplicate and the obtained average 
absorbance value was divided by two to obtain the OD260/μl concentration. OD260/µl 




was used as an ODN concentration unit in ODN conjugation reactions. The following 
formula was used to convert OD260/µl into molar concentration: 





 x dilution factor 
 
2.1.1.3. Protein estimation by spectrophotometry 
Ovalbumin (OVA) protein concentration was estimated by measuring the absorbance 
at 280 nm in triplicate using the standard extinction coefficient E1%=7.2 at 280 nm specific 
for OVA using the NanoDrop instrument (499,500). The protein concentration was 
calculated using the following formula:  
Protein concetration =
A280
(7.2 x MW(OVA) x 0.1) x 0.1cm
 x dilution factor 
 
2.1.1.4. Preparative size-exclusion chromatography 
Preparative size-exclusion chromatography (SEC) was carried out on a Shimadzu LC-
10ATvp chromatography system (Shimadzu, Columbia, MD, USA). Samples were 
prepared in phosphate buffered saline (PBS, Sigma-Aldrich, St. Louis, MO, USA) or the 
relevant conjugation buffer and 500 µl was injected onto a Superdex™ 200 10/300 GL 
SEC column (GE Healthcare Bio-Sciences, Uppsala, SE) equilibrated in PBS. The flow 
rate was set to 0.5 ml/min and the UV-Vis detector was set to either 260 or 280 nm. 
 
2.1.1.5. Protein estimation by Quant-iT Protein Assay kit 
Quant-iT Protein Assay Kit (Thermo Fisher Scientific) was used to estimate OVA protein 
concentration in conjugates. Quant-iT™ protein reagent was diluted 1:200 in Quant-iT™ 
protein buffer and 200 µl of the working solution were added to wells in a black 96-well 
plate. BSA standard (10 µl) at 0, 25, 50, 100, 200, 300, 400, and 500 ng/µL and conjugate 
samples (5 µl) were added to the designated wells in duplicate in the microplate. The 
fluorescence was measured with a POLARStar Omega microplate reader (BMG Labtech 
GmbH, Ortenberg, Germany) with the excitation and emission filter set to 485/590 nm. 
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A standard curve was plotted from the fluorescence of the supplied standards at known 
concentrations. The protein content of the samples was calculated by extrapolating from 
the standard curve. 
 
2.1.2. Oligodeoxynocleotide preparation 
ODNs were custom-synthesised by GeneWorks Pty Ltd, Hindmarsh, AUS, supplied 
lyophilized and stored at 4 °C as recommended by the supplier. The following ODNs 
were used: PDE CpG 1668 (5’ TCCATGACGTTCCTGATGCT 3’) unmodified or with a 
5’ amine modification, PDE GpC (5’ TCCATGAGCTTCCTGATGCT 3’) unmodified or 
with a 5’ amine modification, PT CpG 1668 (5’ TCCATGACGTTCCTGATGCT 3’) 
unmodified, with a 3’ or 5’ amine modification or a 3’ or 5’ thiol modification. Prior to 
conjugation, ODN were briefly spun down (12,000xg, 1 min) as per suppliers 
recommendation, resuspended in the appropriate buffer, left to rehydrate for 5 min and 
vortexed for equal mixing. ODNs were then desalted into the buffer detailed in the 
relevant sections, the concentrated ODNs were collected and the OD260/μl was 
measured (see Section 2.1.1.1 and 2.1.1.2). For conjugation the OD260/μl concentration 
was adjusted using the relevant buffer to between 0.2 and 0.5. 
 
2.1.2.1. Reduction of thiol modified CpG 
Thiol labelled CpGs were reduced as per manufacturer’s recommendation. Lyophilized 
thiol modified CpG (CpG-SH) were dissolved in reducing buffer containing 10 mM 
dithiothreitol (DTT, Sigma-Aldrich) (Appendix 1) and incubated at room temperature 
for 10 min. CpG-SH were purified from DTT by preparative SEC (see Section 2.1.1.4), 
concentrated in a Vivaspin 2 filter unit (see Section 2.1.1.1) and the OD260/µl 
concentration was determined (see Section 2.1.1.2). 
 
2.1.3. OVA preparation 
Lyophilised OVA (purity ≥98 %, Sigma-Aldrich) was dissolved in PBS at a concentration 
of 10 mg/ml. The OVA solution was purified from aggregates by preparative SEC (see 




Section 2.1.1.4) before conjugation, OVA monomer was collected on ice and the 
concentration was determined by spectrophotometry (see Section 2.1.1.3). 
 
2.1.4. Synthesis of bis-aryl hydrazone linked conjugates 
2.1.4.1. Modification of CpG 
ODNs modified with terminal amines were desalted (see Section 2.1.1.1) into 
modification buffer (Appendix 1). A 20 mg/ml stock solution of succinimidyl 4-
formylbenzoate (4FB, Solulink Inc., San Diego, CA, USA) or succinimidyl-SS-4-
formylbenzoate (4FBSS, Solulink) was prepared in 50 μl anhydrous dimethyl sulfoxide 
(DMSO, Thermo Fisher Scientific). ODNs were reacted with at a 20-fold molar excess of 
the 4FB or 4FBSS linker for 2 h at room temperature. Modified ODNs were then 
exchanged into conjugation buffer (Appendix 1) to remove unreacted linker. The 
OD260/µl concentration was determined following the protocol as detailed in Section 
2.1.1.2. 
 
2.1.4.2. Molar substitution ratio of oligonucleotides 
A 0.5 mM solution of 2-hydrazinopyridine·2HCl (2-HP, Solulink) in 0.1 M 
2-(N-morpholino)ethanesulfonic acid (MES, Appendix 1) buffer was prepared. The 
2-HP solution (18 µl) was added to a microcentrifuge tube and 2 μl of either conjugation 
buffer or modified oligonucleotide were added and mixed. Both tubes were incubated 
at 37° C for 30 min. The samples were then analysed at 360 nm using the NanoDrop 
instrument. The A360 result was adjusted for the 1 mm path length by multiplying the 
result by 10 and the molar extinction coefficient of 24,000 M-1cm-1 was used for the 
chromophore product. The molar substitution ratio (MSR) of S-4FB and S-SS-4FB were 
calculated using the following formula: 
 
𝑀𝑆𝑅 =









2.1.4.3. Modification of OVA 
Purified OVA was exchanged into modification buffer (Appendix 1, see Section 2.1.1.1) 
and the concentration of OVA was determined by spectrophotometry (see Section 
2.1.1.3). A stock solution of 20 mg/ml succinimidyl 6-hydrazinonicotinate acetone 
hydrazone (HyNic) was prepared in 50 μl anhydrous DMSO. OVA was reacted with a 
40-fold exess of the HyNic linker for 2 h at room temperature. Modified OVA was then 
exchanged into conjugation buffer (Appendix 1) to remove unreacted linker (see Section 
2.1.1.1). 
 
2.1.4.4. Molar substitution ratio of OVA 
A 0.5 mM solution of 2-sulfobenzaldehdye (2-SBA, Solulink) in 0.1 M MES buffer 
(Appendix 1) was prepared. The 2-SBA solution (18 µl) was added to a microcentrifuge 
tube 2 μl of either conjugation buffer or the modified OVA were added and mixed. Both 
tubes were incubated at 37° C for 30 min. The samples were then analysed at 345 nm 
using the NanoDrop instrument. The A345 result was adjusted for the 1 mm path length 
by multiplying the result by 10 and the molar extinction coefficient of 28,500 M-1cm-1 




𝐴350 𝑥 𝑀𝑊(𝑂𝑉𝐴) 𝑥 𝑡𝑜𝑡𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝑖𝑛 𝑎𝑠𝑠𝑎𝑦
28,500 𝑥 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑂𝑉𝐴 𝑥 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑂𝑉𝐴 𝑖𝑛 𝑎𝑠𝑠𝑎𝑦
 
 
2.1.4.5. Conjugation of ODN to OVA 
Hydrazine modified OVA and aldehyde modified ODN were reacted at a molar ratio 
of 4:1 in the presence of TurboLink buffer (Appendix 1) at room temperature. The 
samples were analysed every 30 min at 345 nm using the Nanodrop instrument until no 
more change in absorbance was observed. Following completion of the reaction the 
molar extinction coefficient of 29,000 M-1cm-1 was used for the chromophore product 














Unreacted CpG and linker were removed using preparative SEC (see Section 2.1.1.4) 
and the conjugates were collected on ice. Conjugates were concentrated with a Vivaspin 
2 filter unit (see Section 2.1.1.1). The conjugate was exchanged into Dulbecco’s PBS 
(DPBS; Gibco Invitrogen, Green Island, NY, USA) by dialysis (SnakeSkin Dialysis 
Tubing, 10kDa MWCO, Thermo Fisher Scientific, IL, USA) overnight at 4 °C with two 
buffer exchanges to remove residual contaminations from the spin filters. The conjugate 
was quantified using a Quant-iT protein kit (see Section 2.1.1.5). 
 
2.1.5. Synthesis of SPDP linked conjugate 
2.1.5.1. OVA modification 
Succinimidyl 6-(3-[2-pyridyldithio]-propionamido)hexanoate (LC-SPDP) linker vial 
stored at 4 °C was first equilibrated to room temperature then prepared as a 20 mM 
stock in DMSO. Purified OVA in PBS (see Section 2.1.3) was reacted with a 40-fold molar 
excess of the LC-SPDP linker at room temperature for 30 min. Pyridyldithiol-activated 
OVA was then exchanged into fresh PBS to remove unreacted linker (see Section 2.1.1.1). 
 
2.1.5.2. Molar substitution ratio of OVA 
Pyridyldithiol-activated OVA was diluted 1 in 10 in PBS and the absorbance at 343 nm 
was measured by Nanodrop instrument. The pyridyldithiol attached to OVA was 
reduced by adding 1 µl of DTT (15 mg/ml in PBS) to 100 µl of the diluted pyridyldithiol-
activated OVA. After 15 min the absorbance at 343 nm was measured to determine the 
amount of pyridine-2-thione released. The change in absorbance (ΔA343) was calculated 
by subtracting the absorbance of the reduced sample from the absorbance of the initial 
sample. The experiment was performed in triplicate. The molar substitution ratio of 
pyridyldithiol to the protein was calculated with the following formula, using the 
extinction coefficient of 8080 M-1cm-1 for pyridine-2-thione: 










2.1.5.3. Conjugation of pyridyldithiol-activated OVA to CpG-SH 
Reduced CpG-SH (see Section 2.1.2.1) was desalted into PBS (see Section 2.1.1.1) and the 
OD260/μl concentration was measured (see Section 2.1.1.2). CpG-SH was reacted with 
the pyridyldithiol-activated OVA at a molar ratio of 4:1 at room temperature overnight. 
Unreacted CpG was removed by preparative SEC (see Section 2.1.1.4) and the conjugate 
pools were collected on ice. The C-SPDP-O conjugate was concentrated with a Vivaspin 
2 filter unit (see Section 2.1.1.1). The conjugate was exchanged into DPBS by dialysis 
(SnakeSkin Dialysis Tubing, 10kDa MWCO, Thermo Fisher Scientific) overnight at 4 °C 
with two buffer exchanges to remove residual contaminations from the spin filters. The 
conjugate was quantified using a Quant-iT protein kit (see Section 2.1.1.5). 
 
2.1.6. Synthesis of polyethylene glycol spacer linked conjugate 
The heterobifunctional polyethylene glycol (PEG) linker of maleimide (MAL) and N-
Hydroxysuccinimide (NHS) MAL-dPEG4-NHS (Quanta BioDesign, Powell, OH, USA) 
was dissolved in anhydrous dimethylacetamide (DMAc) at a stock concentration of 
500mg/ml, sealed under an inert atmosphere and stored at -20 ºC in 50 µl aliquots. 
Reduced CpG-SH (see Section 2.1.2.1) was desalted into PBS (see Section 2.1.1.1) and the 
OD260/μl concentration was measured (see Section 2.1.1.2). CpG-SH was reacted with 
a 30-molar excess of MAL-dPEG4-NHS for 2 h at room temperature. PEG modified CpG 
was exchanged into fresh PBS (see Section 2.1.1.1) to remove unconjugated linker.  
Purified OVA in PBS (see Section 2.1.3) was reacted with the PEG modified CpG at a 
molar ratio of 4:1 at room temperature overnight. Unreacted CpG and linker were 
removed by preparative SEC (see Section 2.1.1.4) and the conjugate pools were collected 
on ice. The C-PEG-O conjugate was concentrated with a Vivaspin 2 filter unit (see 
Section 2.1.1.1). The conjugate was exchanged into DPBS by dialysis (SnakeSkin Dialysis 
Tubing, 10kDa MWCO, Thermo Fisher Scientific) overnight at 4 °C with two buffer 
exchanges to remove residual contaminations from the spin filters. The conjugate was 
quantified using a Quant-iT protein kit (see Section 2.1.1.5). 
 




2.1.7. Synthesis of peptide linker conjugate 
2.1.7.1. OVA modification 
Dibenzocyclooctyne-N-hydroxysuccinimidyl ester (DBCO-NHS) was prepared at a 
concentration of 10 mM in DMSO. Purified OVA in PBS (see Section 2.1.3) was reacted 
with a 30-fold molar excess of DBCO-NHS for 30 min at room temperature. OVA-DBCO 
was exchanged into fresh PBS to remove unconjugated DBCO linker.  
 
2.1.7.2. Peptide modification 
The heterobifunctional peptide linker of MAL and azide (N3) 
MAL-propyl-GRWPPMGLPWEK-N3 was custom synthesised (Peptide Protein 
Research Ltd., Fareham, UK) and stored at -20 °C. The peptide linker was prepared at a 
concentration of 3 mg/ml in DMSO and then reacted with OVA-DBCO at a molar ratio 
of 4:1 at room temperature overnight. Peptide modified OVA was exchanged into fresh 
PBS (see Section 2.1.1.1) to remove unconjugated peptide.  
 
2.1.7.3. Conjugation of OVA-peptide to CpG-SH 
Reduced CpG-SH (see Section 2.1.2.1) was desalted into PBS (see Section 2.1.1.1) and the 
OD260/μl concentration was measured (see Section 2.1.1.2). OVA-peptide was reacted 
with a 30-molar excess of CpG-SH for 2 h at room temperature. Unreacted CpG was 
removed by preparative SEC (see Section 2.1.1.4) and the conjugate pools were collected 
on ice. The C-peptide-O conjugate was concentrated with a Vivaspin 2 filter unit (see 
Section 2.1.1.1) and then exchanged into DPBS by dialysis (SnakeSkin Dialysis Tubing, 
10kDa MWCO, Thermo Fisher Scientific) overnight at 4 °C with two buffer exchanges 
to remove residual contaminations from the spin filters. The conjugate was quantified 
using a Quant-iT protein kit (see Section 2.1.1.5). 
 
2.1.8. Fluorescent labelling of OVA with NHS-DyLight633 
NHS-DyLight633 ester dye (Thermo Fisher Scientific) stored at -20 °C was first 
equilibrated to room temperature before use. Purified OVA in PBS (see Section 2.1.3) 
was directly added to the lyophilised NHS-DyLight633 at a 3-fold molar excess of NHS-
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DyLight633 over the moles of OVA and incubated for 1 h at room temperature. The 
DyLight633 modified OVA was exchanged into fresh PBS by dialysis (SnakeSkin 
Dialysis Tubing, 10kDa MWCO, Thermo Fisher Scientific) overnight at 4 °C with three 
buffer exchanges to remove excess dye reagent. The absorbance was measured at 
280 nm as well as 627 nm, as the absorbance maximum of DyLight633, using the 
Nanodrop instrument. The OVA-DyLight concentration was calculated with the 
following formula, using the correction factor of 0.110 provided by the manufacturer 
and the extinction coefficient of 30590 M-1cm-1 for OVA: 
𝑂𝑉𝐴 − 𝐷𝑦𝐿𝑖𝑔ℎ𝑡 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝑀)  =  
(𝐴280 − (𝐴627 x 0.110))
30590 𝑀−1𝑐𝑚−1
  
The degree of DyLight633 labelling was then calculated using the extinction coefficient 
of 170,000 M-1cm-1 for DyLight633: 
𝑚𝑜𝑙𝑒𝑠 𝐷𝑦𝐿𝑖𝑔ℎ𝑡633 𝑝𝑒𝑟 𝑚𝑜𝑙𝑒 𝑂𝑉𝐴 =  
(𝐴627)
170,000 𝑀−1𝑐𝑚−1 𝑥 𝑂𝑉𝐴 𝑐𝑜𝑛𝑐. (𝑀)
  
DyLigh633 labelled OVA was used to synthesise fluorescently labelled C-4FB-O, C-
4FBSS-O (see Section 2.1.4), C-SPDP-O (see Section 2.1.5), C-PEG-O (see Section 2.1.6) 
and C-peptide-O (see Section 2.1.7) conjugates. 
 
2.2. Size-exclusion chromatography characterisation of 
conjugates 
2.2.1. Analytical size-exclusion chromatography 
Analytical SEC analysis was carried out on an Agilent Technologies 1290 Infinity 
Chromatograph (Agilent Technologies, Santa Clara, CA, USA). Samples were prepared 
in the buffer detailed in the relevant sections and 25 µl were injected onto a Phenomenex 
Yarra SEC-2000 column (3 µm, 145 Å pore size, 300 x 4.6 mm; Phenomenex Inc., 
Torrance, CA, USA). SEC phosphate buffer (Appendix 1) was used as mobile phase. The 
flow rate was set to 0.35 ml/min and samples were detected with a diode array (G1315D 
1260 DAD VL, Agilent Technologies). Retention times were recorded and samples were 
analysed with the Agilent ChemStation (Agilent Technologies) software. 
 




2.2.1.1. Calibration curve for analytical SEC 
Prior to analysis one sample of mobile phase and one sample of 1 in 10 diluted Protein 
Standard (Phenomenex Inc.) were run to calibrate the Yarra SEC-2000 SEC column (see 
Section 2.2.1). The retention time of the proteins was plotted against the known 
molecular weight of the protein standards to generate a calibration curve. 
 
2.2.1.2. Glutathione reduction assay 
Glutathione (GSH; Sigma-Aldrich) and DTT were prepared in PBS at stock 
concentrations of 20 mM. Conjugates at a concentration of 400 µg/ml were diluted using 
either PBS, GSH or DTT stock to prepare samples at 75 µg/ml in PBS, 10 µM GSH, 5 mM 
GSH or 5 mM DTT. Samples were incubated for 2 h at 37 °C and following incubation, 
25 µl of each sample were analysed by analytical SEC (see Section 2.1.1).  
 
2.2.1.3. Cell culture media and supernatant reduction assay 
Bone marrow-derived dendritic cells (BMDC) were isolated and cultured as described 
in Section 2.3.2. On day 6 of culture, 500 µl of supernatant was collected from each of 6 
culture plate wells and pooled. Complete Iscove’s Modified Dulbeccos’s Medium 
(cIMDM, Appendix 1) was prepared. Conjugates at 400 µg/ml were diluted to 75 µg/ml 
with either PBS, cell culture media containing 2-mercaptoethanol (2-ME) or cell culture 
supernatant. Samples were incubated overnight at 37 °C and following incubation, 25 µl 
of each sample were analysed by analytical SEC (see Section 2.1.1).  
 
2.2.1.4. Cathepsin S cleavage assay 
Lyophilised recombinant Mouse Cathepsin S / CTSS Protein (Cat S, Sino Biological Inc., 
Beijing, China) was reconstituted in sterile water at 0.15 mg/ml and stored at -80 °C. C-
peptide-O conjugate at 400 µg/ml was diluted to a working concentration of 75 µg/ml 
to a total of 50 µl with either PBS or PBS and Cat S to a final concentration of 0.8 µM Cat 
S. Samples were incubated overnight at 37 °C and following incubation, 25 µl of each 




2.2.1.5. pH stability assay 
PBS at pH 7.4 was adjusted to pH 6.0 and pH 5.0 by addition of hydrochloric acid (HCl). 
Conjugates at 400 µg/ml were diluted to 75 µg/ml with either PBS at pH 7.4, 6.0 or 5.0. 
The pH values in the diluted conjugates were tested by adding 10 µl of each conjugate 
solution to pH indicator paper (DuoTest®, Macherey-Nagel GmbH&Co.KG, Dueren, 
Germany) and the resulting colour was compared to the pH colour chart. The conjugates 
in the different pH solutions were incubated overnight at 37 °C. Following incubation, 
25 µl of each sample were analysed by analytical SEC (see Section 2.1.1). 
 
2.3. Immunological assays 
2.3.1. Experimental mice 
Male and female C57BL/6 mice and OT-I and OT-II transgenic mice aged 6-12 weeks 
were obtained from the Hercus Taieri Research Unit, University of Otago. OT‐I mice are 
genetically modified to express T-cell receptors specific to the MHC-I restricted OVA 
257-265 epitope (SIINFEKL) and OT‐II mice are genetically modified to express T cell 
receptors specific to the MHC-II restricted OVA 323-339 epitope. Experiments were 
conducted in accordance with ethical permits granted by the University of Otago 
Animal Ethics Committee (AEC 53/14, AEC 09/14 and AEC ET10/13). All animals were 
euthanized by cervical dislocation or carbon dioxide euthanasia. 
 
2.3.2. Generation of bone marrow-derived dendritic cells 
C57BL/6 mice were sacrificed by cervical dislocation, femurs and tibiae were removed, 
cleaned of muscle and tissue and kept in sterile DPBS on ice. The bones were sterilised 
in cold 70 % ethanol for two minutes and washed twice in sterile DPBS to remove 
residual ethanol. Using sterile scissors and tweezers the ends of the bones were removed 
and bone marrow was flushed out with DPBS+5 % foetal calf serum (FCS, Moregate 
Biotech, Bulimba, Australia) using a 25 gauge needle. The bone marrow in DPBS+5% 
FCS was collected in a 50ml tube. Cells were centrifuged (7 min, 250 x g, 4 °C), the 




supernatant was discarded and the pellet was resuspended by gentle pipetting up and 
down. Red blood cells were lysed for three minutes with warm Ammonium Chloride 
Red Blood Cell Lysis Buffer (RBC lysis buffer, Appendix 1). The cells were filtered 
through a 70 µm cell strainer (Corning Inc., Tewksbury, MA) to isolate single cells and 
remove connective tissue. RBC lysis buffer was neutralized with 45 ml DPBS+5 % FCS 
and cells were centrifuged (7 min, 250 x g, 4 °C) for washing. After centrifugation cells 
were resuspended in warm cIMDM+5 % FCS containing 20 ng/ml recombinant mouse 
Granulocyte-Macrophage Colony- Stimulating Factor (GM-CSF; ProSpec, East 
Brunswick, NJ, USA), a 10 μl aliquot was taken out, diluted with 90 μl trypan blue dye 
and total cell numbers were determined using phase-contrast microscopy. Cells were 
resuspended in warm cIMDM+5 % FCS+20 ng/ml GM-CSF and plated into flat bottom 
6-well plates at a concentration of 0.5 x 106 cells/ml. Cells were incubated at 37 °C, 
5 % CO2 to differentiate into murine BMDCs. Every day the appearance of the cells and 
the medium was checked to determine cell health and growth. At day 4 cells were fed 
by replacing 2 ml of old media with 2.5 ml fresh warm cIMDM+5 % FCS+ 20 ng/ml 
GM-CSF. At day 6 DCs were harvested by gently pipetting the cells up and down, 
centrifuged (7 min, 250 x g, 25 °C) and resuspended in cIMDM+5 % FCS for further 
assays as detailed in the sections below.  
 
2.3.3. Preparation of splenocytes 
Splenocytes were prepared as a single cell suspension by gently pressing spleens 
through a 70 µm cell strainer with the plunger of a 1 ml syringe. The cell strainer was 
washed with DPBS+5 % FCS to isolate any remaining cells. The suspension was 
centrifuged (10 min, 300 x g, 4 °C) and the cells were treated with 3 ml warm RBC lysis 
buffer per spleen for 3 min to lyse red blood cells. Lysis buffer was neutralized with 
20 ml DPBS+5 % FCS and the cell suspension was passed through a 70 µm cell strainer 
to remove any residual tissue. The cells were centrifuged (10 min, 300 x g, 25 °C) and 
resuspended in cIMDM+5 % FCS, DPBS or magnetic-activated cell sorting (MACS) 




2.3.4. Sorting and proliferation dye staining of T-cells 
Splenocytes prepared from OT-I and OT-II mice (see Section 2.3.3) were resuspended in 
MACS buffer (90 µl per 1 x 107 cells). To sort OT-I cells for CD8+ and OT-II cells for CD4+ 
T-cells, 10 μl anti-CD8 or anti-CD4 MicroBeads (Miltenyi Biotech, Bergisch Gladbach, 
Germany) per 1 x 107 cells were added to the appropriate cell suspension, inverted 
immediately for good mixing and the cells were incubated for 15 min in an ice-block. 
The cells were washed with 1 ml of MACS buffer per 1 x 107 cells and centrifuged 
(10 min, 300 x g). The pellet was resuspended in 1 ml MACS buffer per 1 x 108 cells and 
the cells were run through the AutoMACS Pro (Miltenyi Biotech) on the positive 
selection (possel-s) setting using MACS running buffer (Appendix 1) to sort out CD8+ 
and CD4+ T-cells. Following the cell sort, cells in the collected positive fraction were 
washed with cIMDM+5 % FCS, centrifuged (10 min, 300 x g) and resuspended at a 
concentration of 1 x 108 in cIMDM+5 % FCS. Cells were stained with 20 µM 
carboxyfluorescein succinimidyl ester (CFSE) (Invitrogen) for 7 min in the dark at room 
temperature. An equal amount of FCS as in the cell suspension was added to the cells 
to quench the reaction. The cells were washed three times with cIMDM+5 % FCS to 
remove residual CFSE with centrifugation steps of 10 min at 300 x g in between. After 
the last washing step the cells were resuspended at a concentration of 1 x 106 cells/ml in 
cIMDM. 
 
2.3.5. Flow cytometry staining 
Cells cultured in 96-well plates were stained for flow cytometry analysis in the plate 
with centrifugation of the plate for 2 min at 350 x g after each wash and staining step. 
Cells from mouse genotyping (see Section 2.3.6) and in vivo cytotoxicity experiments 
(see Section 2.3.12) were stained in 5 ml fluorescent activated cell sorting (FACS) tubes, 
with centrifugation of the tubes for 5 min at 300 x g after each wash and staining step.  
Following a first wash with DPBS+5 % FCS, cells were stained with a Live Dead dye, 
either LIVE/DEAD® Fixable Near-IR Dead Cell Stain (Life technologies™, Eugene, 
Oregon, USA) or Fixable Viability Stain 450 (BD Horizon™, Piscataway, NJ, USA) for 




15 min at 4 °C to allow analysis of live cells. Cells were washed twice in DPBS+5 % FCS 
and were then incubated with CD16/CD32 Fc blocking antibody (Appendix 2) for 5 min 
at 4 °C to block non-specific binding of staining antibodies to Fc receptors.  The cells 
were washed with FACS buffer (Appendix 1) and incubated for 15 min at 4 °C with the 
antibody mix diluted in FACS buffer prepared for the appropriate experiment. The cells 
were washed with FACS buffer and fixed with 2 % paraformaldehyde (PFA) for 15 min 
at room temperature. Following fixing of the cells, they were washed and resuspended 
in FACS buffer for acquisition. Cells stained in 96-well plates were transferred into 5 ml 
tubes for acquisition. Flow cytometry analysis was performed on a Gallios flow 
cytometer (Beckman Coulter, Brea, CA, USA) with three laser (405 nm, 488 nm and 
633 nm) ten colour configuration. Flow cytometry data was analysed with FlowJo 
software version 9.2 or version 10.6.8 (Tree Start Inc., OR, USA) or Kaluza software 
version. 
All antibodies and Live Dead dyes were titrated before use for optimal staining, 
depending on the type and concentration of cells stained. The antibodies used are 
detailed in Appendix 2. 
 
2.3.6. Testing of transgenic mice 
To genotype OT-I and OT-II transgenic mice, the transgenic mice and one C57BL/6 
control mouse were held in a mouse restrainer, the tip of their tail was cut with sterilized 
scissors and 4-5 drops of blood were collected in a tube containing 1 ml Alsevier’s 
solution (Appendix 1). The blood samples were centrifuged (5 min, 350 x g, 25 °C), the 
supernatant was discarded and the cells were resuspended by vortexing. To lyse the red 
blood cells, 2 ml of RBC lysis buffer were added to each tube and the tubes were 
incubated for 3 min at room temperature. The RBC lysis buffer was neutralized with 
5 ml FACS buffer, the tubes were centrifuged (5 min, 350 x g, 25 °C), the supernatant 
was discarded and the cell pellets were resuspended by vortexing. The cells were 
stained with FITC anti-mouse TCRVα2 and APC anti-mouse TCRVβ5.1,5.2 for 15 min 
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at 4 °C (Appendix 2). The cells were washed twice with FACS buffer as above and 
resuspended in FACS buffer for flow cytometry (see Section 2.3.5). 
 
2.3.7. BMDC activation assay 
BMDC from C57BL/6 mice harvested on day 6 of culture (see Section 2.3.2) were 
resuspended in cIMDM+5 % FCS at a concentration of 1 x 106 cells/ml and were plated 
into a round bottom 96-well plate with 200 ul per well. The cells were pulsed with 
0.2 µM CpG, 3.5 µg/ml OVA, a mixture of CpG and OVA, 3.5 µg/ml of a conjugate or 
2.5 µg/ml LPS as positive control for 24 h at 37 ºC + 5 % CO2. In each experiment, two 
wells were left untreated for the untreated cell control and the unstained control for flow 
cytometry analysis. The cells were harvested by centrifuging the plate (2 min, 350 x g), 
the media was removed by inverting the plate and the cells were resuspended by gentle 
vortexing. The cells were washed twice with DPBS+5 % FCS, stained with Live Dead 
near IR, treated with Fc block and stained with FITC anti-mouse I-A/A-E (MHC-II), 
PE anti-mouse CD86, PE/Cy7 anti-mouse CD40 and APC anti-mouse CD11c (Appendix 
2, see Section 2.3.5). The cells were then analysed by flow cytometry. 
 
2.3.8. BMDC – T-cell co-culture 
BMDC from C57BL/6 mice harvested on day 6 of culture (see Section 2.3.2) were 
resuspended in cIMDM+5 % FCS at a concentration of 1 x 105 cells/ml and were plated 
into a round bottom 96-well plate with 100 ul per well. The cells were pulsed with 
0.2 µM CpG, 3.5 µg/ml OVA, a mixture of CpG and OVA or 3.5 µg/ml of a conjugate for 
24 h or 2.5 µg/ml SIINFEKL or OVA323-339 peptide for 3 h. In each experiment, two 
wells were left untreated for the untreated cell control and the unstained control for flow 
cytometry analysis. Four wells of BMDC were pulsed for each treatment to measure 
proliferation of sorted CFSE stained CD8+ and CD4+ T-cells and IFN-γ production of 
OT-I and OT-II splenocytes.  
 




2.3.9. T-cell proliferation assay 
Sorted and CFSE stained CD8+ and CD4+ T-cells (see Section 2.3.4) were resuspended 
at 1 x 106 cells/ml in cIMDM+5 % FCS and 100 µl were each added to the appropriate 
pulsed BMDCs for co-culture (see Section 2.3.8). The co-culture was incubated for 24, 48 
or 72 h at 37 ºC, 5 % CO2. Following incubation the cells were harvested by centrifuging 
the plate (2 min, 350 x g), the media was removed by inverting the plate and 
resuspended by gentle vortexing. The cells were washed twice with DPBS+5 % FCS, 
stained with Live Dead near IR, treated with Fc block and stained with PE-CF594 anti-
CD3 and APC anti-CD8α or APC anti-CD4 (Appendix 2, see Section 2.3.5). The cells 
were then analysed by flow cytometry. Percent proliferation of T-cells was calculated 
using the “Proliferation” feature in FlowJo which assesses the proliferation peaks of 
CFSE stained cells. 
 
2.3.10. Cytokine production assay 
Splenocytes prepared from OT-I and OT-II mice (see Section 2.3.3) were resuspended at 
1 x 106 cell/ml in cIMDM+5 % FCS and 100 µl were each added to the appropriate pulsed 
BMDC for co-culture (see Section 2.3.8). The co-culture was incubated for 48, 72 or 96 h 
at 37 ºC, 5 % CO2. Following incubation the cells were centrifuged (1 min, 350 x g) and 
the supernatants were harvested. The concentration of interferon (IFN γ) in the 
supernatants was determined by enzyme-linked immunosorbent assay (ELISA) (see 
Section 2.3.13). 
 
2.3.11. Immunofluorescent analysis of conjugate 
internalisation 
Splenocytes from C57BL/6 mice (see Section 2.3.3) were resuspended at 1 x 106 cell/ml 
in cIMDM+5 % FCS and were plated into a round bottom 96-well plate with 100 ul per 
well. The cells were either pre-cooled to 4 °C or pre-warmed to 37 °C for 30min. The 
cells were pulsed with 7 µg/ml of DyLight366 labelled OVA mixed with CpG or 7 µg/ml 
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of a DyLight633 labelled conjugate (see Section 2.1.8). In each experiment, two wells 
were left untreated for the untreated cell control and the unstained control for flow 
cytometry analysis. Following incubation at 37 °C, 5 % CO2 or 4 °C for 1, 4 or 24 h, the 
cells were harvested by centrifuging the plate (2 min, 350 x g), the media was removed 
by inverting the plate and cells were resuspended by gentle vortexing. The cells were 
washed twice with DPBS+5 % FCS, stained with Live Dead near IR, treated with Fc 
block and stained with antibodies to identify the following cell populations: DCs 
(APC anti-CD11c), macrophages (PE anti-F4/80), B-cells (FITC anti-CD45R/B220) and T-
cells (CD3 anti-PE-CF594) (Appendix 2, see Section 2.3.5). The cells were then analysed 
by flow cytometry. 
 
2.3.12. Cross-presentation of conjugate 
BMDC from C57BL/6 mice harvested on day 6 of culture (see Section 2.3.2) were 
resuspended in cIMDM+5 % FCS at a concentration of 0.5 x 106 cells/ml and incubated 
with the cross-presentation inhibitors lactacystin (20 µM), primaquine (50 µM) or 
brefeldin A (10 µg/ml). Following incubation for 15 min at 37 °C, 5 % CO2, warm 
cIMDM+5 % FCS was added to the cells to adjust the concentration to 1 x 105 cells/ml 
and the cells were plated into a round bottom 96-well plate with 100 ul per well. The 
cells were pulsed with 0.2 µM CpG, 3.5 µg/ml OVA, a mixture of CpG and OVA or 
3.5 µg/ml of a conjugate for 24 h or 2.5 µg/ml SIINFEKL or OVA323-339 peptide for 3 h. 
One well of cells for each was each left untreated as a negative control. Following 
incubation at 37 ºC, 5 % CO2, splenocytes from OT-I or OT-II cells (100 µl) at a 
concentration of 1 x 106 cells/ml were added to the pulsed BMDC and the co-culture was 
incubated for 72 h at 37 ºC, 5 % CO2. The supernatant of the co-cultures was harvested 
and IFN-γ levels were measured by ELISA (see Section 2.3.13). 
 





The wells of 96-well ELISA plates (Nunc, Thermo Fisher Scientific) were coated with 
50 μl of purified anti-mouse IFN-γ antibody (Appendix 2) diluted 1/250 in coating 
buffer (Appendix 1). The plates were incubated for 1 h at 37°C and washed six times in 
wash buffer (Appendix 1). The wells were blocked with 200 μl/well of PBS+1 % BSA for 
2 h at room temperature and consequently washed six times in wash buffer. A two-fold 
serial dilution of the IFN-γ cytokine standard (BD Pharmingen, San Jose, CA, USA) 
starting at 10 ng/ml and diluted in PBS+1 % BSA was prepared and 50 µl/well of the 
standard or samples were added to duplicate well. The plates were incubated overnight 
at 4°C, washed six times in wash buffer and 100 µl biotinylated anti-mouse IFN-γ 
antibody (Appendix 2) was added at a dilution of 1/500 in PBS+1 % BSA at . The plates 
were incubated for 30 min at 37°C, washed six times in wash buffer and 100 µl 
Streptavidin-HRP (BioLegend, San Diego, CA, USA) diluted 1/3000 in PBS+1 % BSA 
were added to plates. The plates were incubated for 20 min at 37°C and washed six times 
in wash buffer. To develop the signal, 100 µl TMB substrate (Invitrogen) were added to 
the wells and the reaction was stopped with 100 μl 1N H2SO4 when sufficient colour 
development was observed. The absorbance at 450 nm of the standards and samples 
was measured using a POLARStar Omega microplate reader (BMG Labtech GmbH). 
Using the standard curve prepared from the cytokine standards the IFN-γ concentration 
of the samples was calculated.  
 
2.3.14. In vivo cytotoxicity assay 
The conjugates C-4FB-O, C-4FBSS-O, C-SPDP-O, C-PEG-O and C-peptide-OVA and a 
mixture of unconjugated CpG and OVA were prepared in sterile DPBS pH 7.0 at a 
concentration of 66.6 μg/ml. This corresponded to 10 μg of OVA in 150 μl DPBS with a 
ratio of 2.5 CpGs per OVA molecule. Naïve female C57BL/6 mice were vaccinated 
subcutaneously (s.c.) with 10 µg of the appropriate conjugate, mixture of CpG and OVA 
or DPBS as a control (n=6 mice per group). On day 24 the mice were give a boost 
vaccination with the same treatment and on day 31 they received a mixed population of 
CFSE stained target cells and control cells.  
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In order to generate the target and control cells, splenocytes from donor mice (one donor 
spleen per three recipient mice) were prepared as described in Section 2.3.3, 
resuspended at 2 x 107 cell/ml and separated into two population. The target cell 
population was pulsed with 10 µM SIINFEKL for 2 h at 37 ºC, 5 % CO2 while the control 
cell population was left unpulsed. The cell populations were washed three times in 
DPBS with centrifugation steps of 10 min at 300 x g in between. The cells were 
resuspended at 2 x 108 cells/ml, the target cell population was stained with 50 µM CFSE 
and the control cell population was stained with 5 µM CFSE for 7 min at room 
temperature in the dark. The reaction was quenched with an equal volume of FCS and 
the cell populations were washed three times in DPBS with centrifugation steps of 
10 min at 300 x g in between to remove any residual FCS. The two cell populations were 
combined and resuspended at 1 x 108 cells/ml. 
The mice were injected intravenously (i.v.) with 100 µl of the mixed target and control 
cell populations. The recipient mice were sacrificed 40 h after target cell injection, their 
spleens were prepared as described in Section 2.3.3 and the splenocytes were 
resuspended in DPBS. For flow cytometry analysis, the cells were stained with Live 
Dead near IR and fixed with 2 %PFA (see Section 2.3.5). 
Two million single cells were acquired per sample and gated for target and control cells. 
The antigen-specific killing was calculated with the following formula: 
 









]  x 100 
 
2.3.15. Culturing of B16-OVA tumour cells 
B16-OVA tumour cells (NOC99008, passage 9) in liquid nitrogen were thawed at 37 °C 
and cultured in complete Roswell Park Memorial Institute medium (cRPMI, Appendix 
1) containing 5 % FCS and 0.5 mg/ml Geneticin® selective antibiotic (Gibco Invitrogen) 
at 37 ° C, 5 % CO2 overnight. Following attachment of the cells to the tissue culture flask 
(TCF), the old medium was replaced with fresh cRPMI+5 % FCS+Geneticin. The cells 




were split when they reached 80 % confluence, they were washed with DPBS, detached 
with 0.25 % Trypsin/Ethylenediaminetetraacetic acid (EDTA), resuspended in 
cRPMI+5 % FCS+Geneticin and plated in a new TCF. The cells were harvested when 
they reached 80 % confluence in passage 10, they were washed with DPBS, detached 
with 0.25 % Trypsin/EDTA and washed three times with DPBS with centrifugation steps 
of 10 min at 300 x g in between to remove any residual FCS. Cells were resuspended at 
3.33 x 105 cell/ml for the therapeutic tumour trial.  
 
2.3.16. Therapeutic tumour trial 
Naïve female C57BL/6 mice were injected s.c. with 0.5 x 105 B16-OVA tumour cells in 
150 µl DPBS in the left flank. Five days after tumour cell injection mice were vaccinated 
s.c in the left flank above the palpable tumour with 10 µg of the appropriate conjugate, 
mixture of CpG and OVA (2.5 CpG per OVA) or DPBS as a control (n=10mice per 
treatment group). On day 80 tumour free mice were re-challenged with 0.5 x 105 B16-
OVA tumour cells in 150 µl DPBS in the right flank. A new control group of DPBS (n=5 
mice) was added at this time point to ensure the B16-OVA tumour cells in the re-
challenge induced tumour growth. The tumour growth was monitored every two to 
three days by measuring the width and length of the tumour. The tumour size was 
calculated as the product of the two tumour bisecting diameters. The mice were 
euthanized then the tumours reached a size of 150 mm2.  
 
2.3.17. Statistical analysis: 
Statistical analysis was performed using GraphPad Prism version 6.0f (GraphPad 
Software, La Jolla, CA, USA). Statistical analysis was carried out using one-way analysis 
of variance (ANOVA) with Dunnett’s post-hoc test to compare the difference of one 
variation in more than two different treatment groups, two-way ANOVA with 
Bonferroni’s post-hoc test to compare the difference of two variations in different 
treatment groups and a Log-rank (Mantel-Cox) test to compare survival rates. The 
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particular type of statistical analysis is indicated in each relevant figure legend. Error 
bars in the graphs represent standard error of the mean (SEM).  
 
 


















The generation of a T-helper (TH) 1 immune response is important for the development 
of anti-cancer vaccination strategies. The immune system has evolved to generate 
strong cellular immune responses to complex microbial pathogens delivered to 
antigen-presenting cells (APC). This is attributed to the fact that complex pathogens 
comprise of both antigen and pathogen-associated molecular patterns (PAMP), 
thereby inducing APC maturation through pattern-recognition receptor (PRR) binding 
as well as antigen processing and presentation at the same time (382). Co-delivery of 
tumour antigens used for cancer vaccination and vaccine adjuvant into the same APC 
is a way to mimic microbial infection. Therefore by designing tumour 
immunotherapies by co-delivering antigen and adjuvant to the same APC, cellular, 
TH1-type immune responses targeted against cancer cells can be generated. Reports in 
the literature show successful induction of a cellular immune response through co-
delivering antigen and adjuvant in both soluble and particulate systems (see 
Introduction Section 1.4). This work focusses on designing a conjugate of the model 
tumour antigen ovalbumin (OVA) and the vaccine adjuvant cytosine-phosphate-
guanosine oligodeoxynucleotide (CpG ODN) for generation of an improved anti-
tumour immune response. We hypothesise that using reversible chemistry to induce 
triggered release of OVA and CpG inside an APC induces a stronger TH1 immune 
response compared to stable conjugates.  
In this study OVA was selected as the model antigen as it is a well characterised model 
tumour antigen with the availability of transgenic mice expressing either major 
histocompatibility complex (MHC) class-I restricted T-cell receptors (TCR) specific for 
SIINFEKL (OT-I mice) or MHC class-II restricted T-cell receptors for OVA323-339 (OT-
II mice) (271,272).  
The toll-like receptor (TLR) 9 agonist CpG was chosen as a vaccine adjuvant in this 
study as it induces a strong TH1 type immune response (43). CpG is additionally a 
clinically relevant adjuvant that has been investigated in over 100 clinical trials, as 
elaborated in Introduction Chapter 1.  
 




3.1.1. Phosphodiester and phosphorothioate backbone in CpG 
CpG ODN are available with different properties, with each class of CpG inducing a 
different immune response, as elaborated in Chapter 1. For induction of a TH1-type 
immune response as part of an antigen-adjuvant conjugate, class B 1668 and 1826 CpGs 
have been used (122,335,383,431–433,465,501–505). Class B CpGs traditionally have a 
phosphorothioate (PT) backbone for enhanced stability towards nucleases, but for 
investigations on the effect of the PT backbone, class B CpGs have also been made with 
a phosphodiester (PDE) backbone (506). Class B ODN with a PT backbone were shown 
to strongly bind to TLR9, however only ODN that included a CpG motif functioned as 
a TLR agonist while ODN lacking a CpG motif acted as a TLR antagonist (368,507). 
PDE backbone CpGs induce weaker activation of TLR9 compared to PT CpG as shown 
by direct comparison of the DC specific 1668 class B CpG synthesised with either a PT 
or PDE backbone (368,506). In contrast to the PT ODN, induction of TLR9 activation 
by PDE CpG does not strictly depend on the CpG motif. PDE ODNs without CpG 
motifs have been shown to bind and activate TLR9 although PDE ODN with a CpG 
motif still binds three times more efficient to TLR9 compared to ODN without the CpG 
motif (368). Apart from lower activation of TLR9, PDE CpGs induce a different 
immune response with a higher interferon (IFN) α production compared to a stronger 
IFN-γ production by PT CpGs (354,508). PDE CpGs have therefore been under 
investigation as an alternative to PT CpGs for vaccination uses where an enhanced 
IFN-α response is desirable. Modifications to the ODN sequence in PDE CpG and 
addition of protective molecules to the ends of the ODNs have been studied to reduce 
the susceptibility of the PDE backbone to nucleases (354,508,509). This chapter 
therefore looks at the importance of a CpG motif and a PT backbone for induction of a 
strong cellular immune response.  
 
3.1.2. Direction of conjugation of CpG to OVA 
CpG can be either modified on the 3’ or the 5’ end with functional groups for 
conjugation, thereby changing the direction of conjugation. Detailed studies to 
investigate the sequence of ODNs and the importance of the location of certain bases 
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and motifs to activate a TLR9-mediated immune response suggest that a free 5’ end is 
essential for the immunostimmulatory effect of CpG (509–515). Blocking the 5’ end of 
CpG by either conjugation to a second ODN in a 5’-5’ linking strategy or through 
conjugation onto a peptide was shown to reduce the immunostimmulatory activity of 
CpG compared to free CpG or 3’ end blocked CpG (510,513,515). Lenert et al showed 
that the 5’ thymidine base of CpG is crucial for TLR9 activation as deletion of the base 
resulted in a 98 % reduction in activity, suggesting that the thymidine base takes part 
in binding to TLR9 (511). Truncation or blocking of the 3’ end of CpG resulted in no or 
minimal loss of immunostimmulatory activity. The change in immunostimmulatory 
activity of modified or blocked CpGs was determined with a focus on NF-κB activation 
and cytokine production of total splenocytes in vitro and in vivo while for CpG 
conjugated to antigen the immunostimmulatory effect on DCs as well as the 
subsequent degree of cross-presentation of antigen and priming of T-cells is important. 
Although conjugation via the 3’ end of CpG was suggested in the above mentioned 
publications, most studies that co-delivered CpG and antigen did not consider the 
direction of conjugation. The majority of studies that were found conjugated CpG via 
the 5’ end (431–433,465,501,516), which was reported to be cheaper to synthesise (517), 
several studies only stated the conjugation method but not the direction of conjugation 
(335,504), while two studies were found that conjugated CpG via the 3’ end without 
stating why the 3’ end was chosen (122,503,518). Only one study was found to compare 
the effect of 3’ or 5’ conjugation of CpG on DC activation. Beaudette et al conjugated 
CpG via 3’ and 5’ end to an NP and reported an on average 10 % increased CD86 
expression and IL-12 production in bone marrow-derived dendritic cells (BMDC) 
stimulated with 3’ conjugated CpG compared to 5’ conjugated CpG to NP (383). One 
aim of this chapter is to determine the impact of the direction of conjugation of CpG 
onto OVA on cross-presentation of antigen epitope by BMDC and subsequent T-cell 
proliferation.  
 




3.1.3. Conjugation of CpG to OVA with stable and cleavable 
linkages 
Antigen and adjuvant have been conjugated with a variety of linking strategies either 
as a stable or reversible formulation. Stable conjugation of CpG to antigen has been 
reported with thiloated CpG using either the non-cleavable amine-to-thiol crosslinkers 
sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (sulfo-SMCC) 
(335,516) or m-maleimidobenzoyl-N-hydroxysulfosuccinimide ester (sulfo-MBS) (431–
433,505) or by direct formation of a thioether bond with a maleimide modified OVA or 
OVA peptide (122,501,504). Another stable method was described by Herbáth et al that 
used biotinylated CpG to conjugate to streptavidin as a model antigen (503). Daftarian 
et al compared a thioether linkage to a hydrazone linkage which was made by reacting 
an aldehyde group modified CpG with a hydrazine group modified peptide. The 
hydrazone linking strategy proved to be more efficient than a thioether linkage as it 
produced over double the yields and higher purity of the conjugate. The stability of 
the hydrazone linked conjugate towards low pH was however not evaluated in the 
respective study (501). To follow on the success of stable conjugation of antigen to 
adjuvant the idea of using a reversible linker was developed in recent years. Reversible 
formulations are designed to allow concurrent uptake of antigen and adjuvant by 
APCs but to then be cleaved by a specific trigger once inside the cell to induce 
enhanced processing of antigen and adjuvant. Direct reversible conjugation of CpG 
onto antigen has not been reported yet, however a series of reversible formulations 
have been developed to target APCs. These include reversible conjugation of CpG or 
antigen to NPs (383,465,466,519,520), reversible conjugation of OVA to either chitosan 
(521) or polymers (392,467) as antigen carriers or reversible conjugation of transferrin 
as an ODN carrier to a polycation (522). The majority of reversible formulations are 
based on a disulphide bond that is supposed to be stable at low extracellular 
concentrations of glutathione (GSH) but reduced by the high intracellular 
concentration of GSH. While disulphide bonds are cleaved by high concentrations of 
GSH or the strong reducing agents dithiothreitol (DTT) and 2-mercaptoethanol (2-ME), 
their stability towards low concentrations of reducing agents depends on the 
availability and nature of chemical side groups around the disulphide bond. The 
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amine-to-thiol crosslinker succinimidyl 3-(2-pyridyldithio)propionate (SPDP) which 
comprises a reducible disulphide bond without any chemical side groups around the 
disulphide bond has been shown to be rapidly cleaved in in vivo experiments. Letvin 
et al used SPDP to conjugate an antibody to a cytotoxic agent and reported that 24 h 
after injection only 10 % of the initial concentration of conjugates were detectable while 
at the same time free antibodies were detected which suggested extracellular cleavage 
of the SPDP bond (523). Two studies followed up on Letvin et al’s findings by 
synthesising linkers that were structurally similar to SPDP but with hindered 
disulphide bonds. The conjugates made from hindered disulphide bond linkers were 
found to be considerably more stable than SPDP, with one conjugate showing five-
times higher levels in the blood 48 h after intramuscular injection and the other 
conjugate showing 6.3-times higher levels in the blood 24 h after injection compared to 
the SPDP linked conjugate (497,498). Disulphide linked monoclonal antibody (mAb)–
drug conjugates tested in clinical trials as cytotoxic anti-cancer drugs were designed 
with different degrees of steric hindrance around the disulphide bond. Coltuximab 
ravtansine, the conjugate with the highest degree of steric hindrance was shown to be 
more stable to reductive cleavage compared to conjugates with less steric hindrance 
(524,525). Although these studies show that disulphide bonds without steric 
hindrance, like SPDP only display moderate stability in vivo, SPDP is still a popular 
crosslinker for reversible delivery of antigen and adjuvant, designed to be reduced 
inside APCs (521,522). These SPDP linked immune-conjugates, alongside other 
conjugates designed to be reduced inside APCs were not tested for their stability 
towards extracellular concentrations of reducing agents and only some of the reported 
formulations were tested for their reducibility by high concentrations of reductants 
(392,465–467,519,520,522).  
In addition to exploiting the reductive environment inside the cell for triggered release, 
enzyme cleavable peptides as well as pH-sensitive linkers have also been explored for 
targeted release in APCs. Peptide linkers that are designed as substrates for specific 
proteases have been previously developed for triggered release of anti-cancer drugs 
(469). Additionally a peptide antigen-adjuvant conjugate has been reported which 
incorporates a proteolytic cleavage site in the peptide. This conjugate was designed to 




release the peptide antigen from the adjuvant upon intracellular enzymatic cleavage 
of the proteolytic peptide sequence (526). Peptides designed to be cleaved by a specific 
enzyme could therefore also be used as linkers for reversible antigen-adjuvant 
conjugates.  
pH-sensitive nanoparticles (NP) have been developed that release their antigen and 
adjuvant load in the acidic environment of the late endosome (383). While the acid-
degradable NP were tested for the release of antigen and adjuvant at low pH, in the 
majority of studies the formulations were not tested for their designated properties. 
Another aim of this research is therefore to synthesise a series of antigen-adjuvant 
conjugates and develop reliable in vitro tests to predict their stability or reversibility 
towards the environmental triggers that they were designed for.  
 
3.1.4. Chapter aim 
Based on the known characteristics of CpG and linking strategies used to conjugate 
antigen to adjuvant, the aims of this chapter were: 
 Synthesise stable and reversible CpG-OVA conjugates 
 Establish the differences in immune cell stimulation for conjugates linked via 
the 3’ or 5’ end of CpG 





3.2.1. Synthesis of stable oligodeoxynucleotide-OVA 
conjugates  
The model tumour antigen OVA was used for conjugation to ODN. SEC analysis of 
the OVA protein prior to conjugation showed monomer OVA as well as higher 
molecular weight aggregates (Figure 3.3 B). To remove the higher molecular weight 
material prior to conjugation OVA was purified by size-exclusion chromatography 
(SEC) using a Superdex™ 200 10/300 GL SEC column (see Methods Section 2.1.1.4). 
Figure 3.1 shows the OVA monomer eluted between 29-35 min and aggregates eluted 
between 13-28 min. The OVA monomer fractions between 29-35 min were collected 
with a pooled volume of approximately 3 ml. The protein concentration was analysed 
by UV spectrometry at 280 nm and was determined to be typically 2.5±0.5 mg/ml (see 
Methods Section 2.1.1.3). The OVA monomer was stored at 4 °C for a maximum of 
three weeks.  
 
Figure 3.1: Size-exclusion chromatographic analysis of ovalbumin.  
Non-purified OVA (500 μl) was applied onto Superdex™ 200 10/300 GL SEC column using a 
mobile phase of phosphate buffered saline (PBS) at pH 7.4. The absorbance at 280 nm was 
recorded for the run time of 45 min at a flow rate of 0.5 ml/min. The data is shown as a 
representative chromatogram for OVA analysis.  





The purity of the OVA pool was analysed using an analytical Yarra-2000 SEC column 
(see Section 2.1.1). The chromatograph showed a single peak eluting at 9.2 min, this 
retention time equated to the molecular weight of OVA predicted from the analysis of 
protein standards of differing molecular weights from 17,000 to 670,000 Da (Figure 3.3 
C). The retention times are summarised in Table 3.1. Figure 3.2 shows the linear 
relationship between retention time and the log molecular weight of proteins ranging 
from 17,000 Da to 670,000 Da. Uridine at 244.2 Da was not within the separation range 
of the analytical column which has a molecular weight range of 1,000 to 300,000 Da as 
specified by the supplier.  
Figure 3.3 B and C show the elution profile of OVA before and after purification, as 
analysed on the analytical Yarra-2000 SEC column (see Methods Section 2.2.1). High 
molecular weight aggregates eluted at 8.5 and 7.9 min while the OVA monomer eluted 
at 9.2 min after injection.  
 
Table 3.1: Elution times of the protein standards analysed on Yarra-2000 SEC column 
Protein name MW [Da] 
Retention time 
[min] 
Bovine Thyroglobulin 670000 6.42 
Immunoglobulin A 300000 7.305 
Immunoglobulin G 150000 8.386 
Ovalbumin 44000 9.214 
Myoglobin 17000 10.287 




Figure 3.2: Calibration curve of molecular weight and corresponding retention times 
for protein standards on Yarra-2000 SEC column 
 
 
Figure 3.3: Analytical size-exclusion chromatography of protein standards and 
ovalbumin.  
(A) Protein Standard (Phenomenex) was diluted 1 in 10 in PBS and 25 µl were injected onto 
Yarra-2000 column. 25 µl of (B) 1 mg/ml non-purified OVA and (C) OVA monomer purified on 





















2000 column. For all three samples, absorbance at 280 nm was recorded for the run time of 
20 min at a flow rate of 0.35 ml/min. The data in (A) is a representative chromatograph for the 
proteins standard run as calibration before every analytical SEC analysis. The data in (B and C) 
show representative chromatographs from three independent experiments.  
The purified OVA was then conjugated onto an ODN using a bis-aryl-hydrazone 
linking strategy of Solulink Inc. The three step process is shown in reaction Scheme 3.1. 
Our conjugation method was based on the protocol provided by Solulink for the 
conjugation of protein to ODN (452). Firstly, the terminal amine group the 5’ end of 
the ODNs was modified to an aromatic aldehyde by reacting the terminal amine group 
with the activated ester of the linker succinimidyl 4-formylbenzoate (4FB). Following 
completion of the reaction after incubation for 2 h at room temperature, the unreacted 
4FB linker was removed by spin. The molar substitution ratio (MSR) was determined 
by reacting the aldehyde group on CpG with 2-hydrazinopyridine·2-hydrochloric acid 
(2-HP) and measuring the colorimetric bis-aryl hydrazone bond formed by UV at 
360 nm (see Methods Section 2.1.4.2). Using the molar extinction of 24,500M-1cm-1 the 
average MSR of the ODN with the 4FB linker was 1.0 ± 0.2. 
To introduce a hydrazine functional group on to OVA, the amine groups on the protein 
were modified by reaction with the activated ester of the linker succinimidyl 6-
hydrazinonicotinate acetone hydrazone (HyNic). After 2 h at room temperature the 
unreacted HyNic linker was removed by spin filtration. Spectroscopic analysis of the 
colorimetric bond formed between 2-sulfobenzaldehdye (2-SBA) and hydrazine 
groups determined the average MSR to be 6.1 ± 1.6 (see Methods Section 2.1.4.4).  
The aldehyde modified ODN was then reacted with the hydrazine modified OVA at a 





Scheme 3.1: Synthesis of the bis-aryl hydrazone linked C-4FB-O conjugate 
The kinetics of the conjugation reaction was monitored by absorbance measurement at 
354 nm as the 4FB-HyNic conjugation couple specifically absorbs at this wavelength. 
Absorbance measurements at 354 nm were made every 30 min during the conjugation 
process and confirmed completion of the reaction after 2 h, as there was no change in 
absorbance after 2 h. Using the molar extinction coefficient of 29,000 m-1cm-1 for the 
colorimetric conjugate bond the conjugation ratio of 2.8±0.3 CpG per OVA was 
calculated (see Methods Section 2.1.4.5; see Appendix 3 for wavelength scan of C-4FB-
O). The OVA-ODN conjugate was then purified by preparative SEC on a Superdex 200 
10/300 GL SEC column measuring the absorbance of the conjugate at 260 nm. The 
conjugate eluted between 15 min – 28 min and un-reacted ODN eluted at 35-39 min 
(Figure 3.4 B). The identity of free CpG was confirmed by chromatographic analysis of 
a mixture of CpG and OVA, the OVA eluted at 31 min and CpG eluted at 36 min 
(Figure 3.4 A). The pooled conjugate was concentrated using a Vivaspin 2 filter unit 
and the concentration of the conjugates was determined using the Quant-iT kit (see 
Methods Section 2.1.1.5). The concentration of the conjugates ranged between 400 -




600 µg/ml and they were adjusted to a stock concentration of 50 µg/ml OVA protein 
equivalent for all cell culture experiments or 400 µg/ml for all HPLC analysis. The 
ODN-OVA conjugates were stored at 4 °C for a maximum period of four weeks. 
 
 
Figure 3.4: Preparative SEC analysis of a mixture of unconjugated CpG and OVA 
and the C-4FB-O conjugate 
(A) a mixture of 75 µM CpG and 1mg/ml OVA and (B) C-4FB-O conjugate following completion 
of conjugation reaction were injected (500 µl) onto Superdex™ 200 10/300 GL SEC column 
equilibrated in PBS buffer, pH 7.4 at a flow rate of 0.5 ml/min . Absorbance at 260 nm was 
recorded. The chromatograph in (A) is representative for three independent experiments. The 






Three different OVA-ODN conjugates were synthesised using a stable bis-aryl 
hydrazone linkage, the conjugates and their properties are summarised in Table 3.2.  
Table 3.2: 4FB conjugates synthesised with oligonucleotides and ovalbumin 








5’ C-4FB-O 5’ CpG PDE 2.8±0.3 66 15-28 
5’ G-4FB-O 5’ GpC PDE 2.8±0.3 63 15-28 
5’ C-4FB-O 5’ CpG PT 2.8±0.3 64 15-28 
CpG, cytosine-phosphate-guanine; GpC, guanine-phosphate-cytosine; PDE, phosphodiester; PT, 
phosphorothioate; OVA, ovalbumin 
 
3.2.2. Immunostimmulatory effect of phosphorothioate CpG 
ODN 
3.2.2.1. Comparison of CpG and GpC motifs in ODN 
Dendritic cell activation  
Previous studies have shown that in ODN with a PDE backbone CpG motifs induce 
greater activation of TLR9 compared to GpC motifs (see Section 3.1). The two class B 
1668 PDE ODN used in this study have the same sequence with exception of a reversed 
CpG motif in the control ODN (GpC). GpC ODN have been widely used as a control 
for the effectiveness of CpG ODNs (67,335,527). In this experiment in vitro immune cell 
activation assays were used to confirm the immunostimulatory activity of our custom 
synthesised CpG and GpC ODN. The ODN were linked via the 5’ end (PDE C-4FB-O 
and PDE G-4FB-O, Table 3.2) to OVA, similar to previously reported CpG-OVA 
conjugates (431,432,505,516,528). The immunostimulatory activity of the conjugates 
was tested by their ability to activate BMDCs, which was measured by the expression 
of the activation markers MHC-II, CD86 and CD40 (see Methods Section 2.3.7). BMDCs 
were pulsed with either non-purified or purified OVA to test whether purification 
resulted in a change in the activation of BMDC. To confirm the specific activity of the 
CpG motif over GpC, BMDC were pulsed with either PDE CpG or PDE GpC. To test 
whether co-delivery of antigen and adjuvant affects the activation status of BMDC, 
these cells were pulsed with mixtures of either PDE CpG with OVA or PDE GpC with 
OVA or the conjugates PDE C-4FB-O or PDE G-4FB-O. The dose of 17.6 µg/ml for OVA 




and conjugates and 1 µM for CpG was adopted from a previous study (431), in Section 
3.2.2.2 the dose for the conjugates was titrated to give optimal results for this study. 
Lipopolysaccharide (LPS) was added as the positive control for BMDC activation and 
untreated cells were the negative control. The dose of LPS was 2.5 µg/ml. This was 
determined by the titration of LPS to give the highest BMDC activation (see Appendix 
3). Following incubation of the pulsed BMDC for 24 h, cells were harvested and stained 
with live-dead dye as well as antibodies against the DC marker CD11c and surface 
activation markers CD40, CD86 and MHC-II for analysis by flow-cytometry as 
outlined in Methods Section 2.3.5. Cells were gated on single cells (excluding doublets), 
size (forward scatter), granularity (side scatter), viability (live-dead dyelow) and CD11c+ 
to distinguish DCs (Figure 3.5 A).  
 
Figure 3.5: CpG induces increased expression of BMDC activation markers.  
BMDC were incubated for 24 h with 1 µM CpG or GpC either alone, in combination with 
17.6 µg/ml OVA or conjugated to OVA or 17.6 µg/ml purified or non-purified OVA, 2.5 µg/ml 
LPS or pure media. (A) Gating strategy to remove doublet and dead cells and gate on CD11c+ 
cells. (B) Expression of activation markers MHC-II, CD86 and CD40 expressed in median 
fluorescent intensity (MFI). Bars represent three independent experiments ±SEM, statistical 
significance was determined by one-way ANOVA with Dunnett’s post-hoc test, ****p<0.0001, 
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**p<0.01, *p<0.05. Statistical significance displayed is the comparison between untreated cells 
and treated cells  
Figure 3.5 B shows that LPS induced significant upregulation of all activation markers 
compared to untreated cells. For all other treatments MHC-II and CD86 were not 
significantly upregulated over the untreated control group. No statistically significant 
difference between purified and non-purified OVA was observed for any of the 
activation markers. All treatments including PDE CpG induced a significant higher 
upregulation of CD40 over untreated cells while all treatments including PDE GpC did 
not induce upregulation of CD40. These activation assays show that PDE CpG ODN 
induces upregulation of the activation marker CD40 over PDE GpC ODN.  
 
T-cell proliferation  
The BMDC activation study confirmed the specificity of PDE CpG over PDE GpC. 
OVA internalised by APC is processed and presented as the antigen epitopes 
SIINFEKL or OVA323-339 either on MHC-I or MHC-II molecules, respectively. CD8+ 
T-cells from OT-I mice proliferate in response to SIINFEKL peptide presentation on 
MHC-I in combination with binding of co-stimulatory factors while CD4+ T-cells from 
OT-II mice proliferate in response to OVA323-339 peptide presented on MHC-II also 
in combination with co-stimulatory factors (86). To determine whether the enhanced 
BMDC activation by PDE CpG over PDE GpC translates to increased T-cell priming 
and proliferation, an in vitro T-cell proliferation assay was performed. BMDCs were 
pulsed for 24 h with the same treatments including PDE CpG, PDE GpC and OVA as 
above (see Section 3.2.2.1, BMDC activation assay). As a positive control, BMDC were 
incubated for 3 h with the MHC-I epitope peptide of OVA, SIINFEKL for CD8+ T-cell 
activation or the MHC-II epitope peptide, OVA323-339 for T-cell activation (see 
Methods Section 2.3.8). The reduced incubation time for the peptides was chosen as it 
has been shown that the peptides do not require processing within the cell but directly 
bind to MHC-I and MHC-II molecules (86). Splenocytes from OT-I and OT-II mice 
were sorted for CD8+ and CD4+ T-cells, respectively (see Appendix 3 for a 
representative CD8+ T-cell sort) and stained with the cell proliferation dye 




carboxyfluorescein succinimidyl ester (CFSE). The CFSE dye stains T-cells and with 
every cell division, the daughter cells only contain half of the original dye 
concentration which facilitates detection of proliferation of T-cells by flow cytometry. 
CD8+ and CD4+ T-cells were co-cultured with the activated BMDC at a ratio of 1:10 as 
this co-culture ratio has been shown previously by our group to produce the best 
proliferation results (529). Following co-culture, cells were harvested and stained for 
flow cytometry analysis. Figure 3.6 A shows the gating strategy used for analysis of 
proliferation experiments, with isolation of single, live cells with appropriate size and 
granularity, followed by gating on CD3+ and subsequently CD8+ or CD4+ (not shown) 
cells. Proliferation was visualised on the FlowJo software using the dilution of CFSE 
dye in progenitor cells as an indication of T-cell proliferation. Results are shown as 
percent proliferation of CD8+ and CD4+ T-cells (Figure 3.6). Co-culture times of 24, 48 
and 72 h were compared to determine the incubation time of co-culture that results in 
the highest percent proliferation of T-cells. Figure 3.6 B shows that both CD8+ and 
CD4+ T-cells showed the highest proliferation after 72 h of co-culture following 
SIINFEKL treatment. Similarly the mixture of CpG and OVA induced higher 
proliferation of CD8+ T-cells after 72 h while for CD4+ T-cells there was no difference 
in percent proliferation following CpG and OVA mixture treatment at the three time 
points. In all subsequent proliferation experiments co-culture times of 72 h were used.  
Figure 3.6 C shows that the peptides SIINFEKL and OVA323-339 induced statistically 
significantly higher T-cell proliferation in CD8+ and CD4+ T-cells compared to OVA 
treated T-cells. Untreated BMDC and BMDC pulsed with PDE CpG or PDE GpC and 
co-cultured with T-cells resulted in no proliferation of either CD8+ or CD4+ T-cells. 
Treatment with OVA induced similar percentage of CD8+ T-cell proliferation as 
treatment with the PDE CpG and OVA mixture, the PDE GpC and OVA mixture or 
the PDE G-4FB-O conjugate. CD8+ T-cells co-cultured with the PDE C-4FB-O conjugate 
showed a significantly higher percentage of proliferation compared to cells cultured 
with OVA. In CD4+ T-cells the same trend as for CD8+ T-cells was observed, however 
there was no statistical significant difference in proliferation following treatment with 
any sample except for the positive control compared to proliferation of OVA treated 
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T-cells. The T-cell activation assay confirmed that an augmented BMDC activation by 
PDE CpG conjugated to OVA is crucial to induce CD8+ T-cell proliferation.  
 
Figure 3.6: PDE CpG conjugate induces enhanced proliferation of CD8+ T-cells.  
BMDC were pulsed with 1 µM of PDE CpG or PDE GpC either alone, or mixed with 17.6 µg/ml 
OVA, OVA alone, 17.6 µg/ml of PDE C-4FB-O or PDE G-4FB-O or a control of 2.5 µg/ml of 
either SIINFEKL or OVA323-339 peptide or media. Sorted, CFSE stained CD8+ or CD4+ T-cells 
were co-cultured with pulsed BMDCs at a ratio of 1:10. (A) Gating strategy to identify 
proliferation peaks of CD8 T-cells, (B) comparison of co-culture times of CD8+ T-cells with 




BMDCs activated with PDE CpG mixed with OVA or controls for 24 h, 48 h and 72 h. (C) 
Percent proliferated CD8+ and CD4+ T-cells after incubation with activated BMDC for 72 h. 
Bars represent the mean of three independent experiments ±SEM, statistical significance was 
determined by one-way ANOVA with (B) Tukey’s post-hoc test and (C) Dunnett’s post-hoc 
test, ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05. Statistical significance displayed in (B) is the 
comparison between the same treatment groups and in (C) is the comparison of all treatment 
groups to OVA treated cells. 
 
Cytokine production  
CD8+ and CD4+ T-cells produce the cytokine IFN-γ when stimulated with IL-12 
released from activated APCs. As IFN-γ induces a positive feedback-loop that further 
drives TH1 and effector T-cell differentiation, it is a key cytokine for a strong TH1-type 
response and is therefore a good indicator for T-cell activation (109). IFN-γ production 
in BMDC-T-cell co-cultures was measured to confirm the high T-cell proliferation 
induced by the PDE C-4FB-O conjugate in the previous assay. BMDC activated with a 
mixture of PDE CpG and OVA or the SIINFEKL or OVA 323-339 peptides were co-
cultured with splenocytes from OT-I or OT-II mice for 48, 72 and 96 h to determine the 
time period of co-culture that results in the highest IFN-γ production. Supernatants 
were analysed for IFN-γ by enzyme-linked immunosorbent assay (ELISA) (see 
Methods Section 2.3.13). Figure 3.7 A shows that co-culture for 72 h induced 
significantly higher IFN-γ production for both CD8 and CD4 T-cells stimulated with 
the SIINFEKL peptide or OVA323-339 peptide, respectively compared to 24 or 96 h co-
culture times. No IFN-γ production was observed following treatment with the PDE 
CpG and OVA mixture. For following IFN-γ production assays, co-cultures were 
harvested after 72 h. In order to compare IFN-γ production of T-cells activated with 
formulations containing PDE CpG or PDE GpC, BMDCs were activated as for the T-
cell proliferation assay with either conjugates or controls and co-cultured with CD8+ 
and CD4+ T-cells from OT-I and OT-II mice. IFN-γ production of T-cells correlated 
with the results obtained from T-cell proliferation. Figure 3.7 B shows that following 
treatment with the SIINFEKL or OVA323-339 peptide, CD8+ and CD4+ T-cells 
produced the statistical significant higher amounts of 20 ng/ml and 8 ng/ml IFN-γ, 
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respectively compared to IFN-γ produced following OVA treatment. Both CD8+ and 
CD4+ T-cells showed a statistically significant higher production of IFN-γ following 
PDE C-4FB-O treatment compared to OVA treated T-cells. No other treatment induced 
IFN-γ production in either CD8+ or CD4+ T-cells. In summary, the IFN-γ produced in 
BMDC-T-cell co-cultures supported the findings from the T-cell proliferation assay, 
showing that T-cells proliferate following PDE C-4FB-O treatment. 
 
 
Figure 3.7: CpG conjugate enhances IFN-γ production of T-cells.  
(A) CD8+ and CD4+ T-cells from OT-I and OT-II mice were co-cultured for 24 h, 48 h and 72 h 
with 1 µM PDE CpG and 17.6 µg/ml OVA or 2.5 µg/ml peptide activated BMDC. Supernatants 
were analysed for IFN-γ by ELISA. (B) BMDC pulsed with 1 µM of PDE CpG or PDE GpC 
either alone, or mixed with 17.6 µg/ml OVA, OVA alone, 17.6 µg/ml of PDE C-4FB-O or PDE 
G-4FB-O or a control of 2.5 µg/ml of SIINFEKL or OVA323-339 peptide or media, were co-
cultured with CD8 or CD4 T-cells isolated from OT-I and OT-II mice. After 72 h the 
supernatants were harvested and IFN-γ levels analysed by ELISA. Bars represent the mean of 




three independent experiments ±SEM, statistical significance was determined by (A) two-way 
ANOVA with Bonferroni post-hoc test or (B) by one-way ANOVA with Dunnett’s multiple 
comparisons test, ****p<0.0001, ***p<0.001; **p<0.01, *p<0.05. Statistical significance displayed 
in (B) is the comparison between the same treatment groups and in (C) is the comparison of all 
treatment groups to OVA treated cells. 
 
3.2.2.2. Titration of the PDE C-4FB-O conjugate 
The initial dose of 17.6 µg/ml of OVA protein for conjugates and OVA and 1 µM of 
PDE CpG for BMDC activation was chosen in accordance to previously reported doses 
of CpG-OVA conjugates for DC activation (431,465). With this dose, the percent 
proliferation of CD8+ T-cells following PDE C-4FB-O treatment was on average 60 %, 
which was very similar to the percent proliferation induced by the positive control 
SIINFEKL. Since the treatment proliferation was similar to that of the positive control 
it is unlikely that further elevation of proliferation is possible. Therefore BMDCs were 
activated with 17.6 µg/ml, 3.5 µg/ml, 0.7 µg/ml and 0.14 µg/ml of the PDE C-4FB-O 
conjugate. SIINFEKL or OVA323-339 peptides were used as positive controls at 
2.5 µg/ml as in the previous assays. Activated BMDCs were co-cultured with CD8+ 
and CD4+ T-cells from OT-I and OT-II mice, respectively, and the production of IFN-
γ in the cell culture supernatant was measured by ELISA. Figure 3.8 A shows that in 
CD8+ T-cells, treatment with 17.6 µg/ml and 3.5 µg/ml of PDE C-4FB-O induced 
comparable IFN-γ production. Treatment with 0.7 µg/ml and 0.14 µg/ml of PDE C-
4FB-O resulted in statistically significant lower production of IFN-γ, comparable to 
untreated cells. In CD4+ T-cells no statistical significant difference in IFN-γ production 
was observed following treatment with any concentration of the conjugate.  
PDE C-4FB-O conjugate at 3.5 µg/ml was then tested in a T-cell proliferation assay to 
compare it to the initial dose of 17.6 µg/ml. Figure 3.8 B shows that in CD8+ T-cells a 
statistically significant reduction of proliferation was observed following treatment 
with 3.5 µg/ml conjugate of on average 40 % proliferation compared to 65 % 
proliferation with 17.6 µg/ml of the conjugate. In CD4+ no statistically significant 
change in T-cell proliferation was seen following treatment with either 17.6 µg/ml or 
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3.5 µg/ml of the conjugate. As the 3.5 µg/ml concentration of PDE C-4FB-O resulted in 
medium percent proliferation of around 40 % in CD8+ and 30 % in CD4+ T-cells, the 
assay got more suitable to assess further conjugates with possible higher percent 
proliferation. Therefore for all subsequent proliferation and IFN-γ assays BMDCs were 
activated with 3.5 µg/ml conjugates or OVA and 0.2 µM CpG.  
 
 
Figure 3.8: Dose responsiveness of cytokine and proliferation assays. 
BMDCs were pulsed for 24 h with C-4FB-O conjugate at the initial concentration of 17.6 µg/ml, 
3.5 µg/ml, 0.7 µg/ml or 0.14 µg/ml or medium or 2.5 µg/ml of SIINFEKL or OVA323-339 
peptide. (A) CD8+ and CD4+ T-cells from OT-I and OT-II mice were added to pulsed BMDCs 
at a ratio of 1:10 and after 72 h the supernatants of co-culture were analysed by ELISA. (B) 
Sorted, CFSE stained CD8+ and CD4+ T-cells from OT-I and OT-II mice were added to activated 
BMDCs and after 72 h percent proliferation of T-cells was determined by proliferation peaks of 
diluted CFSE. Bars represent the mean of three independent experiments ±SEM, statistical 




significance displayed is the comparison between all treatment groups by one-way ANOVA 
with Tukey’s post-hoc test, *p<0.05. 
 
3.2.2.3. Comparison of phosphodiester and phosphorothioate backbone 
in CpG ODN 
As the previous experiments confirmed that PDE CpG ODN induce activation of 
BMDC and subsequent T-cell proliferation when conjugated to OVA, the next study 
was to determine the effect that the PT backbone has on immune cell activation. CpG 
ODNs with a PT backbone have been shown to induce stronger activation of TLR9 than 
ODN with a PDE backbone, as reported in a NF-κB assay (354,506,509). In this assay 
we compared CpG with a PT backbone to CpG with a PDE backbone to activate BMDC. 
Subsequently PT C-4FB-O and PDE C-4FB-O were compared for their ability to induce 
T-cell proliferation. BMDC were activated with either PDE CpG or PT CpG, a mixture 
of PT CpG or PDE CpG with OVA, PDE C-4FB-O or PT C-4FB-O conjugate or a control. 
Figure 3.9 A shows that no treatment induced statistically significant upregulation of 
MHC-II compared to untreated cells. For the CD86 activation marker, only the positive 
control LPS induced statistically significant upregulation compared to untreated cells. 
The CD40 activation marker was significantly upregulated by PT CpG, PT CpG mixed 
with OVA, the PT C-4FB-O conjugate and the positive control LPS compared to 
untreated cells. There was no upregulation observed for OVA or any treatment that 
included PDE CpG.  
For the subsequent T-cell proliferation, activated BMDCs were co-cultured with sorted 
and CFSE stained CD8+ or CD4+ T-cells. The percent proliferation of CD8+ and CD4+ 
T-cells were determined using FlowJo to assess the proliferation peaks visualised by 
different concentrations of CFSE in proliferated cells. Figure 3.9 B shows that in both 
CD8+ and CD4+ T-cells the peptides SIINFEKL and OVA323-339 used as positive 
controls induced statistically significant higher proliferation than OVA while 
untreated cells and cells treated with PDE or PT CpG induced no proliferation which 
was statistically significantly lower compared to cells treated with OVA. The mixtures 
of either PDE CpG or PT CpG with OVA induced similar percentages of proliferation 
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of CD8+ T-cells as OVA. The PDE C-4FB-O conjugate induced 41 % proliferation of 
CD8+ T-cell proliferation which was a small increase compared to percent proliferation 
of OVA treated cells. The PT C-4FB-O conjugate induced 80 % proliferation in CD8+ T-
cells, which was about twice the percentage of proliferation compared to the PDE C-
4FB-O conjugate and similar to the proliferation induced by the peptide. In CD4+ T-
cells, the mixtures of PDE CpG and PT CpG with OVA as well as the PDE C-4FB-O 
conjugate induced a similar percentage of proliferation as OVA did. In a similar 
manner to that seen with CD8+ T-cells, the PT C-4FB-O conjugate induced a 
significantly higher proliferation of CD4+ T-cells of 67 %, comparable to the 
proliferation induced by the peptide. 
In order to confirm the strong activation of T-cells by PT C-4FB-O conjugate, IFN-γ 
levels in the supernatant of BMDC-T-cell co-cultures following activation with PDE 
and PT CpG treatments were measured. Production of IFN-γ matched the results 
obtained from the proliferation assay and confirmed strong activation of both CD8+ 
and CD4+ T-cells by the PT C-4FB-O conjugate. In both T-cell cultures, the IFN-γ 
produced following treatment with the PT conjugate of 28 ng/ml and 6 ng/ml, 
respectively, was comparable to IFN-γ produced following peptide treatment and 
significantly higher than IFN-γ produced by any other treatment (Figure 3.9 C). This 
confirmed that a PT backbone in the CpG ODN induces a stronger immune cell 
response than the same CpG ODN with a PDE backbone. 
 





Figure 3.9: CpG with phosphorothioate backbone increases immune cell activation. 
BMDC were incubated for 24 h with 0.2 µM PDE CpG or PT CpG either alone, mixed with 
3.5 µg/ml OVA or conjugated with OVA or with positive and negative controls. (A) Expression 
of activation markers MHC-II, CD86 and CD40 following BMDC activation. (B) Sorted, CFSE 
stained CD8+ and CD4+ T-cells from OT-I and OT-II mice were co-cultured with activated 
BMDCs for 72 h. Percent proliferation of T-cells was determined by flow cytometry through 
analysing CFSE dilution of proliferation peaks. (C) Unsorted CD8+ and CD4+ T-cells from OT-
I and OT-II mice were co-cultured with activated BMDC for 72 h and IFN-γ in the supernatant 
was measured by ELISA. Bars represent the mean of three independent experiments ±SEM, 
statistical significance was determined by one-way ANOVA with Dunnett’s multiple 
comparisons test, ****p<0.0001, ***p<0.001; **p<0.01, *p<0.05. Statistical significance displayed 
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in (A) is the comparison of all treatment groups to untreated cells and in (B and C) is the 
comparison of all treatment groups to OVA treated cells. 
 
3.2.3. Synthesis of cleavable and stable CpG-OVA conjugates 
PT ODN with a CpG motif was confirmed in the above experiments to induce BMDC 
activation and to generate a strong T-cell proliferation when conjugated to OVA. PT 
CpG conjugated to OVA has been reported to induce an enhanced immune response 
over a mixture of CpG and OVA both in vitro and in vivo (335,432,504). To test whether 
a reversible linker or a linker with a spacer arm could generate an enhanced TH1-type 
immune response over a stable linker, PT CpG-OVA conjugates were synthesised with 
different linking strategies (Table 3.3). The bis-aryl hydrazone linked conjugate C-4FB-
O was synthesised to test the immune response generated by a stable CpG-OVA 
conjugate. A second stable conjugate was synthesised with a polyethylene glycol (PEG) 
spacer arm as a linker to test if the spatial distance between CpG and OVA has an effect 
on the generated immune response. Reduction and enzyme triggered release were 
used as two strategies for the synthesis of reversible conjugate. Two different 
disulphide bond containing linkers (4FBSS and SPDP) were used which were designed 
to be cleaved by reduction. Cathepsin S (CatS) which is a protease resident in the 
endosome of APCs was chosen as an enzymatic trigger. The peptide sequence 
GRWPPMGLPWEK was chosen as the CatS substrate, as Lützner et al reported it to be 
specifically cleaved by CatS but resistant to related proteases (476).  
Previous reports have shown that which end of the CpG is conjugated onto OVA 
effects the ability of CpG to activate TLR9 (see Introduction). To test whether the 
direction of conjugation effects BMDC activation and subsequent T-cell proliferation, 
all conjugates were synthesised with CpG conjugated via the 3’ or 5’ end. Table 3.3 
shows a summary of all conjugates made with the CpG and the linkers used.  
 
 




Table 3.3: Overview of PT CpG and OVA conjugates 
Conjugate ODN Linker 
5’ C-4FB-O 5’ CpG-NH2 4FB, HyNic 
3’ C-4FB-O 3’ CpG-NH2 4FB, HyNic 
5' C-4FBSS-O 5’ CpG-NH2 4FBSS, HyNic 
3' C-4FBSS-O 3’ CpG-NH2 4FBSS, HyNic 
5' C-SPDP-O 5’ CpG-SH LC-SPDP 
3' C-SPDP-O 3’ CpG-SH LC-SPDP 
5' C-PEG-O 5’ CpG-SH MAL-PEG4-NHS 
3' C-PEG-O 3’ CpG-SH MAL-PEG4-NHS 
5' C-peptide-O 5’ CpG-SH DBCO, MAL-peptide-N3 
3' C-peptide-O 3’ CpG-SH DBCO, MAL-peptide-N3 
CpG, cytosine-phosphate-guanine; DBCO, dibenzocyclooctyne; LC-SPDP, succinimidyl 6-
(3-[2-pyridyldithio]-propionamido)hexanoate, MAL, maleimide group; N3, azide group; 
NH2, amine group; NHS, N-Hydroxysuccinimide; OVA, ovalbumin; PEG4, four-unit 
polyethylene glycol; SH, thiol group 
 
3.2.3.1. Synthesis of C-4FB-O 
The C-4FB-O conjugate was synthesised as described in Section 3.2.1 with the 
exception that CpG was conjugated either via the terminal 5’ or 3’ amine group.  
 
3.2.3.2. Synthesis of C-4FBSS-O 
The disulphide bond containing conjugate C-4FBSS-O was made similar to the C-4FB-
O conjugate, following the protocol provided by Solulink (452). The terminal amine 
group either at the 5’ or 3’ end of CpG was modified to an aromatic aldehyde by 
reacting the amine with the activated ester of the linker succinimidyl-SS-4-
formylbenzoate (4FBSS), an analogue of the 4FB chemical containing a disulphide 
bond (see Scheme 3.2). Following completion of the reaction after incubation for 2 h at 
room temperature, unreacted 4FB linker was removed by spin filtration. The average 
MSR of CpG with 4FBSS was 1.0 ± 0.2, as determined by using the absorbance of the 
colorimetric bond between 2-HP and the aldehyde group (see Methods Section 2.1.4.2). 
Hydrazine functional groups were then introduced on to OVA by modifying the amine 
groups on OVA by reaction with the activated ester of the linker HyNic. Unreacted 
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4FB linker was removed using spin filtration units. Spectroscopy analysis of the 
colorimetric bond formed between 2-SBA and hydrazine groups determined the 
average MSR to be 6.1 ± 1.6 (see Methods Section 2.1.4.4), the same as in the 4FB 
conjugation, see Section 3.2.1. The 4FBSS modified CpG was then reacted with the 
HyNic modified OVA at a molar ratio of 4:1. Equal to the C-4FB-O conjugation, the 
conjugation process was completed after 2 h and the conjugation ratio was determined 
to be on average 2.8±0.3, as confirmed by absorbance measurement at 354 nm (see 
Methods Section 2.1.4.5). The C-4FBSS-O conjugates were purified by SEC analysis 
(Superdex™ 200 10/300 GL SEC column). The conjugates eluted between 
15 min – 28 min and were collected on ice (Figure 3.10 B).  
 
Scheme 3.2: Synthesis of the disulphide bond containing linker C-4FBSS-O 
 
3.2.3.3. Synthesis of C-SPDP-O 
For the synthesis of the disulphide bond containing conjugate C-SPDP-O, thiol 
modified CpG were used. Our conjugation method was based on the protocol 




provided by Thermo Scientific Inc. (530) which involves a two-step process as shown 
in Scheme 3.3. As thiol groups are prone to oxidation when stored at 4 °C, they were 
reduced by DTT prior to conjugation (see Methods Section 2.1.2.1). Purification of the 
reduced CpG from DTT was performed using SEC (Superdex™ 200 10/300 GL SEC 
column), with the CpG eluting between 32 – 40 min (Figure 3.10 A). The pooled CpG 
fractions were then concentrated with a Vivaspin 2 spin filter unit and the ODN 
concentration was determined by spectrometry at 260 nm. Amine groups on purified 
OVA (see Section 3.2.1) were reacted with N-hydroxysuccinimide (NHS) ester groups 
on the heterobifunctional, disulphide containing cross-linker succinimidyl 6-(3-[2-
pyridyldithio]-propionamido)hexanoate (LC-SPDP). A pyridine-2-thione assay 
determined the level of pyridyldithiol-modification to be 7.8±0.8 moles of 
pyridyldithiol per mole of OVA by measuring the change of absorbance at 343 nm after 
reduction of SPDP modified OVA with DTT (see Methods Section 2.1.5.2). As a second 
step the terminal thiol group either at the 5’ or 3’ end of CpG was reacted with the 
pyridyldithiol-activated OVA at a ratio of 4:1 to form the conjugate C-SPDP-O (see 
Scheme 3.3). The C-SPDP-O conjugates were purified by SEC analysis (Superdex™ 200 
10/300 GL SEC column). The conjugates eluted between 20 min – 28 min and these 
fractions were collected on ice (Figure 3.10 C) and stored at 4 °C.  
 




3.2.3.4. Synthesis of C-PEG-O 
The stable conjugate C-PEG-O was synthesised in a two-step reaction (see Scheme 3.4). 
Incubation times of reactions were based on previously reported times for reactions 
with maleimide (MAL) and NHS ester groups (439). Thiol modified CpG was reduced 
and the terminal thiol group either on the 5’ or 3’ end of CpG was reacted with the 
MAL group on the heterobifunctional four-unit PEG (MAL-PEG4-NHS) linker to form 
a thioether bond. Unconjugated linker was removed by spin filtration. Amine groups 
on purified OVA were subsequently reacted with the NHS ester groups on the PEG4 
modified CpG at a ratio of 4:1 to form the conjugate C-PEG-O. As above, the C-PEG-O 
conjugates were purified by SEC analysis (Superdex™ 200 10/300 GL SEC column). 
The conjugates eluted between 25 min – 28 min and these fractions were collected on 
ice were collected on ice (Figure 3.10 D) and stored at 4 °C.  
 
Scheme 3.4: Synthesis of the polyethylene glycol spacer containing conjugate C-
PEG-O  
 




3.2.3.5. Synthesis of C-peptide-O 
The conjugate C-peptide-O was synthesised in a three-step process (Scheme 3.5, 3.6 
and 3.7). Our conjugation method was based on the protocol provided by Interchim 
Inc (531). The amine groups of purified OVA were reacted with NHS ester groups on 
the heterobifunctional linker dibenzocyclooctyne (DBCO), see Scheme 3.5. Unreacted 
DBCO linker was removed using spin filtration units. The azide-group on the Cat S 
substrate (MAL-peptide-N3) was then reacted with the DBCO modified OVA via 
copper free click chemistry, see Scheme 3.6. Unconjugated peptide was removed by 
using spin filtration. Thiol modified CpG was reduced by DTT (see Methods Section 
2.1.2.1) and the terminal thiol group either on the 5’ or 3’ end of CpG was reacted with 
the maleimide group on the peptide at a ratio of 4:1 to form the C-peptide-O conjugate, 
see Scheme 3.7. The C-peptide-O conjugate was purified by SEC analysis (Superdex™ 
200 10/300 GL SEC column). The conjugates eluted between 9 min – 28 min and these 
fractions were collected on ice (Figure 3.10 E) and stored at 4 °C.  
 





Scheme 3.6: Modification of OVA-DBCO with MAL-peptide-N3 
 
 
Scheme 3.7: Synthesis of the Cathepsin S substrate containing conjugate C-peptide-
O  
Following SEC purification, the collected conjugate was concentrated using a Vivaspin 
2 filter unit and the concentration of the conjugates was determined using the Quant-
iT kit. The protein concentration of the conjugates ranged between 400 -600 µg/ml and 
they were adjusted to a stock concentration of 50 µg/ml for all cell culture experiments 




or 400 µg/ml for all HPLC analysis. Table 3.4 shows a summary of all synthesised 
conjugates with the yields of conjugation and the elution times on the Superdex SEC 
column. The yield was calculated as the percentage of OVA measured in the final 
concentration of the conjugate divided by the initial amount of OVA used for each 
conjugation. 
 
Table 3.4: Yield and elution times on Superdex SEC column of CpG-OVA 
conjugates 




5’ C-4FB-O 64 15-28 
3’ C-4FB-O 67 15-28 
5' C-4FBSS-O 66 15-28 
3' C-4FBSS-O 65 15-28 
5' C-SPDP-O 49 20-28 
3' C-SPDP-O 50 20-28 
5' C-PEG-O 25 25-28 
3' C-PEG-O 23 25-28 
5' C-peptide-O 68 9-28 








Figure 3.10: Size-exclusion chromatographic analysis of CpG and conjugates. 
(A) Reduced, thiol modified CpG or (B) C-4FBSS-O, (C) C-SPDP-O, (D) C-PEG-O, or (E) C-
peptide-O conjugate following conjugation reaction were injected onto Superdex™ 200 10/300 
GL SEC column equilibrated in PBS buffer, pH 7.4 at a flow rate of 0.5 ml/min. Absorbance at 
260 nm was recorded. The chromatographs shown are representative for analysis of reduced 
CpG and synthesised conjugates.  
 
3.2.4. Immune cell activation by CpG linked via 3’ end or 5’ end 
to OVA  
CpG as the vaccine adjuvant can be conjugated onto OVA either via the 3’ end or the 
5’ end of the CpG. Publications in the past state that an accessible 5’ end of CpG is 
necessary for splenocyte activation and therefore conjugation via the 3’ end is believed 
to be advantageous for immune cell activation (510,512,513,532). To determine whether 
the end of CpG conjugated to OVA affects BMDC activation and subsequent T-cell 
proliferation, CpG modified with functional groups on either the 3’ end or the 5’ end 
were used for conjugation to OVA to make the five different conjugates C-4FB-O, C-
4FBSS-O, C-SPDP-O, C-PEG-O and C-peptide-O (see Table 3.3). The conjugates were 
characterised on SEC (Yarra-2000 column) and their elution profiles were compared. 
SEC analysis showed no difference between the 3’ and 5’ version of each conjugate, as 
a representative overlay of the elution profiles of the 3’ C-4FB-O and 5’ C-4FB-O 
displays (for chromatographs of all 3’ and 5’ linked conjugates, see Appendix 3). For 
the immune activation assays, BMDC were activated with either a 3’ or 5’ conjugate, a 
mixture of OVA and CpG or a control (see Method Section 2.3.7). Level of activation 
was determined by comparing the samples on the upregulation of the markers MHC-
II, CD86 and CD40. Figure 3.11 B shows that LPS, the positive control, induced strong 
activation of BMDC as observed by high expression of all three activation markers. 
There was no significant difference in upregulation for all treatment groups containing 
CpG, whether CpG conjugated to OVA via the 3’ or 5’ end. 
In order to determine whether the direction of conjugation of CpG has an effect on T-
cell activation by conjugate pulsed BMDC, T-cell proliferation and IFN-γ release were 
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measured following a BMDC-T-cell co-culture. Following the method described in 
Section 3.2.2 for T-cell proliferation, sorted, CFSE stained CD8+ and CD4+ T-cells were 
co-cultured with activated BMDCs after which the proliferation of T-cells was 
determined. For the IFN-γ assay unsorted T-cells were co-cultured with BMDCs to 
analyse the cell culture supernatant for IFN-γ by ELISA. Figure 3.11 C and D show no 
significant difference in either T-cell proliferation or IFN-γ production when 
comparing the same conjugate made either by 3’ or 5’ conjugation of CpG. The 3’ and 
5’ C-4FB-O and 3’ and 5’ C-4FBSS-O conjugates induced strong CD8+ and CD4+ T-cell 
activation both observed by a high percentage of proliferation as well as high 
production of IFN-γ. In contrast to that, the 3’ and 5’ C-SPDP-O, 3’ and 5’ C-PEG-O 
and 3’ and 5’ C-peptide-O conjugates induced no or only low T-cell activation, as both 
observed by low T-cell proliferation and IFN-γ production with also no difference in 
proliferation or IFN-γ production whether CpG was conjugated via the 3’ or 5’ end. In 
the following experiments 3’ linked conjugates were used following recommendations 
from previous studies (513), however as in this study no difference between the 3’ or 
5’ linked conjugates was observed, we expect that using 5’ linked conjugates would 
have resulted in the same outcomes.  
The differences in T-cell proliferation between conjugates was not statistically analysed 
here, as the scope of this experiment was to determine the differences in CpG linked 
via the 3’ or 5’ end. Further immunological testing of the CpG-OVA conjugates is 
reported in Chapter 4.  
 







Figure 3.11: Conjugation of CpG via 3’ or 5’ end to OVA does not result in a 
difference in immune cell activation.  
CpG was conjugated to OVA either via 3’ (darker colour) or 5’ (lighter colour) to form the 
conjugates C-4FB-O (blue), C-4FBSS-O (red), C-SPDP-O (green), C-PEG-O (purple) or C-
peptide-O (yellow). (A) 3’C-4FB-O and 5’C-4FB-O were injected onto analytical Yarra-2000 SEC 
column. Absorbance at 260 nm was recorded for the run time of 20 min at a flow rate of 
0.35 ml/min. Results are presented as an overlay of representative elution profiles of three 
independent experiments. (B) BMDCs were activated with 3.5 µg/ml of a conjugate, OVA alone, 
0.2 µM CpG alone, a mixture of CpG and OVA, 2.5 µg/ml of LPS, SIINFEKL or OVA323-339 as 
positive control, or media alone as negative control. Expression of activation markers MHC-II, 
CD86 and CD40 is shown as median fluorescent intensity (MFI). (C) Sorted, CFSE stained CD8+ 
and CD4+ T-cells were co-cultured with activated BMDCs for 72 h. Percent proliferation of T-
cells was determined by flow cytometry through analysing CFSE dilution of proliferation 
peaks. (D) Unsorted CD8+ and CD4+ T-cells were co-cultured with activated BMDC for 72 h 
and IFN-γ in the supernatant was measured by ELISA. Bars represent the mean of three 
independent experiments ±SEM. 
 
3.2.5. Characterisation of CpG-OVA conjugates 
3.2.5.1. Size-exclusion chromatography 
All conjugates were characterised via SEC to determine their relative size to OVA and 
CpG. Since the conjugation ratio for C-SPDP-O, C-PEG-O and C-peptide-O could not 
be determined by simple UV spectroscopy, the level of conjugation was determined by 
monitoring the change in size by SEC. This was done by comparing their conjugate 
size to that of the characterised C-4FB-O and C-4FBSS-O conjugates which have known 
conjugation ratios. The results displayed here show elution profiles as measured by 
260 nm absorbance however a wavelength scan of 190 – 400 nm was done for the C-
4FB-O and C-4FBSS-O conjugate to compare the elution profiles at different 
wavelengths. The wavelength scan gave additional confirmation for conjugation of 
OVA to ODN, as the two conjugates showed high absorption at the ODN specific 
wavelength of 260 nm as well as at 220 nm, at which OVA strongly absorbs due to 
double bonds in the amino acids (533) (see Appendix 3 for a 3D wavelength plot of 




CpG, OVA and the C-4FB-O conjugate). Figure 3.12 A shows the elution profile of the 
mobile phase, the observed peak and subsequent dip at 11.4 min was characteristic of 
the Yarra-2000 SEC column and can be observed in all chromatograms. Unconjugated 
CpG and OVA were analysed by SEC and their retention times were noted to detect 
any free, unconjugated OVA or CpG in the conjugates. Figure 3.12 B shows that OVA 
eluted 8.7±0.1 min after injection and CpG eluted after 9.4±0.1 min.  
Figure 3.12 C shows that the C-4FB-O conjugate pool eluted between 6 – 8.5 min, the 
elution profile identified different populations of conjugates in this range which 
implies a heterogeneous conjugation ratio of CpG to OVA. The conjugation ratio 
average was 2.8±0.3 CpG per OVA as determined by absorbance measurement (see 
Section 3.2.1). A small peak at 9.5 min indicated small amounts of residual 
unconjugated CpG. The elution profile of the C-4FBSS-O conjugate pool was similar to 
the one displayed by C-4FB-O, with an elution time between 6 – 8.5 min, indicating a 
similar distribution ratio of CpG and OVA as C-4FB-O (Figure 3.12 D). Similarly for 
the C-4FBSS-O conjugate a small amount of residual free CpG was detected. Figure 
3.12 E shows the C-SPDP-O conjugate eluted between 5.5 – 9 min with a heterogeneous 
elution profile. As no ratio of CpG to OVA was determined for the C-SPDP-O 
conjugate, the similar elution time of the conjugate as the C-4FB-O and C-4FBSS-O 
conjugates indicates a similar size of the conjugate and therefore similar conjugation 
ratio of approximately 2.8 CpG per OVA. The C-PEG-O conjugate resulted in a more 
homogeneous elution profile, as shown in Figure 3.12 F, with one distinct peak at 
8.0 min, however the elution time was between 6 – 8.8 min, comparable to the C-4FB-
O, C-4FBSS-O and C-SPDP-O conjugates, which lead to approximation of the 
conjugation ratio of 2.8 CpG per OVA. Figure 3.12 G shows that the elution profile of 
the C-peptide-O conjugate differed from the other conjugates. The elution of the 
conjugate started at 5 min and the peak has a flat face, indicating that it may be at the 
exclusion limit of the column. This early elution time and flat peak shape indicates a 








Figure 3.12: Elution profiles of conjugates on SEC.  
The conjugates (C) C-4FB-O, (D) C-4FBSS-O, (E) C-SPDP-O, (F) C-PEG-O and (G) C-peptide-O 
as well as (A) the mobile phase and (B) a mixture of OVA and CpG as control were adjusted to 
a concentration of 75 µg/ml in PBS. 25 µl of each conjugate or control were injected onto a Yarra-
2000 SEC column. The absorbance at 260 nm was recorded for the run time of 15 min at a flow 
rate of 0.35 ml/min. The chromatographs shown are representative for analysis of synthesised 
conjugates.  
 
3.2.5.2. Reduction of conjugates by glutathione 
GSH is the main reducing agent present inside the cell responsible for reducing 
disulphide bonds to regulate nutrient metabolism, gene expression and immune 
responses among others (490). The susceptibility of the conjugates to GSH and 
especially the reducibility of the disulphide bond in the C-4FBSS-O and C-SPDP-O 
conjugates was determined in an in vitro cleavage assay using SEC. GSH dissolved in 
PBS was used to mimic the known high intracellular and low extracellular reducing 
conditions. The concentration of 5 mM GSH for intracellular conditions and 10 µM for 
extracellular conditions were chosen as representative concentrations of GSH from the 
reported range of 0.5-10 mM and 2-40 µM GSH present intra- and extracellularly 
(478,490). DTT at 5 mM was used as a control as it is a very potent reductive agent 
(478). The conjugates C-4FB-O, C-4FBSS-O, C-SPDP-O, C-PEG-O and C-peptide-O 
were incubated either with PBS or PBS containing either 10 µM GSH, 5 mM GSH or 
5 mM DTT for 2 h at 37 °C (see Methods Section 2.2.1.2). As a control also a mixture of 
CpG and OVA was incubated with DTT. The cleavage of conjugates was determined 
by change in elution peak size as monitored by SEC. The results are presented as an 
overlay of elution profiles for each conjugate, the original chromatograms are included 
in Appendix 3. Figure 3.13 A shows that DTT did not influence the chromatographic 
profile of free CpG or OVA. The C-4FB-O, C-PEG-O and C-peptide-O conjugates were 
not cleaved by either GSH or DTT, as their chromatographic profiles did not change as 
shown in the overlays in Figure 3.13 B, E and F. Elution profiles of conjugates or the 
CpG/OVA mixture treated with DTT showed an additional peak at 12.8 min, 
representing the free DTT. Figure 3.13 C shows that the disulphide bond containing 
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linker C-4FBSS-O was stable at the extracellular concentrations of GSH of 10 µM as 
there was no change in the elution profile. However at the higher intracellular GSH 
concentration of 5 mM the conjugate was cleaved, the peak between 6 – 8.5 min were 
reduced while the peak at 9.4 min, representing free CpG, increased. No peak was 
observed at 8.7 min, specific for free OVA. C-4FBSS-O was also cleaved following 
treatment with DTT, resulting in no more elution between 6 -8 min, however peaks at 
8.7 min and 9.4 min appeared, representing free OVA and CpG. Figure 3.13 D shows 
that the other disulphide bond containing conjugate, C-SPDP-O was cleaved at both 
intracellular (5 mM) and extracellular (10 µM) concentrations of GSH. Following both 
GSH treatments, only minimal elution peaks were recorded at 5.5 – 8.1 min, however 
a peak eluted after 9.4 min representing free CpG. As in the C-4FBSS-O conjugate, no 
peak at 8.7 min was observed following GSH treatment in the C-SPDP-O conjugate. 
DTT treatment in C-SPDP-O resulted in a similar elution profile as for the DTT treated 
C-4FBSS-O conjugate, with no more peaks recorded at the previous conjugate elution 
times but with peaks at 8.7 min and 9.4 min, representing free OVA and CpG. The GSH 
reduction assay showed that the C-4FBSS-O conjugate was cleaved at intracellular but 
not extracellular concentrations of GSH while the C-SPDP-O conjugate disulphide 
bond was cleaved at both extra- and intracellular concentrations of GSH. All other 
conjugates were stable to reduction.  
 





Figure 3.13: C-SPDP-O is cleaved by extracellular and C-4FBSS-O by intracellular 
concentrations of glutathione (GSH).  
A mixture of CpG and OVA was incubated with PBS (pink) or 5 mM DTT (blue) and the 
conjugates (B) C-4FB-O, (C) C-4FBSS-O, (D) C-SPDP-O, (E) C-PEG-O and (F) C-peptide-O were 
incubated with either PBS (pink), 10 µM GSH (green), 5 mM GSH (red) or 5 mM DTT (blue) for 
2 h at 37 °C. 25 µl of each treated conjugate and control were then run on a Yarra-2000 SEC 
column. The absorbance at 260 nm was recorded for the run time of 15 min at a flow rate of 





3.2.5.3. Stability of conjugates in cell culture supernatant 
The conjugate C-SPDP-O was shown to be reduced by GSH at 10 µM which represents 
the extracellular reducing conditions. In order to confirm the validity of GSH as a 
model, the stability of the conjugates in cell culture supernatant harvested from a 
BMDC cell culture and in fresh cell culture media (Complete Iscove’s Modified 
Dulbeccos’s Medium, cIMDM) was determined. 2-ME is routinely added to cell culture 
media as a strong reductant to prevent harmful levels of oxygen radicals, therefore this 
assay also tests whether the conjugates are cleaved by the low concentration (55 µM) 
of 2-ME present in cell culture media. Conjugates at 400 µg/ml were diluted to 
75 µg/ml with either PBS, cell culture medium or cell culture supernatant from BMDC 
cell culture at day 6 and were incubated overnight at 37 °C (see Methods Section 
2.2.1.3). Following incubation, the conjugates and supernatant as a control were 
analysed on SEC. The results are presented as an overlay of elution profiles for each 
conjugate, the original chromatograms are included in Appendix 3. Figure 3.14 A 
shows the elution profile of cell culture supernatant, peaks at 8.14, 11.5, 12.4 and 
13.6 min were noted for the supernatant alone. The peak at 8.14 min was observed for 
all conjugates incubated in cell culture supernatant. Incubation of conjugates with cell 
culture media showed the same peaks at 11.5, 12.4 and 13.6 min as in the supernatant, 
however no peak at 8.14 min was observed. Figure 3.14 B, E and F show no change in 
profile for the conjugates C-4FB-O, C-PEG-O and C-peptide-O following incubation 
with either cell culture media or supernatant. C-4FBSS-O conjugate also showed no 
change in elution profile following incubation with the supernatant, except for the 
mentioned interfering peak at 8.14 min as shown in Figure 3.14 C. However following 
incubation with media an additional peak at 9.4 min was observed. The elution profile 
of the C-SPDP-O conjugate showed no difference following treatment with PBS or 
media (Figure 3.14 D). However after incubation with cell culture supernatant, the 
conjugate peak between 5.5-9 min dropped in intensity indicating cleavage of the 
conjugate by the cell culture supernatant. The chromatogram showed the formation of 
a larger peak at 5.6 min while a disappearance of the peak at 8.14 min. 





Figure 3.14: C-SPDP-O conjugate is cleaved in cell culture supernatant. 
The conjugates (B) C-4FB-O, (C) C-4FBSS-O, (D) C-SPDP-O, (E) C-PEG-O and (F) C-peptide-O 
were incubated overnight at 37 °C in either PBS, IMDM cell culture medium containing 55 µM 
2-ME or cell culture supernatant from a BMDC cell co-culture. 25 µl of the treated conjugates 
or (A) the cell culture supernatant as a control were injected onto a Yarra-2000 SEC column. The 
absorbance at 260 nm was recorded for the run time of 15 min at a flow rate of 0.35 ml/min. 





3.2.5.4. Activity of Cathepsin S on C-peptide-O conjugate 
Cat S has been shown to cleave the substrate GRWPPMGLPWEK between the glycine 
and the leucine, while resistant to digestion by Cat B and Cat L (476). As Cat S has been 
reported to be selectively expressed in the endo-lysosome of APCs (469,475), the 
GRWPPMGLPWEK peptide may be a suitable peptide linker for targeted cleavage in 
the endosome of APCs. In order to test the ability of Cat S to cleave the C-peptide-O, 
the conjugate was incubated with 15 µg/ml Cat S or PBS overnight at 37 °C and was 
analysed the next day on a Yarra-2000 SEC column (see Methods Section 2.2.1.4). 
Figure 3.15 shows that the elution profile of C-peptide-O with or without incubation 
with Cat S were identical, indicating no cleavage of the C-peptide-O conjugate by Cat 
S. The results are presented as an overlay of elution profiles for C-peptide-O, the 
original chromatograms are included in Appendix 3. 
 
 
Figure 3.15: CatS does not cleave C-peptide-O. 
The conjugate C-peptide-O was incubated with 0.15 µg/ml CatS or PBS overnight at 37 °C and 
25 µl of each treatment were injected onto Yarra-2000 SEC column. The absorbance at 260 nm 
was recorded for the run time of 15 min at a flow rate of 0.35 ml/min. Results are presented as 
an overlay of representative elution profiles of C-peptide-O following incubation with PBS or 
CatS of three independent experiments. 
 
3.2.5.5. pH stability of conjugates 
Antigen internalised by APC are predominantly processed in the endosome, with the 
early endosome being characterised by a pH of 6.0 - 6.8. The pH further drops during 
endosomal processing to reach a pH of 5.0 – 6.0 in the late endosome and 4.0 – 5.0 in 
the lysosome (478). The C-4FB-O and C-4FBSS-O conjugates were linked via a bis-aryl 
hydrazone bond which has been shown previously to be stable to hydrolysis while 




stable thioether and amide bonds were used to link the other conjugates. In order to 
confirm that the conjugate linkers are not hydrolysed in the low pH of the endosome, 
the stability of the conjugates towards low pH was tested. The conjugates were 
incubated overnight at pH 7.4, 6.0 and 5.0 at 37 °C to mimic the time, temperature and 
pH conditions they encounter when being internalised by BMDCs (478) (see Methods 
Section 2.2.1.5). To ensure the conjugates were at the correct pH value, concentrated 
conjugates at 400 µg/ml were diluted to the analysis concentration of 75 µg/ml with 
buffers set to the desired pH and pH-paper was used to confirm the resulting pH in 
the conjugate solution (see Appendix 3). SEC was used to determine the stability of the 
conjugates in the different pH conditions, and the resulting chromatographs at 260 nm 
for each conjugate at the three different pH conditions were overlaid to compare the 
elution profiles. The original chromatograms are included in Appendix 3. Figure 3.16 
shows that all five conjugates were stable as no cleavage products occurred at either 
pH of 7.4, 6.0 or 5.0. The elution profiles of C-4FBSS-O at pH 6.0 and C-SPDP-O at pH 
5.0 showed the same elution profile of the respective conjugate, however an additional 





Figure 3.16: Conjugates are not cleaved in low pH conditions.  
The conjugates (A) C-4FB-O, (B) C-4FBSS-O, (C) C-SPDP-O, (D) C-PEG-O and (E) C-peptide-O 
were incubated overnight at 37 °C in PBS at either pH 7.4, 6.0 or 5.0. 25 µl of each treated 
conjugate were run on Yarra-2000 SEC column. The absorbance at 260 nm was recorded for the 
run time of 15 min at a flow rate of 0.35 ml/min. Results are presented as an overlay of 
representative elution profiles of three independent experiments. 
  





This chapter has reported the synthesis of five CpG-OVA conjugates designed to 
generate a TH1-type immune response. The conjugates were synthesised with either 
stable or reversible linkers and the stability of the linkers towards triggers mimicking 
the extra- and intracellular environment of immune cells was analysed.  
Before comparing the linking strategies between CpG and OVA, the components of 
CpG and OVA conjugates were analysed individually and as part of a stable conjugate. 
SEC analysis of the commercially sourced OVA (Sigma-Aldrich) showed high 
molecular weight aggregates in the OVA preparation. The aggregates were estimated 
to be about three to four times the size of the OVA monomer by comparing retention 
times of the OVA aggregates on SEC to the calibration curve set up from retention 
times of the protein standard. The determined molecular weight should be treated as 
an estimate only, as the standards were supplied for qualitative performance testing 
only. For a more accurate size determination, protein standards designed for 
calibration should have been used. Calculation of the calibration curve could have then 
been done by plotting the Stoke’s radius of the proteins as size with the distribution 
coefficient Kd for each protein. Kd is calculated as the difference between the elution 
volume for each protein and the void volume of the column, divided by the total 
volume of the column (534,535). For future studies set up of an analytical calibration 
curve for the Yarra-2000 analytical SEC column should be considered, or the mass of 
OVA and the conjugates could be determined using liquid chromatography–mass 
spectroscopy. Conjugation of CpG to un-purified OVA which contains OVA 
aggregates would result in the generation of a larger molecular range of conjugate 
populations which would have to be purified out. These high molecular weight 
aggregates may interfere with the generation of a TH1-type immune response, since 
previous studies have shown that aggregated antigens generate lower 
immunogenicity for cytotoxic T lymphocytes (CTL) compared to native antigens in 
vivo (536). OVA was therefore purified from aggregates for all experiments in this work 
and we suggest that for any future work analysis and purification of antigens should 
be considered.  
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The stable 4FB conjugates were synthesised with a hydrazone linker, using 
components and following the protocol supplied by Solulink. The comprehensive 
conjugation protocol did not require optimisation as the conjugation resulted in high 
yields of above 64 % (see Table 3.4) and expected conjugation ratios similar to previous 
studies (501). Previous studies conjugating CpG to OVA reported conjugation ratios 
between two to three CpG per OVA, the average conjugation ratio of 2.8±0.3 CpG per 
OVA in this study therefore facilitates comparisons to conjugates made in the previous 
studies (335,431,432,465,521,528).  
TLR9 has been shown to be activated by binding of CpG ODN which triggers pro-
inflammatory gene description, leading to phenotypic changes in APCs as well as 
release of pro-inflammatory cytokines (42,351). Upregulation of the markers MHC-II, 
CD86 and CD40 were used as a readout for activation of APCs, as in conjunction with 
immunostimulatory cytokines and antigen epitope presentation on MHC-I or MHC-II 
molecules, CD86 and CD40 play an essential role in priming T-cells for the induction 
of an immune response (42,92,351).  
As the focus of this study was to generate a conjugate that could elicit optimal TH1 
responses, a class B 1668 CpG ODN was used for the CpG component of the conjugate, 
without comparing different classes or modifications of CpGs. Therefore, only class B 
CpGs were tested in order to confirm the strong immunostimmulatory effect of the 
CpG ODN with a PT backbone by comparing it to PDE ODN with a CpG or control 
GpC motif. PDE ODN without a CpG motif have been shown to activate TLR9, albeit 
not to the same extend as PDE ODN with a CpG motif (368,507). Interestingly, in this 
study there was no significant difference in upregulation of the MHC-II and CD86 
markers by PDE ODN with either a CpG or a GpC motif while the PDE CpG induced 
much stronger activation of CD40 than the PDE GpC ODN. As the PDE CpG conjugate 
subsequently induced enhanced T-cell proliferation while the PDE GpC ODN did not, 
it can be followed that that the PDE CpG ODN did indeed lead to an enhanced APC 
activation over the PDE GpC ODN. Although activation of TLR9 by GpC ODN has 
been reported previously, TLR9 activation by the PDE control ODN GpC may have 




been too low to detect by BMDC activation assay as also PDE ODN with a CpG motif 
only induced a low upregulation of activation markers.  
CpGs with a PT backbone have been shown to induce a much stronger activation of 
APCs compared to PDE backbone CpGs through stronger TLR9 activation (507). Our 
studies have confirmed increased APC activation by PT CpG as PT CpGs induced 
significantly higher upregulation of the CD40 activation marker compared to PDE 
CpG. Additionally conjugation of the PT CpG to OVA was shown to induce a much 
stronger CD4+ and CD8+ T-cell proliferation compared to the PDE C-4FB-O conjugate. 
This supports that PT CpGs induce enhanced APC activation, as a key factor for T-cell 
differentiation is the interaction with a fully activated APC (44). The difference was 
especially noticeable as the dosing of PDE C-4FB-O was titrated to a fifth of previously 
reported doses being used (431,465). As the highest percentage of proliferation by the 
positive control SIINFEKL peptide was 70%, and the initial concentration of PDE C-
4FB-O conjugate induced 60% proliferation in T-cells not much space for improvement 
was allowed. The titrated, lower concentration of 3.5 µg/ml however induced a 40 % 
difference in T-cell proliferation following PDE and PT conjugate treatment.  
IFN-γ produced by the T-cells is an indication for their activation, however it does not 
always correspond with the level of proliferation observed for the T-cells. In the 
titration assay the 17.6 µg/ml and 3.5 µg/ml concentrations of conjugate induced 
similar production of IFN-γ while lower doses of conjugates induced no production of 
IFN-γ. This may indicate that from a certain threshold an increasing amount of 
conjugate internalised by BMDC may not lead to a change in T-cell activation. The lack 
of statistical difference in CD4+ T-cell proliferation following treatment with the two 
concentrations of the PDE C-4FB-O conjugate would support this idea while the 
statistical difference observed in CD8+ T-cell proliferation does contradict it. The total 
amount of conjugate internalised by APCs could also lead to differences in activation 
and proliferation of the different T-cell populations, with CD8+ T-cells displaying an 
enhanced response to an increased amount of antigen while CD4+ T-cells displaying 
the same response to low and high concentrations of antigen. In order to determine 
whether the total amount of conjugate internalised by APC induces a difference in T-
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cell activation and proliferation further studies should be conducted in the future. 
Previous studies have reported that the dose of antigen internalised by DCs affects the 
development of naïve CD4+ T-cells into either TH1 or TH2 cells, this should be taken 
into account in a more thorough conjugate titration assay (537).  
The C-4FBSS-O, C-SPDP-O and C-peptide-O conjugates designed to be reversible as 
well as the stable conjugate C-PEG-O were synthesised additionally to the C-4FB-O 
conjugates using PT CpG and purified OVA. The yield differed between the linking 
strategies. As expected the thioether linkage used in C-SPDP-O and C-PEG-O resulted 
in lower yields compared to the hydrazone linkages as described earlier (501,521,538). 
Interestingly, the C-peptide-O conjugation resulted in high yields comparable to the 
hydrazone conjugations. The difference in yield might be caused by a difference in 
quality of the maleimide group on the PEG4, SPDP and peptide linkers as the same 
batch of thiolated CpG was used for each of the thioether reactions. This was 
substantiated by the observation that SPDP was successfully conjugated to OVA which 
makes the maleimide to thiol reaction of SPDP to CpG the limiting step.  
Determination of the conjugation ratio of CpG and OVA has been a challenge in this 
and previously reported studies. Conjugation ratios have been previously 
approximated by a variety of methods. Spectrophotometric analysis at either 260 nm 
(122,335) to determine the ODN or the use of the colorimetric techniques BCA (539), 
Lowry (431,432,528) or Bradford to determine the protein content in the conjugate were 
only accurate to a certain degree, as the protein and ODN content interfered with the 
respective method. SDS-PAGE was used in a number of studies to confirm conjugation 
and the shift in the conjugate band compared to unconjugated OVA was used to 
calculate the conjugation ratio (335,431,433,501). We used a combination of 
spectrophotometric and SEC analysis. The conjugation ratio of C-4FB-O and C-4FBSS-
O were determined by spectrophotometric analysis of the colorimetric bond. The 
conjugation ratios of C-SPDP-O, C-PEG-O and C-peptide-O were subsequently 
estimated by comparing the elution times of the conjugates on SEC to the elution times 
of C-4FB-O and C-4FBSS-O. SEC analysis works well to confirm the conjugation as a 
distinct shift in elution times can be observed compared to unconjugated CpG and 




OVA (521). However for future work a more accurate method for determining the 
conjugation ratios of C-SPDP-O, C-PEG-O and C-peptide-O should be developed. 
Blocking of the 5’ end of CpG by conjugation has been reported to reduce the 
immunostimmulatory effect of CpG, leading to the suggestion that CpG should be 
conjugated via the 3’ end (510–513,515). However, in previous studies that showed 
enhanced immune responses induced by CpG-antigen conjugates, CpG was mainly 
conjugated to the antigen via the 5’ end, as elaborated in Section 3.1.2. In order to 
investigate whether the end through which CpG was conjugated to OVA has an effect 
on APC activation and subsequent cross-presentation, all conjugates in this study were 
synthesised with CpG conjugated via the 3’ and the 5’ end. The conjugation ratio and 
size of each conjugate pair were kept the same to ensure any differences observed were 
not due to a change in these parameters. Conversely to the reduction in 
immunostimmulatory effect of 5’ conjugated CpG reported in a TLR9 model and total 
splenocytes (510,513), we have shown that BMDCs were activated to the same extent 
with CpG conjugated to OVA either via the 3’ or 5’ end or unconjugated CpG. The 
activation of BMDC also translated to proliferation of CD4+ and CD8+ T-cells co-
cultured with 3’ and 5’ conjugate activated BMDCs, as no difference in proliferation 
and IFN-γ production between each 3’ and 5’ conjugation pair was observed. No 
difference was observed with reversible linked conjugates and this may be explained 
with release of CpG from the OVA before binding to the TLR. However this does not 
explain why no difference was seen in stable linkers. A possible explanation may be 
the choice of method to determine TLR9 activation. In the studies that showed reduced 
TLR activation by 5’ blocked CpG compared to 3’ blocked or unblocked CpG, TLR9 
activation was determined by direct quantification of NF-κB activation through a 
secreted form of human embryonic alkaline phosphatase (SEAP) assay and through an 
electrophoretic mobility shift assay (EMSA) (510,511,513,540). Additionally the 5’ 
blocked CpGs were analysed for their ability to induce IL-12, IL-6, MIP-1α and TNF-α 
in total splenocyte cultures and their ability to induce total splenocyte proliferation 
after direct incubation with the CpG in vitro as well as induction of IL-12 production 
and change in spleen weight following CpG injection in vivo (510,513,515). Conversely, 
we looked at the difference in BMDC activation measured through upregulation of 
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activation markers. Therefore an explanation for the difference in results may be that 
5’ conjugated CpG does induce lower level of NF-κB activation compared to a 3’ 
conjugated or free CpG as shown in the previous studies, but that the difference in NF-
κB release does not translate in a difference in upregulation of co-stimulatory 
molecules. Another theory may be that a free 5’ end is important for TLR9 stimulation 
in B-cells and macrophages, but that the TLR9 in BMDCs has a slightly different 
confirmation, making it less susceptible to changes in CpG sequence. Further 
experiments are required to test whether TLR9 in different cell types respond 
differently to CpGs and to test the correlation of NF-κB release with upregulation of 
co-stimulatory markers by BMDCs.  
The five conjugates C-4FB-O, C-4FBSS-O, C-SPDP-O, C-PEG-O and C-peptide-O were 
characterised for their stability and reversibility in different pHs, intra- and 
extracellular concentrations of GSH, cell culture media and cell culture supernatant as 
well as reversibility of the C-peptide-O conjugates towards Cat S. Previously reported 
stable and reversible antigen-adjuvant conjugates and reversible particles have been 
poorly characterized for their stability and reversibility characteristics and the 
properties of the linker were assumed without testing. We synthesised the two 
reversible disulphide bond containing conjugates C-4FBSS-O and C-SPDP-O as the 
linkers have different chemical groups in proximity to the disulphide bond. The SPDP 
conjugate with an aliphatic chain as linker has an acetamide group in proximity of the 
disulphide bond but no aromatic groups in the linker. Previous studies have reported 
rapid cleavage of SPDP linked conjugates in vivo following injection, as elaborated in 
Section 3.1.3 (497,498,523). The 4FBSS linker has an acetamide group on either side as 
well as an aromatic ring in close proximity to the disulphide bond. The cleavage of 
SPDP linked conjugates in extracellular conditions was confirmed here, as the C-SPDP-
O conjugate was reduced by 10 µM GSH, representing extracellular concentrations of 
GSH. In contrast to C-SPDP-O, the C-4FBSS-O conjugate which included an aromatic 
group close to the disulphide bond was not cleaved in extracellular concentrations of 
GSH but only at the higher, intracellular concentration of GSH. As GSH was used to 
model the reducing conditions in extra- and intracellular environments, conjugates 
were also exposed to cell culture media and supernatant from a BMDC culture to 




substantiate the results found in pure GSH. 2-ME is routinely added to cell-culture 
media to prevent harmful levels of oxygen radicals and it was feared that the strong 
reductant in the media could induce cleavage of the disulphide bond containing 
conjugates. SEC analysis of the conjugates following incubation with 2-ME containing 
media however disproved this theory as no cleavage could be detected in any 
conjugate, suggesting that the concentration of 2-ME in cell culture media is too low to 
reduce the conjugates. Interestingly though for the C-4FBSS-O a high peak with the 
same elution time as CpG was detected following incubation with media although the 
same peak height and area was recorded for the conjugate itself, suggesting that the 
peak was due to contamination in the media. Incubation of conjugates with cell culture 
supernatant from a BMDC culture showed the same degree of reduction as incubation 
with extracellular concentrations of GSH. This further proved that the C-SPDP-O 
conjugate is cleaved at extracellular reducing conditions while the C-4FBSS-O 
conjugate is stable towards them. However while cleavage of the C-SPDP-O conjugate 
following incubation with GSH was seen as elution of a free CpG peak, incubation with 
cell culture supernatant lead to the formation of a high molecular weight aggregate. 
Only minimal peaks of the C-SPDP-O conjugate were observed while a large peak with 
a low retention time appeared, indicating aggregation of the conjugate. Aggregates 
may have formed by interactions between cleaved CpG and OVA with proteins in the 
cell culture supernatant.  
As expected, the stable conjugates and C-peptide-O were not cleaved by either 
concentration of GSH or cell culture media or supernatant, as their linkers did not 
include a reducible disulphide bond. Reduction of the SPDP linked conjugate in 
extracellular concentrations of GSH and cell culture supernatant supports the early 
findings by Worrel et al and Thorpe et al. It shows additionally that not only a side 
group directly attached to the disulphide bond but also groups in close proximity to 
the disulphide bond as in the C-4FBSS-O conjugate are able to enhance the stability of 
disulphide bond containing linkers towards reducing conditions. Cleavage of C-SPDP-
O in cell culture supernatant suggests that BMDC release a reducing agent while 
cultured at concentrations high enough to cleave the more reduction susceptible 
conjugate C-SPDP-O but not the less reduction susceptible C-4FBSS-O conjugate. The 
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released reducing agent is possibly GSH. Østergaard et al developed a GSH-specific 
green fluorescent protein–based redox probe, termed redox sensitive YFP (482). This 
probe could be used to evaluate whether the reduction potential in the BMDC cell 
culture supernatant is due to release of GSH and if it is, at what concentrations GSH 
can be found in the cell culture supernatant.  
Cleavage of C-SPDP-O and stability of C-4FBSS-O in cell culture supernatant 
additionally confirmed the validity of using low and high concentrations of GSH to 
mimic the impact of reducible extra- and intracellular environments on disulphide 
containing linkers. To further evaluate the targeted reversibility of conjugates inside 
APCs, antigen and adjuvant could be labelled with different fluorescent dyes. Confocal 
microscopy could then be used to detect whether conjugates are internalised by APCs 
as an intact conjugate as well as in which cell compartment and after what length of 
time following internalisation the conjugate is cleaved. Additionally the fluorescently 
labelled conjugates could be injected into mice to evaluate their stability in vivo. This 
would provide further insight into the reversibility and also the processing of the 
conjugates by APCs.  
This work highlights that conjugates designed to be intracellularly reversible should 
be routinely characterised by in vitro incubation with GSH at intra- and extracellular 
concentrations. This is especially important for conjugates linked through the SPDP 
linker. This suggests that previously reported antigen-adjuvant conjugates that were 
linked through the SPDP linker may have been cleaved before they were internalised 
by APCs (521,522). Also reversibility of antigen or adjuvant conjugated onto particles 
should be characterised (392,465–467,519,520) as just the inclusion of a disulphide bond 
in the linker does not ensure intracellular specific cleavage or stability in the 
extracellular space.  
Hydrazone bonds have been identified as acid-labile bonds that hydrolyse easily at 
low pH and are therefore routinely used for reversible delivery systems designed to 
be cleaved in the acidic environment of the endo-lysosome. However as with 
disulphide bonds, the stability of hydrazone bonds towards hydrolysis is highly 
dependent on the chemical side groups around the hydrazone bond (480,481). The bis-




aryl hydrazone bond chosen in this study to conjugate C-4FB-O and C-4FBSS-O has 
been reported to display a robust stability. It has been shown to be stable to pH values 
ranging between pH 2.3 and 11.3, stable up to 92 °C as well as stable in solution at 4 °C 
at pH 7.4 for over 12 weeks (439,452,541). The stability towards hydrolysis for all 
synthesised conjugates in this study was confirmed as all conjugates remained stable 
following overnight incubation at pH 6.0 and 5.0, mimicking the acidic environment 
of endo-lysosomes.  
A final stability study was carried out on the C-peptide-O conjugate designed to be 
cleaved by the protease Cat S. Cat S is selectively expressed in endo-lysosomes of APCs 
(469,475). Using a selectively expressed protease as a trigger to cleave antigen from 
adjuvant would have given an alternative method to the reduction triggered reversible 
conjugates, however incubation of the conjugate with Cat S did not result in any 
cleavage. The specific activity of Cat S was reported to be >300 pmol/min/µg by the 
manufacturer (Sino Biological Inc.). With a total amount of 0.75 µg of Cat S and an 
estimated amount of 60 pmol of the C-peptide-O conjugate, assuming a molecular 
weight of 60,000 Da for the conjugate, the peptide substrate would be expected to be 
cleaved within a minute of incubation. The elution profile of the C-peptide-O conjugate 
analysed on analytical SEC showed very early elution of the conjugate, suggesting 
aggregation of the conjugate. Cat S may not have been able to cleave the substrate 
peptide in aggregated conjugates. Another theory may be that the large OVA molecule 
and the CpG molecule flanking the peptide blocked access for Cat S to cleave the 
substrate. A molecular spacer between OVA and the peptide as well as CpG and the 
peptide might have enabled access of Cat S to the peptide for cleavage, this could be 
investigated in future experiments (542). Future work to confirm the peptide linker is 
cleaved by Cat S needs to be done. To eliminate the potential steric effects, the peptide 
will only be incubated with the enzyme and the cleavage of the enzyme will be 
monitored by reverse phase high performance liquid chromatography. 
The stability of the conjugates in extracellular conditions is important to ensure co-
delivery of antigen and adjuvant into the APC. In addition to testing their stability 
towards extracellular levels of GSH, cell culture supernatant and low pH, as was done 
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in this study, it would in interesting to test their stability in the target tissue and in 
blood. Different routes of administration have been explored for delivery of antigen 
and adjuvant, including subcutaneous, intradermal and intravenous injection 
(383,465,543). Depending on their route of administration, the conjugates may reside 
at the site of injection or circulate in the blood stream or lymphatic system before they 
are internalised by APC. It would therefore be important to establish the stability of 
the conjugates towards these conditions in future studies.  
In conclusion, the work presented in this chapter reported the synthesis and 
characterisation of a series of stable and cleavable CpG-OVA conjugates. Particularly, 
in vitro cleavage assays showed that the disulphide bond containing C-4FBSS-O 
conjugate was cleaved at intracellular reducing conditions while the other disulphide 
bond containing conjugate C-SPDP-O was cleaved at the lower, extracellular reducing 
conditions. The C-4FB-O, C-PEG-O and C-peptide-O conjugates remained stable at 
either reducing condition. The C-peptide-O conjugate designed to be cleaved by the 
protease Cat S was not cleaved when exposed to the pure enzyme. This suggests that 
C-4FBSS-O is a suitable conjugate to test the hypothesis of this research since it is stable 
in the extracellular environment for co-delivery of antigen and adjuvant and cleaved 
in the intracellular environment, thereby releasing antigen and adjuvant inside the 
APC. The following chapter focuses on testing the stable and cleavable conjugates 
compared to a mixture of antigen and adjuvant in vitro and in vivo for their ability to 



























Antigen-adjuvant conjugates have the potential to induce strong anti-tumour immune 
responses as immunotherapeutic vaccines. In the previous chapter we have reported the 
synthesis of five antigen-adjuvant conjugates which displayed differences in stability 
towards extracellular and intracellular reducing conditions. Therefore we wished to 
investigate how these conjugates were acquired, processed and presented by antigen-
presenting cells (APC) as well as their potential in inducing anti-tumour immunity in 
vivo.  
Internalisation of antigen-adjuvant conjugates by APCs is a key factor for initiation of a 
TH1 immune response. The method of uptake for CpG-OVA conjugates into APCs has 
not been determined yet. The CpG-OVA conjugate could potentially be taken up into 
APCs by two different receptor mediated systems. Soluble molecules including antigens 
have been shown to be internalised by macropinocytosis as well as by receptor-
mediated endocytosis (55,137,391) (see Introduction Section 1.2.2 and 1.7). The soluble 
model antigen ovalbumin (OVA) has been reported to be preferentially internalised by 
the mannose receptor (MR), CD206, which is highly expressed on both DCs and 
macrophages (68,137). The MR is a C-type lectin endocytic receptor which primarily 
binds carbohydrates including mannosylated protein such as OVA (335,544). Recent 
studies have also shown that class B CpG binds to the receptor DEC-205 which thereby 
facilitate its uptake into APCs (67). DEC-205, like the MR receptor, is a C-type lectin 
receptor and part of the macrophage mannose receptor family (545). Therefore a 
conjugate of CpG and OVA could be internalised by both the MR receptor and the DEC-
205 receptor in addition to uptake via macropinocytosis. Different studies have shown 
that the conjugation of CpG onto OVA enhances the total amount of OVA internalised 
by APCs by 10 to 50 fold compared to internalisation of unconjugated OVA (431,432). 
Addition of free CpG to the CpG-OVA uptake during internalisation reduced the total 
amount of conjugate uptake (431). This observation suggests that the increased uptake 
of CpG-OVA conjugate over free OVA was due to the internalisation of the conjugate 
through the CpG specific DEC-205 receptor. Conjugates of CpG and OVA therefore 




increase the amount of antigen in the APC that can be processed and presented on MHC 
molecules to activate CD8+ and CD4+ T-cells.  
The pathway of antigen internalisation by an APC has been shown to determine the 
pathway through which the antigen is processed and thereby determines whether it is 
cross-presented on major histocompatibility complex (MHC) I to CD8+ T-cells or 
presented on MHC-II to CD4+ T-cells (137,546,547). The exact mechanisms how antigens 
are sorted for presentation on either MHC-I or MHC-II molecules is not yet fully 
understood. However antigen internalised and transported into late endosomes have 
been shown to be predominantly processed for presentation on MHC-II molecules 
(55,548) as the late endosome fuses with the MHC-II compartment (MIIC), see 
Introduction Section 1.2.3. By contrast, antigen internalised into early endosomes have 
been associated with processing and loading onto MHC-I molecules for cross-
presentation to CD8+ T-cells (133). Uptake of antigen through macropinocytosis has 
been shown to be targeted into late endosomes, which correlates with presentation of 
the antigen epitopes on MHC-II molecules (55,390,548–550). In contrast to 
macropinocytosis, receptor-based endocytosis has been prominently associated with 
targeting of antigen into early endosomes with enhanced cross-presentation of antigen 
on MHC-I molecules. However, different endocytic receptors have been reported to 
induce different degrees of cross-presentation of antigen. Burgdorf et al have shown that 
the MR, which mediates OVA internalisation, specifically introduces OVA into stable 
early endosomes for cross-presentation to CD8+ T-cells (137,435). In addition to receptor 
mediated endocytosis, OVA was also internalised by macropinocytosis into late 
endosomes/lysosomes for presentation on MHC-II molecules (137). Apart from 
internalisation of CpG, the DEC-205 receptor has also been reported to bind soluble 
antigens for internalisation. Previous studies on DEC-205 have shown that antigen 
internalised by DEC-205 is predominantly transported into late endosomes for MHC-II 
presentation (551) while further studies also reported that antigen internalised by DEC-
205 is cross-presented onto MHC-I molecules (121,436,546,552).  
In addition to the dependence on the uptake mechanism for cross-presentation of an 
antigen, cross-presentation has also been shown to be increased and altered by 
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induction of a toll-like receptor (TLR) response in APCs (391,435,553). Increase in cross-
presentation is supported by the finding that TLR9 activation induces APC maturation 
which includes upregulation of co-stimulatory molecules and enhancement of antigen 
processing and presentation (114,554), see Introduction Section 1.2.1. Soluble antigen 
has been reported to be mainly cross-presented through the receptor-recycling pathway 
(131,435,555). However, Crespo et al showed that through addition of a TLR agonist, 
which modifies the mechanism of uptake of soluble antigen, also the pathway for cross-
presentation of antigen was changed. Instead of degradation of the antigen in endocytic 
compartments, processing of antigen was shown to be dependent on the proteasome 
which indicated cross-presentation through the cytosolic pathway (128). 
For the induction of a robust TH1-type anti-tumour immune response, both CD8+ T-cells 
and CD4+ T-cells must be activated to differentiate into cytotoxic T lymphocyte (CTL) 
and TH1 cells, respectively. TH1 cells drive further differentiation of CD8+ T-cells to CTL 
by direct contact and interferon (IFN) γ production. Differentiated CTL primed for the 
respective tumour antigen are then able to induce apoptosis in cancer cells that display 
the tumour antigen (192,196,197,199–202). Presentation of OVA on both MHC-I and 
MHC-II following uptake of a CpG-OVA conjugate through MR, DEC-205 receptor and 
macropinocytosis could therefore potentially induce a stronger, longer lasting anti-
tumour immune response than an antigen that is predominantly presented on MHC-I.  
In addition to potentially induce OVA presentation on both MHC-I and MHC-II, co-
delivery of adjuvant and antigen is advantageous for the induction of a strong cellular 
immune response as it both enhances the amount of antigen internalised by the APC 
and induces APC maturation. With a CpG-OVA conjugate, induction of APC 
maturation depends on activation of TLR9 by CpG and presentation of OVA epitopes 
on MHC-I or MHC-II molecules depends on processing of the antigen. In a stable 
conjugate of CpG and OVA the proximity of CpG to OVA through the stable linker 
between them may impact both binding of CpG to TLR9 and processing of OVA for 
presentation to T-cells. A reversible linker that is cleaved inside the APC once the 
conjugate is internalised may therefore result in enhanced APC activation and antigen 
presentation. Upon cleavage of the conjugate, CpG may be more accessible for TLR9 




activation. Additionally, processing of OVA by endosomal proteases or the cytosolic 
proteasome for loading of epitopes onto MHC-I or MHC-II might be more effective 
without obstruction by the attached CpG molecule. A stable conjugate with a spacer 
arm between CpG and OVA such as C-PEG-O may also be able to enhance APC 
activation and OVA processing by creating a spatial distance between the adjuvant and 
antigen.  
 
4.1.1. Chapter aims: 
Following the synthesis and characterisation of five CpG-OVA conjugates linked with 
either stable or cleavable linkers in Chapter 3, the aims of this chapter were: 
 Compare the uptake of the different CpG-OVA conjugates by immune cells 
 Determine the generation of a T-cell response in vitro 
 Explore the potential of the CpG-OVA conjugates to generate anti-tumour 





4.2.1. Activation of immune cells by conjugates in vitro 
4.2.1.1. Uptake of conjugates by splenocytes  
Fluorescent labelling of conjugates 
To determine the uptake of the different conjugates into immune cells, conjugates were 
fluorescently labelled. The amine-reactive fluorescent tag NHS-DyLight633 (DyLight) 
was used to label the primary amine groups on OVA which was then conjugated to CpG 
as performed for the synthesis of non-labelled conjugates (see Methods Section 2.1.8). In 
order to ensure there is enough amine groups on OVA remaining for further 
conjugation to CpG, the reaction was performed at a suboptimal molar ratio of 3:1 
DyLight to OVA, compared to a recommended molar ratio of 12:1 by the manufacturer 
(556). The degree of fluorescent labelling of the protein was determined by measuring 
the absorbance at 280 nm and 627 nm, for protein and DyLight633 content, respectively. 
Using the molar extinction coefficient of 30590 M-1cm-1 for OVA and 170,000 M-1cm-1 for 
DyLight633 the average molar ratio of DyLight per OVA was 1.5. The fluorescently 
labelled OVA was then used to conjugate with CpG using the various linking strategies 
as described in Section 3.2.3. 
 
Titration of fluorescently labelled conjugate for uptake assay 
The fluorescently labelled conjugates were used to assess the amount of conjugate that 
are internalised by splenocytes isolated from mice. A similar approach was taken in 
previous uptake studies where CpG and OVA conjugates have been labelled with 
fluorescent tags (335,431,432). Based on these studies a titration assay was set up to 
establish the minimum concentration of fluorescently labelled conjugate to detect 
internalisation into APCs. Splenocytes isolated from C57BL/6 mice were pulsed with 
DyLight-C-4FB-O conjugate at three different concentrations for 1 h, 4 h and 24 h at 4 °C 
or 37 °C. Incubation of the splenocytes at 4 °C functioned as a control to internalisation 
at 37 °C, as at low temperatures cell metabolism and membrane fluidity are greatly 
reduced which leads to a nearly complete abrogation of antigen uptake by APCs (557). 




Uptake of DyLight-conjugate into splenocytes was determined by flow cytometry 
(Figure 4.1). A difference between DyLight-conjugate treated splenocytes at 4 °C and 
37 °C can be seen at all three concentrations, however the distinction between the two 
temperatures is more prominent at a DyLight-conjugate concentration of 7 µg/ml. 
Increasing the concentration to 15 µg/ml did not lead to a better distinction between the 
DyLight curves, therefore the concentration of 7 µg/ml of DyLight-conjugates was 
chosen for the subsequent uptake assay.  
 
Figure 4.1: Titration of DyLight633-NHS labelled conjugate for uptake into 
splenocytes.  
Splenocytes were incubated with 3.5 µg/ml, 7 µg/ml or 15 µg/ml of DyLight labelled C-4FB-O for 




Uptake assay in splenocyte populations 
The uptake of the various fluorescently labelled conjugates was compared on four 
different splenocyte populations including DCs, macrophages, B-cells and T-cells. 
Splenocytes obtained from C57BL/6 mice were incubated at 4 °C or 37 °C with either a 
fluorescently labelled conjugate, a mixture of CpG and fluorescently labelled OVA or 
media (see Methods Section 2.3.11). After 1 h, 4 h and 24 h of incubation, splenocytes 
were harvested and stained for flow cytometry with a live-dead dye and antibodies to 
identify DCs (CD11c), macrophages (F4/80), B-cells (B220) and T-cells (CD3). After 
gating on single cells and live cells (as in Figure 3.6 A), the populations of DCs, 
macrophages, B-cells and T-cells were identified (Figure 4.2 A). The amount of conjugate 
taken up by the specific cell population was determined by measuring the median 
fluorescent intensity (MFI) of DyLight. Figure 4.2 B shows that across all four cell 
populations only a minimal extent of binding of conjugates was observed at 4 °C. At 
37 °C, statistically significant enhanced uptake of the C-4FB-O, C-4FBSS-O and C-
peptide-O conjugates was displayed by all cell types following 24 h of incubation 
compared to uptake of the CpG and OVA mixture. The conjugates C-SPDP-O and C-
PEG-O did not display statistically significant enhanced uptake by any cell population 
at any length of incubation compared to uptake of the CpG and OVA mixture. DCs were 
the main cell population to display uptake of conjugates with MFI values of Dy-Light 
labelled conjugates of approximately 60 for the C-4FB-O and C-4FBSS-O conjugates and 
an MFI up to 140 for C-peptide-O. While in DCs an MFI of 10 for the CpG OVA mixture 
and C-PEG-O and 20 for the C-SPDP-O conjugate were measured, indicating a minimal 
amount of uptake of these formulations. These were not statistically significant 
compared to the MFI of 0.8 measured in untreated cells as determined by two-way 
ANOVA. Macrophages also showed uptake of conjugates, however not as pronounced 
as DCs, with an approximate MFI of 30 for DyLight labelled C-4FB-O, C-4FBSS-O and 
50 for C-peptide-O. In contrast to the high amount of uptake by DCs and macrophages, 
B-cells and T-cells only showed a small amount of uptake of conjugates with maximum 
MFI levels of approximately 15. In both DCs and macrophages uptake peaked at 24 h of 
incubation with conjugates, whereas after 1 h and 4 h only a small amount of uptake 
was seen with maximum MFI values of approximately 15. Figure 4.2 C shows the 




comparison of uptake of the C-4FBSS-O conjugate after incubation for 24 h at 37 °C by 
the different cell populations. DCs internalised significantly higher amounts of C-
4FBSS-O than the other cells types. There was no significant difference in the amount of 




















Figure 4.2: Conjugates C-4FB-O, C-4FBSS-O and C-peptide-O enhance uptake by 
splenocytes.  




Splenocytes were incubated with a DyLight labelled conjugate, mix of CpG and DyLight labelled 
OVA or media as control at 4 °C and 37 °. (A) Gating strategy to analyse uptake of DyLight 
labelled conjugates into splenocytes. Cells were gated on single, live cells (compare Figure 3.5 A) 
followed by gating on DCs, macrophages, B-cells and T-cells to identify uptake by the specific 
cell populations. (B) Binding and uptake of conjugates was compared between 4 C and 37 °C, at 
1 h, 4 h and 24 h of incubation time and between DCs, macrophages, B-cells and T-cells. Results 
are expressed as median fluorescent intensity (MFI)  measured by flow cytometry in gated cells 
of interest analysed on Kaluza. (C) Comparison of uptake of the C-4FBSS-O conjugate at 37 °C 
after 24 h incubation in DCs, macrophages, B-cells and T-cells. Bars represent the mean of three 
independent experiments ±SEM, statistical significance was determined in (B) by two-way 
ANOVA with Bonferroni’s post-hoc test and in (C) by one-way ANOVA with Dunnett’s post-
hoc test, ****p<0.0001, ***p<0.001; **p<0.01, *p<0.05. Statistical significance displayed in (B) is the 
comparison of conjugate treatment to treatment with mixture of CpG and OVA and in (C) is the 
comparison of uptake by macrophages, B-cells and T-cells to uptake by DCs.  
 
4.2.1.2. T-cell activation and proliferation following co-culture with 
conjugate pulsed BMDC 
All five conjugates C-4FB-O, C-4FBSS-O, C-SPDP-O, C-PEG-O and C-peptide-O were 
compared for their ability to generate an immune response in vitro, using a BMDC 
activation, T-cell proliferation as well as cytokine production assay as a readout. C-4FB-
O was used before to determine the co-culture time of 72 h (see Chapter 3.2.2.1), 
however as the processing time for reversible conjugates may be different from stable 
conjugates, BMDCs were co-cultured with T-cells for 48 h as well as 72 h before 
determining proliferation and IFN-γ production of T-cells. Initially BMDCs were 
activated with either conjugate or control (see Methods Section 2.3.7). Figure 4.3 A 
shows that lipopolysaccharide (LPS) as the positive control induced highest expression 
of all markers. Incubation with any conjugate resulted in a similar statistical 
significantly higher expression of CD86 and CD40 as incubation with CpG alone or a 
mixture of CpG and OVA compared to untreated and cells incubated with OVA alone. 
The same trend was seen for MHC-II upregulation, however there was no significant 
difference between the treatment groups.  
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T-cell proliferation and IFN-γ production were determined after co-culture of CD8+ and 
CD4+ T-cells with activated BMDCs for 48 h and 72 h (see Methods Section 2.3.8, 2.3.9 
and 2.3.10). Figure 4.3 B shows that co-culture for 72 h resulted in a higher percentage 
of T-cell proliferation in both CD4+ and CD8+ T-cells compared to co-culture for 48 h 
for all treatments except for the C-SPDP-O conjugate. T-cells activated with the 
conjugate C-4FB-O and C-4FBSS-O in the 72 h co-culture induced the highest amount of 
proliferation of 87 % and 83 % for CD8+ and 81 % and 77 % for CD4+ T-cells, 
respectively. This degree of proliferation was even slightly higher than the 70 % 
proliferation of CD8+ and CD4+ T-cells following treatment with the positive controls 
SIINFEKL and OVA323-339. Treatment with the C-SPDP-O conjugate induced no 
statistically significant difference in proliferation of CD8+ and CD4+ T-cells in a 48 h co-
culture and the CD4+ 72 h co-culture compared to treatment with OVA or the mixture 
of CpG and OVA. In the CD8+ 72 h co-culture, a statistically significant lower percent 
proliferation of CD8+ T-cells was observed for the C-SPDP-O conjugate compared to the 
mixture of CpG and OVA. The conjugates C-PEG-O and C-peptide-O induced very low 
proliferation in CD8+ and CD4+ T-cells, comparable to the proliferation observed in 
untreated and CpG treated cells. An exception was the 35 % proliferation induced by C-
peptide-O in the 72 h co-culture of CD4+ T-cells which was comparable to the 31 % 
proliferation induced by the mixture of CpG and OVA. 
IFN-γ production of CD8+ T-cells showed a similar trend to the results obtained from 
the T-cell proliferation assay for the 72 h time point. At the 48 h time point however, co-
culture of CD8+ T-cells with C-SPDP-O activated BMDCs for 48 h resulted in high 
release of IFN-γ of 23 ng/ml, comparable to the levels release following C-4FB-O and C-
4FBSS-O treatment. No IFN-γ was measured after 48 h of co-culture with CD4+ T-cells. 
Co-culture of CD4+ T-cells for 72 h with C-4FB-O and C-4FBSS-O resulted in high IFN-
γ production comparable to the positive control while C-SPDP-O, C-PEG-O, C-peptide-
O as well as the mixture of CpG and OVA did not result in enhanced IFN-γ production. 
These in vitro cell culture assays indicate that the conjugates C-4FB-O and C-4FBSS-O 
are superior at BMDC and subsequent T-cell activation and proliferation compared to 
the C-SPDP-O, C-PEG-O and C-peptide-O conjugates. 







Figure 4.3: Conjugates C-4FB-O and C-4FBSS-O induce strong in vitro T-cell 
proliferation.  
BMDC were pulsed with 3.5 µg/ml of C-4FB-O (blue), C-4FBSS-O (red), C-SPDP-O (green), C-
PEG-O (purple) or C-peptide-O (yellow) conjugate, OVA alone, OVA and 0.2 µM CpG, CpG 
alone, either 2.5 µg/ml LPS as positive control for the activation assay or the peptides SIINFEKL 
or OVA323-339 as positive controls for co-culture assays or media as negative control. (A) 
Expression of BMDC activation markers MHC-II, CD86 and CD40 after 24 h of activation, results 
presented as median fluorescent intensity (MFI) fold increase over background. (B) Sorted, CFSE 
stained CD8+ and CD4+ T-cells were co-cultured with activated BMDC for 48 h and 72 h and 
percent proliferation was determined by gating on proliferation peaks. (C) IFN-γ measured in 
supernatant of co-culture determined by ELISA. Bars represent the mean of three independent 
experiments ±SEM, statistical significance was determined by one-way ANOVA with Dunnett’s 
post-hoc test, ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05. Statistical significance displayed in (A) 
is the comparison of all treatment groups to untreated cells and in (Band C) is the comparison of 
all treatment groups to C+O treated cells. 
 
4.2.1.3. Cross-presentation of CpG-OVA conjugates by BMDC 
Cross-presentation of peptide epitopes on MHC-I is crucial for activation of CD8+ T-
cells. Soluble OVA is thought to be cross-presented mainly through the receptor-
recycling pathway (131,555) however addition of a TLR agonist to antigen has been 
shown to alter the pathway through which antigen is cross-presented by DC (128). To 
determine the route of cross-presentation of CpG-OVA conjugates a cross-presentation 
blocking assay was set up. BMDCs were treated with either lactacystin, primaquine, 
brefeldin A (Figure 4.4) or left untreated for 15 min before pulsing them with C-4FB-O, 
C-4FBSS-O, C-SPDP-O, OVA alone or SIINFEKL peptide (see Methods Section 2.3.12). 
Splenocytes isolated from OT-I mice were then added to the culture and CD8+ T-cell 
activation was determined by IFN-γ production in the cell culture supernatant. The 
conjugates C-PEG-O and C-peptide-O were not included in this assay as it was shown 
in section 4.2.1.2 that they do not induce IFN-γ production in CD8+ T-cells. The results 
are presented as percent IFN-γ production by inhibitor treated cells compared to IFN-γ 
produced by untreated cells.  




T-cell activation following SIINFEKL treatment was not affected by either lactacystin or 
primaquine treatment as the free peptide is not required to be processed for 
presentation. Brefeldin A pre-treatment of SIINFEKL-pulsed cells resulted in a 60 % 
reduction of T-cell activation compared to untreated cells as shown in Figure 4.5. Pre-
treatment with brefeldin A also abrogated all cross-presentation of antigens either as 
conjugates or in a CpG and OVA mixture. Lactacystin induced an 85 % reduction of 
OVA cross-presentation. Cross-presentation of C-4FB-O and C-4FBSS-O was reduced 
by about 50 % by lactacystin pre-treatment while C-SPDP-O cross-presentation was 
only reduced by 35 %, which was statistically significantly higher than cross-
presentation of OVA. Primaquine induced a similar reduction of cross-presentation of 
about 75 % for OVA, C-4FBSS-O and C-SPDP-O. C-4FB-O cross-presentation was 





Figure 4.4: Cross-presentation inhibitors 
BMDC were treated with cross-presentation inhibitors to determine the pathway of cross-
presentation for CpG-OVA conjugates. Lactacystin inhibits protein degradation in the 
proteasome and thereby blocks cross-presentation through the cytosolic pathway (green) 
(553,558). Primaquine blocks endosomal trafficking and thereby inhibits primarily the receptor 
recycling pathway and to a lesser extend the vacuolar pathway (orange) (435,555). Brefeldin A 
inhibits exocytosis of MHC-I molecules from the endoplasmic reticulum (ER) and the Golgi and 
thereby prevents presentation of MHC-I-peptide complexes on the cell surface (purple) (126,559).  
 





Figure 4.5: CpG and OVA conjugation alters the cross-presentation pathway of 
antigens in DCs. 
BMDCs were treated with either Lactacystin, Primaquine, Brefeldin A or left untreated for 15 min 
and consequently activated with either SIINFEKL peptide (black), OVA (grey), C-4FB-O (blue), 
C-4FBSS-O (red) or C-SPDP-O (green) conjugate for 24 h. Splenocytes from OT-I mice were co-
cultured with activated BMDCs for 72 h. Cell culture supernatants were analysed for IFN-
production by ELISA. The bar graphs show the percent IFN-produced by inhibitor treated cells 
compared to untreated cells from three independent experiments ± SEM. Statistical significance 
was determined by two-way ANOVA with Benferroni’s post-hoc test, ****p<0.0001, ***p<0.001, 
**p<0.01, *p<0.05. Statistical significance displayed is the comparison of all treatment groups in 







4.2.2. In vivo vaccine assays 
4.2.2.1. In vivo cytotoxicity assay 
4.2.2.2. CFSE titration for in vivo cytotoxicity 
An in vivo cytotoxicity assay was set up to determine whether the enhanced activation 
and proliferation of CD8+ and CD4+ T-cells treated with the C-4FB-O and C-4FBSS-O 
conjugates translates into enhanced cytotoxic activity against target cells. As a readout 
for cytotoxicity, the assay relies on two populations of splenocytes that are stained at 
different concentrations of CFSE, injected into mice and analysed after 48 h. Therefore, 
before the assay was set up by vaccinating mice, the concentration of CFSE used was 
titrated to determine concentrations that produce two distinguishable populations of 
CFSE stained splenocytes after incubation in the mouse for 48 h. Previous reported 
studies used ten-fold different concentrations of CFSE between 0.1 µM and 5 µM 
(321,378,383,560). In an initial titration assay splenocytes were divided into three 
populations stained with 0.2 µM, 2 µM and 5 µM CFSE, these populations were 
analysed by flow cytometry to confirm their distinction followed by i.v. injection into a 
C57BL/6 mouse. Spleen cells were harvested 48 h after injection and analysed by flow 
cytometry for CFSE stained cells. Figure 4.6 A shows that before injection into the mouse 
three populations of CFSE stained cells were distinguishable, however the two 
populations of lower concentrations overlapped to a certain extend. Flow cytometry 
analysis after harvesting of the splenocytes showed that only one small population of 
CFSE positive cells was being identified on both a side-scatter dotplot and a histogram 
graph. As two CFSE positive populations were required to analyse the cytotoxicity assay 
a second titration assay was set up with three splenocyte populations stained with 
0.5 µM, 5 µM and 50 µM CFSE. Although CFSE was reported to be toxic at high 
concentrations, there was no difference in cell viability after staining with 0.5, 5 or 50 µM 
concentrations of CFSE (561). Flow cytometry analysis before injection showed three 
clearly separate populations with no overlapping (see Figure 4.6 B). Analysis of 
splenocytes after incubation in the mouse for 48 h showed two clearly distinguishable 
CFSE positive populations on both the side-scatter dotplot and histogram with a third, 
low CFSE population merging into the unstained population. The 5 µM and 50 µM 
CFSE concentrations were therefore used in the subsequent cytotoxicity assay.  





Figure 4.6: CFSE titration for in vivo cytotoxicity assay. 
Splenocytes were divided into three populations, stained with (A) 0.2 µM, 2 µM and 5 µM or (B) 
0.5 µM, 5 µM and 50 µM CFSE and analysed by flow cytometry to determine separation of peaks. 
Stained cells were then injected i.v. into a C57BL/6 mouse and 48 h later splenocytes were 
harvested and analysed for CFSE positive cells, displayed in a side-scatter – CFSE dotplot and 
CFSE histogram. Cells were analysed on the Kaluza flow cytometry software. 
 
4.2.2.3. In vivo cytotoxicity 
In this assay conjugates and controls were compared for their ability to generate a 
cytotoxic effect in vivo against target cells. Naïve C57BL/6 mice were first vaccinated 
with 10 µg of either a conjugate, a mixture of CpG and OVA (molar ratio of 2.5:1 
CpG:OVA) or PBS as a control and then given a booster vaccination 24 days later with 
the same treatment (see Methods Section 2.3.14). The dose of 10 µg was chosen in 
accordance to previous studies published that used the dose to immunise mice with 
antigen and adjuvant to test either the generated cytotoxicity or anti-tumour response 
(434,465,562). On day 31, mice were injected with a pool of target and control cells, the 
target cells were pulsed with SIINFEKL and labelled with 50 µM CFSE while the control 
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cells were left unpulsed and labelled with 5 µM CFSE as determined in the previous 
titration study. The mice were culled 48 h after injection of the target cells (Figure 4.7 A) 
and the percentage of killing of SIINFEKL labelled target cells was determined by gating 
on appropriate single, live cells and comparing the number of CFSEhigh labelled cells 
(SIINFEKL pulsed) to CFSElow labelled cells (unpulsed) in total splenocytes (Figure 4.7 
B). The results are presented as percentage specific lysis normalised against PBS 
vaccinated mice. Figure 4.7 C shows that specific lysis of target cells was observed in all 
mice treated with any conjugate or the mixture of CpG and OVA and was significantly 
higher than the control mice injected with PBS. The three conjugates C-4FB-O, C-4FBSS-
O and C-SPDP-O induced the highest specific lysis with 99 % in all 6 mice in each 
treatment groups which was statistically significant higher compared to mice treated 
with C-PEG-O (48-94 %). Specific lysis of target cells by C-peptide-O (54-98 %) and CpG 
and OVA mixture (59-95 %) vaccinated mice was not significantly lower than the C-4FB-
O, C-4FBSS-O and C-SPDP-O treated mice. 
 







Figure 4.7: Co-delivery of CpG and OVA induces in vivo cytotoxicity against target 
cells.  
(A) Time line of cytotoxicity assay. On day 0 n=6 mice per treatment group were vaccinated with 
10 µg of either C-4FB-O (blue), C-4FBSS-O (red), C-SPDP-O (green), C-PEG-O (purple), C-
peptide-O (yellow), a mixture of CpG and OVA (grey) or PBS (black) as a negative control. 24 
days later mice received a boost with the same treatment and on day 31 mice were injected with 
a pool of 1*107 CFSE labelled cells, pulsed with SIINFEKL peptide as target cells and left 
unpulsed as control cells. Mice were culled 48 h after target cell injection, splenocytes were gated 
as shown in (B) on single, live, CFSEhigh and CFSElow cells. (C) Specific lysis of target cells was 
calculated by comparing unpulsed to target cell ratio. Results show percent specific lysis of 
vaccinated treatment groups normalised against PBS treatment group ± SEM. Statistical 
significance was determined by one-way ANOVA with Tukey’s post-hoc test, ****p<0.0001, 
**p<0.01.  
 
4.2.2.4. Therapeutic tumour trial 
While an in vivo cytotoxicity assay is generally a good indicator for the immune response 
generated by vaccination, it does not take physiological changes associated with tumour 
cells into account. Tumour cells can express immunosuppressive cytokines and recruit 
regulatory T-cells and suppressor cells. Furthermore, tumour cells may present antigen 
on MHC molecules to different degrees as seen with peptide pulsed splenocytes used 
as target cells. Additionally, the cytotoxicity assay measures immune responses 
generated in response to a prophylactic vaccination, while the CpG-OVA conjugates, 
like similar immunotherapeutic agents were developed for therapeutic vaccinations. In 
order to test whether the immune responses generated by the conjugates are able to 
delay tumour growth, a therapeutic tumour trial was performed (see Methods Section 
2.3.16). B16 melanoma cells which stably express OVA (B16-OVA) were used as a 
tumour cell line as an immune response generated by the conjugates would lead to 
specific lysis of the B16-OVA cells. On day 0 of the study C57BL/6 mice were injected 
with B16-OVA into the right flank. After the tumours had established and were visible 
as 1 mm2 dots, the mice were injected with 10 µg of either a conjugate, a mixture of CpG 
and OVA (molar ratio of 2.5:1 CpG:OVA) or PBS as a control (Figure 4.8 A). After 




80 days of the study the surviving mice received a re-challenge of B16-OVA cells into 
the opposite flank to determine whether a long term systemic memory response was 
established by the conjugates. As a control for the tumorigenicity of the B16-OVA cells 
used for the re-challenge, a new group of control C57BL/6 mice were injected with PBS 
and 5 days later were injected with the B16-OVA re-challenge cells. The tumour size was 
recorded over the time of the study and is shown in Figure 4.8 B, if tumour size reached 
150 mm2 (the predetermined humane end point) the mouse was culled. The time point 
of induction of tumour growth and the amount of mice per treatment group that grew 
tumours varied greatly between the different treatment groups. All mice in the PBS 
control group, both at the beginning of the study as well as the re-challenge control 
group started growing tumours within 12 days after tumour cell injection and all mice 
had reached the maximum tumour size after 27 days. Figure 4.8 C shows the survival 
of mice in a Kaplan-Meier graph which confirms statistical significant longer survival 
of all conjugate as well as CpG and OVA treatment groups compared to PBS. Mice 
vaccinated with the reversible conjugate C-4FBSS-O showed the highest probability of 
survival with 9 out of 10 mice remaining at 160 days which is significantly higher than 
the survival induced by the mixture of CpG and OVA. The stable conjugate C-4FB-O 
also induced a survival rate of 6/10 mice alive after 160 days, however it was not 
significantly higher than the survival of 2/10 mice recorded for the mix of CpG and 
OVA. The 3/10 survival following C-PEG-O and 2/10 survival following C-SPDP-O 
treatment as well as C-peptide-O treatment which showed no survival after 122 days 
were not statistically significant different from the 2/10 survival induced by the CpG 
and OVA mixture. Only the reversible C-4FBSS-O conjugate induced significantly 





Figure 4.8: C-4FBSS-O induces prolonged survival in a therapeutic tumour model. 
C57BL/6 mice with n=10 mice per treatment group were injected with 5*105 B16-OVA tumour 
cells. On day 5 after tumour challenge, mice were vaccinated with 10 µg of either C-4FB-O (blue), 
C-4FBSS-O (red), C-SPDP-O (green), C-PEG-O (purple), C-peptide-O (yellow), a mixture of CpG 
and OVA (grey) or PBS (black) as a negative control. On day 80 mice received a re-challenge of 
tumour cells as depicted in the study setup in (B). Tumour size up to a maximum of 150 mm2 
were recoded (A) as well as survival of mice per treatment group (C). Statistical significance was 
determined by a Log-rank (Mantel-Cox) test, the Log-rank Chi value and P value depicted 




correspond to significant analysis of all treatment groups except PBS; the significant levels in the 
graph show significance compared to C+O and significant levels on the legend show significance 





The synthesis and stability characterisation of stable and reversible CpG-OVA 
conjugates was reported in Chapter 3. This chapter investigated the effect of the 
conjugates on induction of a TH1 immune response, including internalisation of 
conjugates by APCs, cross-presentation of OVA to T-cells, in vitro activation and 
proliferation of T-cells and the generated in vivo cytotoxic and anti-tumour response.  
Uptake of the conjugates into APCs is the first important step for induction of a cellular 
immune response. An increased uptake of the extracellular stable C-4FB-O, C-4FBSS-O 
and C-peptide-O conjugates over the mixture of CpG and OVA in DCs is in agreement 
with previous reports which reported enhanced uptake of a stable CpG-OVA conjugate 
over a mixture of CpG and OVA (431,432). In addition this work showed for the first 
time that an enhanced uptake of the extracellular stable conjugates C-4FB-O, C-4FBSS-
O and C-peptide-O over the CpG and OVA mixture occurs for macrophages and to a 
lesser extend for B-cells and T-cells. DCs and macrophages are the major professional 
APCs that sample antigens throughout the body to present them to T-cells in lymphoid 
organs. Both DCs and macrophages have been found to express high levels of the MR 
which has been associated with OVA uptake (68,137,544). In addition to the MR, DCs 
have been shown to express high levels of the DEC-205 receptor which, apart from 
internalisation of antigen, has been reported to internalise CpG ODN (63,67,563,564). 
The difference in conjugate uptake between DCs and macrophages suggests that DEC-
205 is important for conjugate internalisation. As DEC-205 expression has not been 
reported on macrophages, but MR was found to be expressed on both DCs and 
macrophages, conjugates may be internalised via both DEC-205 and MR by DCs but 
only MR by macrophages (544,564). Additional routes of internalisation including 
macropinocytosis and possibly uptake through Fc or other antigen specific receptors 
may have also contributed to conjugate uptake. Further insight into the uptake 
mechanism could be established by targeted blocking of uptake receptors, especially the 
DEC-205 receptor, the MR or blocking of macropinocytosis on DCs and macrophages 
before addition of conjugates or a mixture of CpG and OVA. The mixture of CpG and 
OVA was internalised to a low degree in all tested cell types as expected. The cells may 




have internalised either CpG or OVA instead of both. Fluorescent labelling of CpG with 
a different coloured dye could provide further insight into the mechanism of uptake of 
antigen and adjuvant. Following administration of fluorescently labelled CpG and OVA 
either as a mixture or conjugate, the proportion of CpG and OVA in the same cell could 
be established. 
Although uptake of conjugates was significantly lower in B-cells and T-cells compared 
to uptake by DCs, an enhanced uptake of the conjugates over the mixture was still 
observed. This may be explained with the low expression of the DEC-205 receptor on 
both B-cells and T-cells and uptake of antigen by B-cells through the B-cell receptor 
(565,566). Additionally a subset of B-cells has been reported that expresses the MR, 
which could have further contributed to conjugate uptake (567). 
Both the C-SPDP-O and C-PEG-O conjugates did not result in an enhanced uptake over 
the mixture of CpG and OVA. For the C-SPDP-O conjugate a similar degree of uptake 
as the mixture was expected, as stability studies in Section 3.2.5 showed that it was 
cleaved in the extracellular reducing environment. This was confirmed by cleavage at 
extracellular concentrations of glutathione (GSH) and cleavage in cell culture 
supernatant from a BMDC culture (497,498,523). The low uptake of the C-PEG-O 
conjugate was unexpected, as C-PEG-O was of similar size and conjugation ratio as the 
C-4FB-O conjugate and it was shown to be stable in both reductive environments (see 
Section 3.2.5). As the C-PEG-O conjugate has a longer, flexible spacer arm between the 
CpG and OVA compared to the stable C-4FB-O conjugate, a potential reason for the low 
uptake may be that the CpG and OVA interact, thereby preventing recognition of both 
OVA and CpG by the respective uptake receptors. Further investigations are required 
to understand why the C-PEG-O conjugate was not internalised by APCs to the same 
degree as the other stable conjugate. For this, different lengths in PEG spacers or less 
flexible, long spacers between CpG and OVA could be tested. 
The differences in uptake of the conjugates were not reflected in the degree of activation 
of BMDC as measured by upregulation of activation markers, as all conjugates induced 
a similar degree of upregulation of CD86 and CD40 as unconjugated CpG. This is in line 
with previous reports that showed enhanced uptake of antigen-adjuvant conjugates 
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over antigen and adjuvant mixtures but similar expression of activation markers 
following incubation with the two treatments (122,431). As activation markers have 
been shown to be upregulated following binding of CpG to TLR9, it is suggested that 
from a threshold dose of CpG that is necessary to activate TLR9, the total amount of 
CpG present in the cell does not reflect the degree of upregulation of activation markers. 
This was confirmed by a CpG titration study performed by de Titta et al which showed 
no upregulation of CD86 with a concentration of 0.01 µM CpG but similar degrees of 
upregulation of CD86 on BMDC with CpG concentrations ranging from 0.05 to 1 µM 
(465). These observations that the total amount of CpG internalised by the APC is not 
reflected in their activation status ties in with the observations reported in Chapter 3 
that CpG linked via the 3’ or 5’ end results in the same degree of activation marker 
upregulation by APCs. A titration experiment with free, 3’ and 5’ linked CpG that 
measures both NF-κB production as an indication for TLR9 activation and APC 
activation through activation markers could provide further insight into the relationship 
of CpG induced TLR9 activation and consequent APC activation. 
The high degree of uptake of the C-4FB-O and C-4FBSS-O conjugates by DCs were 
however reflected in a high percentage of T-cell proliferation and IFN-γ production. 
Interestingly, although the C-peptide-O conjugate induced high uptake in DCs, no 
enhanced T-cell proliferation or IFN-γ production was observed following T-cell co-
culture with C-peptide-O activated BMDC. SEC analysis of the C-peptide-O conjugate 
showed the formation of a high molecular weight compound which was much larger 
than the other synthesised conjugates. This suggested that instead of forming soluble 
conjugates with an average of 2.8 CpG per OVA, aggregates might have formed. As 
discussed in Chapter 3, antigen aggregates have been shown to induce lower CTL 
immunogenicity compared to native antigens, which may explain the low T-cell 
activation seen in this study (536). The high uptake of C-peptide-O especially by DCs, 
which was more than double than uptake of the C-4FB-O or C-4FBSS-O conjugates, may 
be explained with internalisation of aggregates through phagocytosis, instead of 
receptor-based endocytosis or macropinocytosis as for the soluble formulations (58,59).  




Since both C-SPDP-O and C-PEG-O induced very low uptake into DCs, the minimal T-
cell proliferation was expected. The high IFN-γ production induced by BMDC activated 
with C-SPDP-O and co-cultured with CD8+ T-cells for 48 h was however very 
interesting, especially as there was no enhanced IFN-γ production following 72 h of co-
culture. It was further noteworthy that this was not reflected in a higher proliferation of 
CD8+ T-cells in the 48 h co-culture. Although C-SPDP-O was shown to be cleaved in the 
extracellular reducing environment in Chapter 3, a small amount of intact conjugate 
may have been internalised by BMDCs shortly after addition of the conjugate, before it 
got cleaved. As the conjugate was shown to be very susceptible to high intracellular 
concertation of GSH (see Section 3.2.5.2), a faster cleavage of the conjugate inside the 
cell compared to cleavage of the C-4FBSS-O conjugate may have induced a different 
processing rate by BMDCs. A faster processing rate of the conjugate paired with a lower 
total amount of OVA internalised by BMDC compared to the C-4FB-O and C-4FBSS-O 
may have induced low CD8+ T-cell activation with production of IFN-γ which did not 
lead to high proliferation of the T-cells.  
The use of the cross-presentation inhibitors lactacystin, primaquine and brefeldin A 
provided further insight into the processing of the conjugates for cross-presentation. C-
PEG-O and C-peptide-O conjugates did not induce T-cell activation or proliferation, 
which suggested that they are not cross-presented on BMDCs, therefore were not 
included in the inhibitor assay. The SIINFEKL peptide which is a positive control for 
antigen presented on MHC-I was not effected by either primaquine or lactacystin 
treatment which confirmed that the peptide did not need processing for presentation on 
MHC-I molecules. Brefeldin A treatment of the BMDCs resulted in a reduction in IFN-
γ produced by SIINFEKL-specific CD8+ T-cells. Brefeldin A inhibits exocytosis of 
proteins from the ER and the Golgi and it thereby reduces the total amount of MHC-I 
molecules on the cell surface (126,559). The lower amount of MHC-I molecules may 
therefore explain the lower amount of IFN-γ produced, as SIINFEKL peptide could bind 
to less MHC-I molecules compared to untreated cells. MHC-I molecules loaded with 
antigen are required for T-cell activation, therefore in cells incubated with conjugates, 
brefeldin A abrogated all T-cell activation through blocking exocytosis of MHC-I 
molecules loaded with processed antigen epitopes. Although OVA has been reported to 
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be mainly cross-presented through the receptor recycling pathway, the reduction in 
cross-presentation of OVA following both lactacystin and primaquine treatment 
suggests that OVA is cross-presented through a variety of routes (131,555). The similar 
reduction of cross-presentation of the C-4FB-O conjugate by both lactacystin and 
primaquine suggested that both degradation of antigen by the proteasome and the 
endo-lysosome contribute to cross-presentation (555,558). As the reduction of cross-
presentation was less than for pure OVA, the addition of CpG in the conjugate may have 
enhanced efficient cross-presentation, confirming previous reports (391,435). The 
stronger reduction of cross-presentation of the C-4FBSS-O and C-SPDP-O conjugates by 
primaquine compared to lactacystin suggested that the reversible conjugates were 
processed to a higher extent by the proteasome than through endosomal degradation. 
This suggested that the reversible conjugates were cross-presented to a higher extend 
through the cytosolic pathway while the stable conjugate was cross-presented to the 
same extend through the vacuolar and cytosolic pathway, indicating different dynamics 
in cross-presentation between stable and reversible conjugates. 
The theory that a reversible conjugate of CpG and OVA induces an enhanced TH1 
response due to improved processing of OVA and activation of BMDC by CpG was not 
demonstrated in the in vitro experiments. The high induction of T-cell proliferation of 
CD8+ and CD4+ T-cells by both the stable C-4FB-O and reversible C-4FBSS-O conjugates 
in vitro however suggested that they may both induce a strong TH1 immune response 
with induction of CTL and TH1 cells in vivo. The lack of difference in T-cell proliferation 
between C-4FB-O and C-4FBSS-O may be due to the limit of the in vitro assay, with the 
highest level of T-cell proliferation at the given dose. The two conjugates induced 
similar responses of T-cell activation and proliferation of over 80 %, similar to the 
positive control peptides. This suggests that even if one of the conjugates was slightly 
better than the other, the proliferation assay would not have shown a difference in 
proliferation of the tested T-cells. Further in vitro T-cell experiments with lower doses of 
C-4FB-O and C-4FBSS-O conjugates could be set up in the future to test whether the 
intracellular cleavable conjugate induces enhanced T-cell proliferation over the stable 
conjugate. However, in vitro cell culture assays are only an indication of what happens 
in vivo. The in vitro assays lack internalisation of the conjugates by APCs at the site of 




injection or tissue, migration of the mature APC into lymph nodes for T-cell activation, 
differentiation and proliferation. Additionally only one subset of APC was tested to 
activate a CTL response while in vivo different subset of APC are available with a variety 
of cross-presentation and T-cell priming functions. The conjugates were therefore tested 
for their ability to generate a TH1 immune response in vivo with generation of CTL which 
kill target tumour cells.  
The in vivo cytotoxicity assay tested the cytotoxic response against target cells generated 
in conjugate vaccinated mice in a tumour free environment. For the in vivo cytotoxicity 
assay target and control cell populations were stained with 5 and 50 µM CFSE to 
distinguish them after harvesting from the mice. Although ten-fold different CFSE 
concentrations with a maximum of 5 µM CFSE were used in previously reported 
studies, this work showed that splenocytes stained with CFSE concentrations of 0.2 and 
0.5 µM were not distinguishable from unstained cells when harvested from mice 48 h 
after injection (321,335,378,383,560). A reason for the low reported concentrations may 
be the reported toxicity of CFSE at high concentrations (561). As we did not see a 
difference in cell viability between 0.5, 5 and 50 µM CFSE stained cells and the 5 and 
50 µM CFSE stained cells resulted in distinguishable cell populations these 
concentrations were used to stain control and target cells. The difference to other 
reported groups might have been due to a different supplier or batch of CFSE or the use 
of a different flow cytometer for analysis.  
Interestingly all the conjugates and the CpG and OVA mixture induced high 
cytotoxicity against target cells. This only partially reflected the observations made in 
the in vitro assays, especially the high degree of cytotoxicity displayed by the mixture of 
CpG and OVA and the C-peptide-O conjugate was noteworthy. The strong cytotoxicity 
generated by the mixture of CpG and OVA was previously also reported in a study by 
Beaudette et al using similar amount of CpG and OVA as in this study, however with 
OVA formulated in a microparticle (383). As the uptake and processing mechanisms 
differ between soluble and particulate formulations, the results shown in the CpG/OVA 
particle study therefore cannot be directly translated to our study. Strong induction of 
a cytotoxicity response by stable CpG-OVA conjugates was also reported previously 
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(335,432). The intracellular cleavable C-4FBSS-O conjugate used in this study to test 
whether intracellular antigen and adjuvant release enhances anti-tumour immunity was 
shown to induce similar high cytotoxicity as the other tested formulations. However, 
since the stable C-4FB-O conjugate induced 100 % target cell lysis, no improvement by 
the reversible conjugate could have been measured. Using a lower antigen dose in this 
assay to significantly reduce the response below 100 % would allow for an opportunity 
to detect a possible enhanced cytotoxic effect by the intracellular cleavable conjugate 
over the other treatment groups. Kreutz et al have demonstrated that reducing the 
injected antigen dose from 2 µg to 0.8 µg results in a 40 % drop of antigen-specific 
cytotoxicity (335). The antigen doses used by Kreutz et al were approximately 10-fold 
lower than the 10 µg used in this study. This suggested that the dose used in this and 
previously reported studies might be too high to distinguish small differences in the 
immune reactions generated by different treatments (383,432). Another point for 
consideration for comparing different treatments of CpG and OVA in mixtures or 
conjugates in the same or between studies are the vaccination schedules, considering 
the time allowed for CTL generation between vaccination and target cell injection. 
Previous studies using soluble formations comparable to the conjugates tested in this 
study reported incubation times of 5 to 7 days between vaccination and target cell 
injection which was considerably less than the 31 days with vaccine boost at day 24 
reported here (335,383,432). The extended period of time between the first vaccination 
with the conjugates and the target cell injection in combination with the high dose of 
antigen may have contributed to the strong cytotoxic response. While the establishment 
of a strong cytotoxic response is important for the success of a tumour vaccine, to 
elucidate the differences in vaccine treatments, an antigen dose titration experiment for 
the induction of a cytotoxic response could be set up.  
In the therapeutic tumour trial, the high survival rate of 9/10 in mice vaccinated with 
the intracellular cleavable C-4FBSS-O conjugate supported our hypothesis that release 
of antigen from adjuvant inside the cell induces enhanced processing of the conjugate 
and leads to an enhanced anti-tumour immunity. The strong cytotoxic response 
generated by all conjugates and the CpG and OVA mixture observed in the in vivo 
cytotoxicity assay were reflected in an enhanced survival of all treatment groups over 




the PBS control group in the in vivo tumour trial. However, compared to the cytotoxicity 
assay, differences in the total survival time and onset of tumour outgrowth were 
observed between the treatment groups. The fast tumour growth in the PBS control 
group both in the first tumour challenge and in the control group for the tumour re-
challenge confirmed the high tumorigenic properties of the B16-OVA cells (568). The 
survival rates mostly matched the predictions made from the in vitro assays, with both 
the stable C-4FB-O and the reversible C-4FBSS-O conjugates inducing enhanced 
survival and the C-SPDP-O, C-PEG-O and C-peptide-O inducing similar or lower 
survival compared to mice vaccinated with the mixture of CpG and OVA. The high 
survival rate of the mice vaccinated with the intracellular cleavable conjugate also 
suggested the generation of a systemic memory response, as in the C-4FBSS-O group no 
mice developed tumours following the tumour re-challenge. In contrast to this, the mice 
treated with the CpG and OVA mixture or the C-SPDP-O, C-PEG-O or C-peptide-O 
conjugates did not develop any tumours for 20 days before the re-challenge but 12 days 
after the re-challenge tumours started growing again. This suggested that the systemic 
memory response generated in those treatment groups was inferior to the one generated 
in the C-4FBSS-O group. While both the C-4FB-O and the C-4FBSS-O induced a high 
survival rate, only the high survival rate of 9/10 after 160 days of tumour trial induced 
by the reversible C-4FBSS-O conjugate was analysed to be statistical significantly higher 
than the survival rate of 3/10 from the mixture group. This enhancement in survival of 
mice treated with the reversible C-4FBSS-O conjugate over the stable C-4FB-O conjugate 
supports our theory that a reversible conjugate of CpG and OVA generates an enhanced 
immune response over a stable conjugate. 
Comparison of the survival rates observed in this tumour trial to previously reported 
studies using similar adjuvant-antigen conjugates is difficult, as the conjugates in 
previous studies were mainly tested in prophylactic tumour trials. In a therapeutic trial, 
the control of the tumour cells by the immune system relies on a rapid establishment of 
an anti-tumour immune response before the tumour mass grows too big for the control 
by the immune system. In a prophylactic setting, as it was used in the in vivo cytotoxicity 
assay, maximised immunity can be generated before the tumour challenge. It would be 
interesting to investigate whether the reversible C-4FBSS-O conjugate would also lead 
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to enhanced survival in a prophylactic tumour trial where there would also be more 
time for the generation of a strong immune response by the other conjugate as observed 
in the in vivo cytotoxicity assay. As previous studies showed similar survival rates for 
the mixture of antigen and adjuvant and antigen-adjuvant conjugates in prophylactic 
tumour trials to the ones reported in our therapeutic tumour trial, the superiority of the 
reversible C-4FBSS-O conjugate may also be valid in a prophylactic trial (383,465,569).  
In conclusion, the reversible, intracellularly cleaved CpG-OVA conjugate C-4FBSS-O 
proved to be superior in generating an anti-tumour immune response compared to a 
mixture of CpG and OVA in vivo. This was confirmed by the findings that the conjugate 
induced enhanced uptake by APCs and enhanced proliferation of both CD8+ and CD4+ 
T-cells following cross-presentation of the antigen. This supported our theory that 
cleavage of the antigen from the adjuvant following uptake into the same cell allows for 
enhanced antigen processing and presentation and enhanced APC activation through 
adjuvant binding to TLR. These results provide further knowledge for the development 
of improved immunotherapeutic vaccines. Intracellular release of antigen from 
adjuvant in a soluble co-delivery strategy was shown to induce enhanced anti-tumour 
immunity over non-cleavable strategies. In the future, intracellular cleavable strategies 





























This research addressed the need for improving immunotherapies for the effective 
treatment of cancer. The co-delivery of tumour antigen and vaccine adjuvant to antigen-
presenting cells (APCs) has shown potential as an immunotherapeutic vaccine. This 
approach has been investigated in a variety of formulations including soluble and 
particulate systems (see Section 1.7). This thesis focused on improving the efficacy of 
soluble antigen-adjuvant conjugate systems. Our hypothesis is that once an antigen-
adjuvant conjugate is taken up by an APC, intracellular processing of the antigen is 
restricted by having the antigen conjugated directly to the adjuvant. To test this 
hypothesis we produced antigen-adjuvant conjugate systems designed to release the 
two active agents from each other once inside the cell by an intracellular trigger (see 
Section 1.9).  
Previous studies have shown that conjugation of antigen to adjuvant as a means for co-
delivering to the APC induces enhanced cellular, TH1-type anti-cancer immune 
responses compared to a mixture of the antigen and adjuvant (335,431,432). In these 
previously reported studies the antigen and adjuvant were conjugated together using a 
stable bond, however it is not known whether having the adjuvant and antigen 
chemically linked together inhibits their processing by the APC for immune stimulation. 
In this research reversibly linked antigen-adjuvant conjugates were designed to be 
stable outside a cell but cleaved once inside an APC. For this to happen efficiently the 
reversible linked conjugates should be stable in extracellular conditions to allow for co-
delivery of antigen and adjuvant into APC. Once inside the cell a specific intracellular 
trigger cleaves the bond releasing the antigen and adjuvant from each other. This may 
allow for improved antigen processing and presentation by the APC as well as enhanced 
APC activation and maturation through the adjuvant. The enhanced antigen processing 
and APC activation may generate an improved anti-cancer immune response compared 
to stable antigen-adjuvant conjugates.  
Antigen-adjuvant conjugates were designed and synthesised to be cleaved inside APCs 
by an intracellular trigger. The vaccine adjuvant CpG and the model tumour antigen 
ovalbumin (OVA) were conjugated through either stable or cleavable conjugation linker 
strategies. Different triggered release strategies were investigated including reduction 




and enzyme. This concept of reduction triggered release of antigen-adjuvant conjugates 
is depicted in Figure 5.1. In vitro cleavage assays showed that the disulphide linked C-
4FBSS-O conjugate was a suitable conjugate as it was stable at extracellular and cleaved 
at intracellular reducing conditions. In a therapeutic tumour trial, the intracellular 
cleavable, reduction sensitive C-4FBSS-O conjugate induced a superior anti-tumour 
immune response compared to all other formulations tested. This work indicates that 
the direct conjugation of antigen to adjuvant may restrict antigen processing by the APC 
as proposed by our hypothesis. Further work is required to confirm this hypothesis and 
understanding the intracellular processing which will lead to better designed soluble 
vaccine formulations. 
 
Figure 5.1: Concept for reduction triggered release of antigen-adjuvant conjugates  
A soluble antigen (OVA) and adjuvant (CpG) conjugate is taken up by an APC and an 
intracellular environmental trigger (glutathione (GSH)) cleaves the antigen from the adjuvant. 
Cleavage of antigen from adjuvant induces enhanced antigen processing for presentation on 
MHC-I and MHC-II to CD8+ and CD4+ T-cells while the adjuvant induces strong APC activation 
and maturation. Antigen presentation and upregulation of co-stimulatory markers induces 




In order to progress this intracellular cleavable technology for the use in 
immunotherapeutic vaccines a greater understanding of the uptake and processing of 
the conjugates by APCs is needed. This is especially important when considering the 
many different APC subsets that all play a diverse role in the immune system. The APC 
subsets display different cell surface markers and have been shown to differ in their 
ability to cross-present antigen and induce a cytotoxic T lymphocyte (CTL) immune 
response (570,571). In this study, murine DCs for in vitro experiments were generated 
from bone marrow precursor cells and identified through the surface marker CD11c. In 
comparison to BMDCs, other APC subsets may generate a different CTL response when 
activated with either the reversible or the stable conjugate. It would be interesting to 
determine the method and extent of uptake as well as cross-presentation of the 
reversible conjugate by different subsets of DCs, macrophages and potentially also B-
cells. Furthermore the subsequent CTL activation and proliferation by the cross-
presenting APC subsets could be determined. This would provide better understanding 
of how the reversible conjugate induces an enhanced anti-tumour response in vivo and 
it could also be used to specifically target one or several APC subsets to further improve 
the anti-tumour immune response.  
The successful reversible, intracellular cleaved linking strategy used in this study relies 
on the stability of the conjugate in extracellular conditions and the cleavage of the 
conjugate in the highly reductive intracellular environment. For the further 
development of the cleavable linking strategy for immunotherapeutic vaccines for the 
clinic the potential reductive extracellular environment in non-target tissues like 
tumours and inflamed tissues should also be considered. A change in extracellular 
redox potential has been associated with persistent inflammation during carcinogenesis 
and the release of thioredoxin and danger-associated molecular patterns (DAMPs) by 
necrotic and stressed cells in hypoxic regions of solid tumours. Various tumour biopsies 
and in vitro cell culture studies have shown that tumour cells actively release 
micromolar amounts of GSH and cysteine (572–578). A higher reduction potential in the 
tumour microenvironment may lead to the cleavage of the reversible conjugate before 
it is internalised by an APC. The stability of reversible antigen-adjuvant conjugates in 




inflamed tissues around the tumour would therefore be an important point of 
investigation for the clinical development of a reversible conjugate. 
Although the intracellular cleavable conjugation strategy for co-delivery of antigen and 
adjuvant worked well in our mouse model, translating this success to the clinic for 
human use is not straight forward. For example it is known that in mice toll-like receptor 
(TLR) 9 is expressed in myeloid cells, plasmacytoid dendritic cells (pDC) and B-cells 
while in humans it is only expressed on pDCs and B-cells (51,52,579). The lack of TLR9 
in myeloid cells in humans may result in differences in the immune response generated 
by CpG compared to mice, since less subsets of APCs can be activated by the CpG. 
However, previous results from pre-clinical studies in mice have shown reasonable 
success in translating the immune responses generated by CpGs in clinical trials in 
humans (348). Another important consideration is the type of CpG used in these studies 
with mice for the immunotherapy translation to human studies. The class B CpG 1668 
used in this study has a preference for mouse TLR9 and has thereby shown strong 
activation of the murine APCs used in this research. To further develop the reversible 
antigen-adjuvant conjugate for use in the clinic, a CpG with preference for human TLR9 
should be considered. The class B CpG 7909 (also known as CpG 2006) is similar to the 
murine specific CpG 1668 and has been successfully used in clinical trials in combination 
with tumour antigens. CpG 7909 is being investigated and has already shown promising 
results as an adjuvant in combination with tumour antigen for tumour immunotherapy 
(358,471,580–585). Considering its proven safety and efficacy in humans, CpG 7909 may 
be a good option for use as the vaccine adjuvant if the reversible CpG-antigen conjugate 
was taken to the clinic. 
The next step planned to move this technology closer to the clinic is to exchange the 
model antigen to a clinically relevant tumour antigen. The model tumour antigen OVA 
was used in this study to determine the anti-tumour response generated by the stable 
and reversible antigen-adjuvant conjugates. The availability of the OVA mouse and 
tumour cell lines allows for proof-of-concept studies to establish the generated anti-
tumour immunity of immunotherapeutic vaccines. However, T-cells from the 
genetically modified OT-I and OT-II mice recognise preferentially the OVA peptides 
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which induces strongly amplified immune responses compared to T-cells from non-
transgenic mice. Therefore, when considering to further develop the reversible 
conjugation strategy of antigen and adjuvant, clinically more relevant tumour antigens 
should be used instead of the model tumour antigen OVA. Tumour antigens used in the 
clinic as a target for immunotherapy need to be immunogenic, expressed at high levels 
on the tumour cells while being absent or showing very restricted expression on healthy 
tissues. Examples for tumour antigens that fit these criteria include the cancer-testis 
antigens NY-ESO-1, LAGE-1 and MAGE-A3 (586–592), the melanocyte-differentiation-
antigen MART-1 overexpressed in melanoma (593–596) or the human epidermal growth 
factor receptor 2 (HER2) overexpressed in HER2-positive breast cancer (597–599). These 
tumour antigens, among others, are currently tested in various clinical trials as targets 
for immunotherapies. A reversible conjugate of a selected clinically relevant tumour 
antigen and CpG could be used to further develop the reversible antigen-adjuvant 
conjugate as an immunotherapeutic vaccine targeted to a specific cancer type. These 
cleavable tumour antigen-CpG conjugates should be tested in pre-clinical studies, 
therefore mouse tumour models for the specific tumour antigen need to be developed.  
In evaluating the potential of this technology to reach the clinic we should consider the 
dose required for a human based on our mouse studies. However this is difficult at this 
stage as the clinical trials to date have investigated a range of therapeutic strategies 
using CpG in combination with radiotherapy and chemotherapy and tumour antigens 
mixed with a variety of adjuvants and cytokines. With respect to CpG, the typical dose 
administered in clinical trials is 0.04-1 mg/kg CpG per patient which is similar to our 
given single dose in mice, when approximated per kilogram body weight 
(361,363,365,600). The dose of antigen and adjuvant conjugates for mice used in this 
study was not optimised, however lower dosages of antigen and adjuvant reported in 
previously reported studies suggest that also with a lower dose of conjugates an 
effective anti-tumour response may be expected (335). The clinical trials investigating 
antigen and adjuvant for immunotherapy have tested these agents on patients with 
multiple administrations. In our studies a single administration of the C-4FBSS-O 
conjugate in the therapeutic mouse tumour trial was sufficient to induce a strong anti-
tumour immunity and establish a memory response to protect from a tumour re-




challenge. The conjugates tested in this mouse study were administered as a single 
subcutaneous dose, while antigen and adjuvant tested in clinical studies have been 
administered via the intradermal or intramuscular routes, as multiple doses over 
months or years (361,363,365,591,601–603). It would be interesting to establish whether 
multiple doses of the intracellular cleaved conjugate delivered in a prime-boost scenario 
could improve the generated immune response. Administration of multiple doses may 
also lead to a lower dose requirement per administration. In addition potential changes 
in the induced immune responses due to the route of administration of the conjugate 
would be of interest. Different subsets of APCs may internalise the conjugates 
depending on their route of administration, therefore immune responses generated 
following subcutaneous, intradermal, intramuscular or intravenous administration 
could be compared. 
In order to further develop the vaccine strategy for use in the clinic, the implications of 
a scale up of the production process under GMP conditions should be considered. CpG 
7909 for human use as well as tumour antigens may be sourced at GMP grade as they 
have been used in previous clinical trials. The conjugation steps should be able to be 
scaled up by multiplying the amounts of chemical used, however purification in 
between the steps and of the end product should be addressed. Large filtration units as 
well as SEC columns may be used or alternative ways for purification may need to be 
considered. The possibility of the production of large batches of vaccines for human use 
may be discussed in collaboration with a GMP grade facility or the production could be 
outsourced. 
The intracellular cleavable C-4FBSS-O conjugate tested in this study induced a strong 
anti-tumour immunity in the therapeutic mouse tumour trial. A limitation of the mouse 
tumour trial is that the tumours were small when the conjugate vaccines were 
administered. When developing the vaccine strategy for the clinic, it is important to 
consider that patients generally have a much larger tumour mass to treat. In order to 
use the immunotherapeutic vaccine strategy in the clinic, it may need to be used in 
combination with a debulking agent such as chemo- or radiotherapy or surgical removal 
of the tumour. Additionally the tumour in patients may be less immunogenic than the 
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B16 melanoma tumour cells used in this study, thereby requiring a strong persistent 
anti-tumour response. It would be interesting to establish whether an intracellular 
cleavable conjugate can induce these required strong anti-tumour immune responses in 
cancer patients.  
In conclusion, the research described in this thesis shows that a conjugate designed to 
be cleaved by the high reducing intracellular environment resulted in greater immune 
responses in vivo. This indicates that direct conjugation of antigen to adjuvant limits 
antigen processing by APCs. This study identified a new soluble formulation strategy 
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7.1. Appendix 1: Recipes 
7.1.1. Synthesis and characterisation of CpG-OVA conjugates 
10x Phosphate buffered saline (PBS)  
160 g  NaCl 
4 g  KCl 
22.7 g   Na2HPO4 
4 g  KH2PO4 
Make up to 2 L with MilliQ water 
 
Reducing buffer:  
60.5 mg  Tris  
14.6 mg Ethylenediaminetetraacetic acid (EDTA) 
77.15 mg DTT 
Adjust to pH 8.0, make up to 50 ml with MilliQ water, filter 
 
NaH2PO4 buffer: 
12 g  NaH2PO4 
8.76 g  NaCl 
Make up to 1 L with MilliQ water 
 
Na2HPO4 buffer: 
14.2 g  Na2HPO4 
8.76 g  NaCl 
Make up to 1 L with MilliQ water 
 
Modification buffer: 
190 ml  NaH2PO4 buffer 
15 ml  Na2HPO4 buffer 







25 ml  NaH2PO4 buffer 
200 ml  Na2HPO4 buffer 
Adjust to pH 6.0, filter 
 
MES buffer: 
9.76 g  MES 
Adjust to pH 5.0, make up to 500 ml with MilliQ water, filter 
 
TurboLink buffer 
25 ml  NaH2PO4 buffer 
200 ml  Na2HPO4 buffer 
2.05 ml  Aniline 
Adjust to pH 6.0, filter 
 
SEC phosphate buffer 
12 g  NaH2PO4 
3.57 ml  7 % NaN3 solution 














7.1.2. Immunological assays 
Ammonium Chloride Red Blood Cell Lysis Buffer (RBC lysis buffer) 
4.15 g   NH4Cl 
0.5 g  KHCO3 
0.0186 g EDTA 
Make up to 500 mL with MilliQ water, filter sterilize. 
 
Complete Iscove’s Modified Dulbeccos’s medium (cIMDM)  
500 mL  IMDM 
5 ml Penicillin Streptomycin (10,000 Units/ml Penicillin, 10,000 µg/ml 
Streptomycin) 
500 µL  5.5 mM 2-mercaptoethanol 
 
MACS buffer  
292.24 mg EDTA 
2.5 g  BSA 
Adjust to pH 7.2, make up to 500 mL with DPBS, filter sterilize 
 
MACS running buffer  
292.24 mg  EDTA  
0.5 g  BSA 
Adjust to pH 7.2, make up to 500 mL with DPBS, filter sterilize 
 
Fluorescence‐activated cell sorting (FACS) buffer 
0.1 g  Sodium azide 
1 g  BSA 









Alsever’s solution  
20.5 g   Dextrose (D-glucose) 
4.2 g  NaCl 
8.0 g  Na Citrate  
Make up to 1 L with MilliQ water 
 
ELISA Coating buffer 
0.42 g  NaHCO3  
Make up to 50 mL with distilled water 
 
ELISA Wash buffer  
20 mL   10x PBS 
1 mL  Tween 20 
Make up to 2 L with distilled water 
 
Complete Roswell Park Memorial Institute medium (cRPMI) 
500 ml  RPMI 





7.2. Appendix 2: Antibody Compendium 
Flow cytometry antibodies: 
Antibody Clone Label Source 
CD11c N418 APC BioLegend 
CD16/CD32 (Mouse BD Fc 
Block™) 
2.4G2 Purified BD 
Pharmingen™ 
CD3 145-2C11 PE-CF594 BD Horizon 
CD4 RM4-5 APC BioLegend 
CD40 3123 PE/Cy7 BioLegend 
CD45R/B220 RA3-6B2 FITC BioLegend 
CD86 GL-1 PE BioLegend 
CD8α 53-6.7 APC BioLegend 
F4/80 BM8 PE BioLegend 
I-A/A-E M5/144.15.2 FITC BioLegend 
TCRVα2 B20.1 FITC BioLegend 
TCRVβ5.1,5.2 MR9-5 APC BioLegend 
 
ELISA antibodies: 
Antibody Clone Label Source 
IFN-y R4-6A2 Purified BioLegend 







7.3. Appendix 3: Supplementary Figures 




Figure 7.1: UV-Vis wavelength scan of C-4FB-O and C-4FBSS-O conjugates.  
The absorbance of (A) C-4FB-O and (B) C-4FBSS-O was measured as a wavelength scan, 




Figure 7.2: 3D wavelength scan of CpG, OVA and C-4FB-O.  
Chromatograms of (A) CpG, (B) OVA and (C) C-4FB-O were re-analysed as 3D wavelength scan 








Figure 7.3: Chromatographs of (A) 3’ C-4FB-O and (B) 5’ C-4FB-O analysed on Yarra-
2000 SEC column 
 
 
Figure 7.4: Chromatographs of (A) 3’ C-4FBSS-O and (B) 5’ C-4FBSS-O analysed on 





Figure 7.5: Chromatographs of (A) 3’ C-SPDP-O and (B) 5’ C-SPDP-O analysed on 
Yarra-2000 SEC column 
 
 
Figure 7.6: Chromatographs of (A) 3’ C-PEG-O and (B) 5’ C-PEG-O analysed on Yarra-







Figure 7.7: Chromatographs of (A) 3’ C-peptide-O and (B) 5’ C-peptide-O analysed on 






Figure 7.8: Chromatographs of C-4FB-O conjugate incubated with (A) PBS, (B) 10 µM 









Figure 7.9: Chromatographs of C-4FBSS-O conjugate incubated with (A) PBS, (B) 
10 µM GSH, (C) 5 mM GSH or (D) 5 mM DTT for 2 h at 37 °C and analysed on Yarra-






Figure 7.10: Chromatographs of C-SPDP-O conjugate incubated with (A) PBS, (B) 
10 µM GSH, (C) 5 mM GSH or (D) 5 mM DTT for 2 h at 37 °C and analysed on Yarra-








Figure 7.11: Chromatographs of C-PEG-O conjugate incubated with (A) PBS, (B) 
10 µM GSH, (C) 5 mM GSH or (D) 5 mM DTT for 2 h at 37 °C and analysed on Yarra-






Figure 7.12: Chromatographs of C-peptide-O conjugate incubated with (A) PBS, (B) 
10 µM GSH, (C) 5 mM GSH or (D) 5 mM DTT for 2 h at 37 °C and analysed on Yarra-








Figure 7.13: Chromatographs of C-4FB-O conjugate incubated with (A) PBS, (B) 
cIMDM cell culture medium containing 55 µM 2-ME or (C) cell culture supernatant 





Figure 7.14: Chromatographs of C-4FBSS-O conjugate incubated with (A) PBS, (B) 
cIMDM cell culture medium containing 55 µM 2-ME or (C) cell culture supernatant 








Figure 7.15: Chromatographs of C-SPDP-O conjugate incubated with (A) PBS, (B) 
cIMDM cell culture medium containing 55 µM 2-ME or (C) cell culture supernatant 






Figure 7.16: Chromatographs of C-PEG-O conjugate incubated with (A) PBS, (B) 
cIMDM cell culture medium containing 55 µM 2-ME or (C) cell culture supernatant 








Figure 7.17: Chromatographs of C-peptide-O conjugate incubated with (A) PBS, (B) 
cIMDM cell culture medium containing 55 µM 2-ME or (C) cell culture supernatant 






Figure 7.18: Chromatographs of C-4FB-O conjugate incubated with PBS at (A) pH 7.4, 








Figure 7.19: Chromatographs of C-4FBSS-O conjugate incubated with PBS at (A) pH 





Figure 7.20: Chromatographs of C-SPDP-O conjugate incubated with PBS at (A) pH 







Figure 7.21: Chromatographs of C-PEG-O conjugate incubated with PBS at (A) pH 7.4, 





Figure 7.22: Chromatographs of C-peptide-O conjugate incubated with PBS at (A) pH 
7.4, (B) pH 6.0 or (C) pH 5.0 and analysed on Yarra-2000 SEC column 
 
 
Figure 7.23: pH values tested in C-4FB-O conjugate incubated with PBS at pH 6.0 and 










Figure 7.24: Chromatographs of C-peptide-O conjugate incubated with (A) PBS or (B) 
0.15 µg/ml Cat S  and analysed on Yarra-2000 SEC column 
 
7.3.2. Cell culture additional figures 
 
 
Figure 7.25: Titration of LPS as positive control for BMDC activation.  
BMDC were incubated for 24 h with 0.5, 1, 2.5 or 5 µg/ml LPS. Expression of activation markers 
MHC-II, CD86 and CD40 was analysed by flow cytometry. Bars represent three independent 




Figure 7.26: AutoMACS CD8+ sort of OT-I splenocytes.  
(A) Representative flow cytometry dot plots of unsorted CD8+ splenocytes from OT-I mice and 
the negative and positive fractions following a CD8α AutoMACS sort. (B) Percentage of CD8+ T-
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